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ABSTRACT 
 
 Fatty acids are an integral part of the lipid membrane of bacteria and plants, and the 
enzyme that initiates fatty acid synthesis, β-ketoacyl-ACP Synthase III (KASIII), is one of 
the most diverse enzymes found in nature. KASIII exhibits vast diversity in its substrate 
specificity.  By virtue of its substrate specificity, KASIII determines the fatty acid profile of 
the organism by dictating the nature of the ω-end of the fatty acids. For example, KASIIIs 
from many bacteria (e.g. Escherichia coli) accept straight chain acyl-CoAs resulting in 
production of straight chain fatty acids and are, therefore, narrow in substrate specificity.  In 
contrast, KASIII from other bacteria (e.g. Staphylococcus aureus) accept both straight and 
branched chain acyl-CoAs resulting in production of both straight and branched chain fatty 
acids and thefore, exhibit broad substrate specificity. Despite the availability of KASIII 
crystal structures from a dozen sources, the molecular basis for its substrate diversity remains 
unclear. Additionally, the enzymatic activity of KASIII enzymes has not been explored with 
substrates other than straight or branched chain acyl-CoAs. However, occurrence of ω-cyclic 
and ω-phenylic fatty acids in certain bacteria and plants suggests that KASIII in such 
organisms may be capable of utilizing atypical substrates such as cyclic acyl-CoAs or 
aromatic acyl-CoAs.  
In this dissertation, we have experimentally established the essentiality of three 
residues in determining KASIII substrate binding and catalysis. We have also characterized 
twelve putative KASIII enzymes from diverse bacterial sources and have identified six 
functional KASIIIs from this set. Additionally, based on phylogenetic and functional 
comparisons of all the characterized KASIIIs, we have developed a structure-function 
viii 
 
 
correlation that can be used for predicting KASIII functionality. Finally, we identified three 
novel KASIII enzymes that can utilize atypical substrates, including hydroxylated, aromatic 
and unsaturated acyl-CoAs. We subsequently demonstrated the in vivo production of novel 
ω-1-hydroxy-branched fatty acids using a novel KASIII. The knowledge gained from this 
study has enhanced our understanding of the KASIII structure-function relationship and has 
paved the way for developing fatty acids with novel chemical functionalities at the ω-end 
using KASIIIs with diverse specifcities.       
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Figure 1. KASIII initiates the type II fatty acid synthesis (FAS) cycle in bacteria and 
plants. KASIII catalyzes Claisen-like condensation of a starter molecule, an acyl CoA, with 
an extender molecule, typically  malonyl ACP, to give a ketoacyl-ACP intermediate that 
undergoes successive steps of reduction, dehydration and reduction to give a reduced acyl 
ACP. 
CHAPTER I 
GENERAL INTRODUCTION 
 
Introduction to β-Ketoacyl-ACP Synthase III 
Biosynthesis of fatty acids is an essential metabolic process for the generation of 
phospholipids and cellular membranes. Mammalian fatty acid synthesis is catalyzed via a type I 
fatty acid synthase that comprises a multi-modular enzyme complex, which carries out iterative 
steps of the fatty acid synthesis (FAS) cycle. In contrast, in most bacteria and plants, fatty acid 
synthesis proceeds via a type II system that has discrete enzymes for catalyzing each step of 
FAS. The enzyme that initiates as well as acts as a ‘pacemaker’ (i.e. the rate limiting step) of 
type II FAS is β-ketoacyl-acyl carrier protein synthase III (KASIII or FabH) (1,2). It initiates de 
novo fatty acid synthesis via a Claisen-type condensation of an acyl-coenzyme A (or acyl-CoA) 
molecule with malonyl-acyl carrier protein (malonyl-ACP) to produce a β-ketoacyl-ACP (figure 
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Figure 2. KASIII determines the fatty acid profile of an organism. The ‘R’ group of 
the starter molecule, acyl CoA, could be straight-chain, branched-chain, cyclic, long-
chain or halogenated, resulting in different types of fatty acid products. 
1) intermediate, that undergoes iterative fatty acid synthesis steps of reduction, dehydration, 
reduction and elongation until a saturated fatty acyl-ACP of typically 14-18 carbons is formed 
(3).   
Depending on the nature of the R group in acyl CoA, KASIII is capable of introducing 
various functionalities into the terminal ω-end (omega end) of the fatty acid molecule (figure 2). 
Therefore, besides initiating fatty acid synthesis, KASIII also determines the fatty acid profile of 
an organism by virtue of its substrate specificity. For example, KASIIIs from Gram-negative 
bacteria such as Escherichia coli  have narrow substrate specificities with preferences for short 
straight chain acyl-CoA primers (acetyl-CoA, propionyl-CoA) (4-8), whereas KASIIIs from 
Gram-positive bacteria, such as Bacillus subtilis (9) or Staphylococcus aureus (10), display 
broad substrate specificities and can use both straight and branched chain acyl-CoAs (e.g. 
isobutyryl-CoA, isovaleryl-CoA), resulting in formation of both straight and branched chain fatty 
acids. In addition to the utilization of straight and branched chain primers, KASIII in several 
bacteria has been shown to utilize long chain acyl primers.  For example, the KASIII from 
Mycobacterium tuberculosis utilizes lauryl CoA resulting in formation of mycolic acids (11).  
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 KASIII has been most extensively studied in E. coli, and has been crystallized both in the 
presence and absence of ligands (12-14) . KASIII crystal structures are available from eight other 
bacterial sources (15-21)and attempts have been made to understand the underlying structural 
basis of their substrate promiscuities (17). However, it yet remains to be understood which 
specific amino acid residues or structural motifs govern KASIII substrate preferences. It has been 
hypothesized that the rotamer conformation of a particular conserved Phe residue (corresponding 
to Phe304 in E. coli KASIII) may be responsible for differences in narrow and broad substrate 
specificity KASIII enzymes (17,18). This hypothesis has not yet been experimentally verified, 
but evidence from sequence alignments of numerous KASIIIs corroborates this theory (17).  
 Thus far, KASIII substrate specificity has been explored with only three classes of acyl-
CoA primers – a) straight chain primers, such as acetyl-CoA, propionyl-CoA, butyryl- or 
hexanoyl-CoA (5,22-24), b) branched chain primers, such as isobutyryl-CoA or isovaleryl-CoA 
(10,22,23), and c) long chain straight primers, such as lauryl-CoA (25). Given the vast diversity 
in KASIII enzymes, it may be possible that KASIII enzymes are capable of utilizing substrates 
other than the three substrate classes listed above. In fact, the presence of unique fatty acids in 
some organisms, such as fatty acids with cyclic groups at their ω-ends in Alicyclobacillus 
acidocaldarius (26), or fatty acids with fluorinated groups at their terminal ω-ends in 
Dichapetalum toxicarium (27), suggests that KASIII in such organisms is capable of utilizing 
unique primers such as cyclic acyl CoA or fluorinated acyl CoAs, thereby incorporating these 
unique functionalities into the ω-end of final fatty acid products. Such KASIIIs have not yet been 
characterized, but these examples illustrate that KASIII enzymes may be capable of condensing 
unique acyl CoA substrates (figure 2), such as cyclic acyl CoA, hydroxylated acyl CoA, aromatic 
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Figure 3. Structural and functional diversity in KASIII enzymes. Co-crystal structures of 
KASIII from E. coli (PDB code – HND), E. faecalis (PDB code – 3IL4), and M. tuberculosis 
(PDB code – 1U6S) are depicted with some of their preferred substrates. 
or even unsaturated acyl CoAs, resulting in novel ω -functionalized fatty acids. This concept 
presents a new direction for research on KASIII enzymes.  
 
Questions being explored in the dissertation 
Given the wide scope of functional divergence displayed by KASIII enzymes, the factors 
that govern KASIII functional promiscuity remain unanswered. Despite the availability of 
several KASIII crystal structures (10,12,28-30) and proposed hypotheses regarding several 
motifs and residues that may affect substrate specificity (17), there is no definite and clear 
understanding of what determines KASIII substrate specificity. Additionally, although KASIII 
enzymes are known to utilize a variety of substrates, specifically straight chain, branched chain 
and long straight chain acyl-CoAs (figure 3), their functionalities with many other acyl-CoA 
substrates (e.g. hydroxylated, cyclic, aromatic or unsaturated acyl-CoAs) have not yet been 
explored. Further investigation in these areas will bridge the gap between KASIII structural and 
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functional information, and will enable development of novel KASIII biocatalysts that could be 
used for synthesizing unique ω-functionalized fatty acids with applications in the bio-based 
chemical industry.  
The goal of this dissertation is two-fold. Firstly, this body of work aims at bridging the 
knowledge gap between the known functional diversity of KASIII enzymes and the structural 
basis for that diversity, and identifying the underlying molecular basis for KASIII substrate 
diversity. Secondly, this research aims to characterize and understand the vast and largely 
unexplored biological diversity of KASIII enzymes, so that ultimately this diversity can be 
exploited to produce novel fatty acids with new functionalities at their ω-ends (e.g. hydroxyl, 
aromatic or cyclic groups).  
 
Dissertation organization 
This dissertation investigates the structure-function relationships of KASIII enzymes, and 
also explores their great functional diversity to identify unique KASIII biocatalysts that can be 
used to synthesize novel fatty acids.  
The dissertation begins in Chapter 1 with a general introduction to KASIII enzymes 
followed by a comprehensive survey of published literature related to KASIII enzyme structure 
and function. 
Chapter 2 presents the determination of specific amino acid residues that govern substrate 
specificity of KASIII enzymes. Biochemical and biophysical approaches (in vitro 
spectrophotometric enzyme activity assay and saturation transfer difference NMR) are applied to 
KASIII enzymes that exhibit narrow (E. coli KASIII) or broad (B. subtilis KASIIIa and 
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KASIIIb) substrate specificities. The experiments were designed and executed by Shivani Garg 
under the supervision of Marna Yandeau-Nelson and Basil Nikolau.  
Chapter 3 builds upon the knowledge gained within chapter 2 and demonstrates how this 
knowledge can be used to predict the functionality of KASIII enzymes. The functionalities of ten 
previously uncharacterized, putative KASIII enzymes are first predicted based on learning from 
previous work described in chapter 1 and our experimental results from chapter 2, and are then 
tested using biochemical and biophysical approaches (in vitro enzyme activity assays and 
thermal shift assays). Within this study, we also determine functional divergence or redundancy 
among KASIII homologs derived from the same bacterial strains. The work in this chapter was 
collaboration between Shivani Garg and Charles Stewart (The Salk Institute for Biological 
Studies).  This work was conducted under the supervision of Marna Yandeau-Nelson and Basil 
Nikolau at ISU, and Joseph Noel at Salk Institute for Biological Studies. Shivani Garg and 
Charles Stewart designed and executed the thermal shift assay experiments at the Salk Institute 
for Biological Studies, and Shivani Garg continued with activity assays and sequence analysis of 
selected KASIII genes at Iowa State University. The journal chapter was prepared by Shivani 
Garg, under the guidance of Marna Yandeau-Nelson and Basil Nikolau. 
After investigating structure-function relationships and exploring the functional diversity 
of KASIII enzymes, Chapter 4, focuses on identifying KASIII enzymes with novel substrate 
specificities. We report an in vivo and an in vitro screen to identify KASIII enzymes that are 
capable of utilizing unusual substrates such as hydroxylated, aromatic or unsaturated acyl-CoAs. 
Discovery of such novel KASIII enzymes paves the way for synthesizing novel functionalized 
fatty acids that can have potential applications in the chemical industry. The work described in 
this chapter was collaboration between Shivani Garg, Huanan Jin (Iowa State University) and 
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Charles Stewart (The Salk Institute for Biological Studies) under the supervision of Marna 
Yandeau-Nelson, Joseph Noel and Basil Nikolau. Experiments were conceived by Shivani Garg 
under the guidance of Marna Yandeau-Nelson and Basil Nikolau. Experiments related to B. 
subtilis deletion mutant and R. rubrum constructs were executed by Huanan Jin. Shivani Garg 
and Charles Stewart executed the thermal shift assays for selected KASIII genes at the Salk 
Institute for Biological Studies. This dissertation chapter was prepared by Shivani Garg, with 
inputs from Huanan Jin, and under the guidance of Marna Yandeau-Nelson and Basil Nikolau. 
Chapter 5 summarizes and synthesizes the new knowledge gained from the research 
presented in this dissertation and discusses the potential impact and future directions emanating 
from this body of research. 
All the chapters in this dissertation were prepared by Shivani Garg, under the guidance 
and supervision from Marna Yandeau-Nelson and Basil Nikolau. 
 
Literature review 
Presented herein is a survey of existing literature describing KASIII enzymes, which 
includes the research previously conducted to both structurally and functionally classify and 
characterize KASIII enzymes from various biological sources.  This includes initial work toward 
elucidating the KASIII reaction mechanism and understanding the role of specific residues in 
determining substrate specificity. 
Classification of KASIII enzymes as thiolases  
KASIII (also termed FabH) enzymes belong to the thiolase superfamily of enzymes, 
which consists of enzymes capable of carrying out Claisen condensation in either a 
decarboxylative or non-decarboxylative manner (31). KASIII is a decarboxylating condensing 
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enzyme and it occurs either as a part of the multi-modular type I fatty acid synthase (in 
mammals, fungi and some bacteria), or as a distinct functional unit in the type II dissociated fatty 
acid synthesis system (in most bacteria and plants).  KASIII differs from the other two KAS 
enzymes of this class, KASI (or FabB) and KASII (or FabF), as it is specific for only acyl-CoA 
primers, which KASIII condenses with malonyl-ACP (4,6). KASI and KASII enzymes use acyl-
ACP primers that are primed by malonyl-ACP, resulting in elongation of products of KASIII and 
formation of long chain fatty acids (3). KAS enzymes are closely related to another class 
comprising highly diverse Polyketide Synthases (PKS) that catalyze synthesis of functionally 
diverse polyketides (32,33).  
Structural and functional characterization of KASIII 
KASIII, a homodimer of molecular weight of approximately 70 kDa, was first identified 
in E. coli in the late 1980s due to the presence of residual condensing activity after inhibiting 
with cerulenin the other two KAS enzymes known at that time (34). Since then, E. coli KASIII 
has been studied extensively; it has been used in drug-design studies as a target for designing 
new antibacterial drugs (35-38), and has been structurally and functionally characterized. E. coli 
KASIII has been crystallized in the presence and absence of ligand by Davies et al., Qiu et al. 
and Gajiwala et al. (12,28,29). In total, 37 crystal structures have been solved from 12 different 
bacterial species, including E. coli, Mycobacterium tuberculosis (20,21,30), Staphylococcus 
aureus (10), Enterococcus faecalis (29) and several more (11,18,39). KASIII has also been 
functionally characterized from several other bacterial, plant and protozoan sources (9,39-45).  
Mechanism of Claisen condensation catalyzed at KASIII active site 
The active site residues and substrate binding pocket are well conserved among KASIIIs 
from different species. Three residues, Cys112, His244 and Asn274, form the catalytic triad in E. 
9 
 
 
coli KASIII and carry out the Claisen condensation of acyl-CoA and malonyl-ACP through two 
half reactions via the ping-pong mechanism (3). Qiu et al. (12) and Davies et al. (28) have 
proposed different chemical mechanisms for the transacylation reaction at the active site citing 
different molecules for enhancing the nucleophilicity of the active site Cys112. Summarized 
herein is the mechanism proposed by Davies et al., which is supported by crystallographic data 
(a modified representation of the mechanism by Davies et al. is shown in figure 4) –  
 First half reaction: Acyl-CoA: enzyme transacylation – The first step is the transfer and 
covalent linkage of the acyl group from the acyl-CoA primer to the Cys112 residue of KASIII. 
As per Davies et al., the thiol group of Cys112 is deprotonated by the dipole effect of the α-helix 
in which it is located. The resulting nucleophilic thiolate ion on Cys112 attacks acyl-CoA and 
forms a thioester with the acyl group, with the release of CoA-SH. 
 
Figure 4. Proposed 
reaction mechanism of E. 
coli KASIII. In the first step 
(transacylation), the acetyl 
group is transferred from 
acetyl-CoA to the Cys112 of 
the enzyme, with the 
concomitant release of 
CoASH. In the second step 
(decarboxylation), malonyl-
ACP is decarboxylated and 
the resulting carbanion on its 
α-carbon acts as a 
nucleophile and attacks the 
carbonyl of the acetate 
bound to Cys112. The other 
two active site residues, 
His244 and Asn274, 
stabilize the transition state, 
which subsequently breaks 
down to yield acetoacetyl-
ACP. 
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Second half reaction: Malonyl-ACP decarboxylation – As malonyl-ACP enters the active 
site, it is in an ionized state and its decarboxylation is aided by Phe205. After decarboxylation, 
the resulting negative charge on the thioester carbonyl of malonyl-ACP is stabilized by His244 
and Asn274. A carbanion is formed on the α-carbon of malonyl-ACP that attacks the acetate 
bound to Cys112. The tetrahedral transition state is stabilized by an oxyanion hole formed by 
Cys112 and Gly306, which eventually breaks down to yield the product, 3-ketoacyl ACP. 
Mutagenesis studies to determine the roles of active site residues 
The roles of the conserved active site residues C112, H244 and N274 in E. coli KASIII 
were confirmed by Davies et al. (28) by site-directed mutagenesis of these residues to generate 
C112S, H244A and N274A active site mutants. The mutants showed significantly decreased 
condensation activity as compared to the wild-type; therefore activity was assessed for each of 
the transacylation and decarboxylation half-reactions to determine the role of each residue in the 
reaction mechanism. It was found that the C112S mutant could not carry out the transacylation; 
however it had a very high decarboxylation activity. In contrast, the H244A and N274A mutants 
could each carry out the transacylation reaction but lost their decarboxylation activities. These 
experiments indicate that C112 was important for transacylation while H244 and N274 played a 
role in decarboxylation of malonyl-ACP. 
Almost at the same time as the Davies study, Smirnova and Reynolds (46) studied the 
KASIII from Streptomyces glaucescens, which makes both branched chain fatty acids (BCFA) 
and straight chain fatty acids (SCFA). Active site residue C122, which is important for 
transacylation, was mutated to C122A, C122Q and C122S. The C112Q mutant was found to 
have lost its transacylation ability and could only catalyze decarboxylation of malonyl-ACP, 
which led to the formation of acetyl-ACP. The mutants were expressed in S. glaucescens and 
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fatty acid profiles of the transformants were studied. The SCFA production in the C122Q mutant 
increased by 500% as compared to the wild-type, indicating an alternative pathway for the 
production of SCFA via an acetyl-ACP intermediate. In another study, Brown et al. (47) probed 
the role of certain key residues in the KASIII from Mycobacterium tuberculosis (mtFabH) by 
site-directed mutagenesis. Three sets of residues were mutated and effects of these mutations on 
the half-reactions and overall condensation reaction of mtFabH were studied. Mutations to the 
putative catalytic residues (i.e., C122A, H258A and N289A) decreased the condensation activity, 
indicating their importance in catalysis. Consistent with the earlier studies on E. coli KASIII, 
C122 was found to be important for transacylation while H258 and N289 were found to be 
critical for decarboxylation. The second set of mutations consisted of residues considered 
important in acyl-CoA binding (i.e., W42A, R46A and R161A). Interestingly, the R46A 
mutation indicated that R46 was more important for ACP binding rather than acyl-CoA binding.  
Another interesting observation reported in this study was the presence of conserved water 
molecules close to the active site, which suggested that these water molecules could be playing a 
role in deprotonation of Cys122. 
Substrate diversity among KASIII enzymes 
KASIII enzymes exhibit diverse substrate specificities. For example, KASIIIs from 
Gram-negative organisms (e.g. E. coli)  are highly selective for acetyl-CoA and can also utilize 
propionyl-CoA (4), whereas KASIIIs from Gram-positive organisms, such as Bacillus subtilis 
(9), Streptomyces glaucescens (40), Staphylococcus aureus (10) and Enterococcus faecalis (29), 
show broad substrate specificities and can accept both straight chain and branched chain primers, 
with a higher selectivity for the latter. There are some exceptions to this apparent rule, as certain 
Gram-negative organisms such as Thermus thermophilus and Bacteroides vulgatus (48) produce 
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BCFAs, which indicates that KASIII in such organisms may prefer both straight and branched 
chain primers. 
Earlier studies have attempted to understand whether the fatty acid profile of an organism 
is determined by the substrate specificity of KASIII or by the availability of appropriate initiating 
primers in the host organism. Choi et al. (9) isolated KASIII isozymes from B. subtilis 
(bsKASIIIa and bsKASIIIb), expressed these in E. coli and reported formation of BCFAs in 
these engineered E. coli strains. Fatty acid synthesis was reconstituted in vitro using a specific 
KASIII (E. coli ecKASIII or B. subtilis bsKASIIIa or bsKASIIIb) along with enzymes from E. 
coli that participate in the fatty acid synthesis pathway (FabD, FabG, FabI, FabZ or FabA 
enzymes). In the presence of isobutyryl-CoA, B. subtilis KASIIIa and KASIIIb catalyzed the 
production of BCFAs, which demonstrated that each enzyme from E. coli was capable of acting 
on branched-chain intermediates.  In contrast, when KASIII from E. coli was added to the in 
vitro system for fatty acid synthesis, BCFA production was not detected.  Taken together, these 
experiments suggested that KASIII from E. coli is the only enzyme in the E. coli fatty acid 
synthesis pathway that is incapable of utilizing branched chain primers, whereas other enzymes 
of the pathway could process branched chain primers. Thus, it was concluded that the fatty acid 
profiles observed in B. subtilis and E. coli (i.e. branched vs. straight-chain fatty acids) are 
determined by the substrate preference of their respective KASIII enzymes. 
However, the production of BCFAs via a reconstituted in vitro E. coli fatty acid synthesis 
system reported by Choi and colleagues (9) were not supported by an in vivo study conducted by 
Smirnova and Reynolds (49). Smirnova and Reynolds showed that low levels of BCFAs could 
be produced upon feeding isobutyric acid to both an E. coli strain that expressed the exogenous 
Streptomyces glaucescens KASIII and an E. coli strain that expressed the native E. coli KASIII. 
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They further demonstrated that BCFA production could be increased in each strain by improving 
cellular uptake of isobutyric acid by adjustment of the acid to pH 5. Moreover, using cell-free 
extracts from E. coli, Smirnova and Reynolds demonstrated that addition of isobutyrate resulted 
in production of BCFA, and the further addition of the KASIII from S. glaucescens improved the 
efficiency of BCFA production four-fold.  In conclusion, synthesis of SCFAs as compared to 
BCFAs was 10- to 15-fold higher in-vitro (in the E. coli cell-free extracts supplied with 
appropriate primers) and 200-fold higher in-vivo (in the E. coli strains expressing native E. coli 
KASIII and supplied with appropriate branched chain primers in the medium). Taken together, 
these data suggest that the KASIII from E. coli is capable of processing branched chain primers, 
however the poor transportation of isobutyrate into the E. coli cells results in lower BCFA 
production in-vivo. Nonetheless, this study, for the first time, established that E. coli KASIII is 
capable of processing branched chain primers, however at a lower efficiency compared to 
straight chain primers.  
Hypotheses for the molecular basis of KASIII substrate diversity 
Despite the availability of 37 crystal structures for KASIII from 12 different biological 
sources and functional data for numerous other KASIIIs, the underlying molecular basis of 
KASIII substrate specificity is not clearly understood. This is partly because only a handful of 
KASIIIs are both structurally and functionally characterized (E. coli, S. aureus and M. 
tuberculosis KASIIIs), which allows for the correlation of functional data with structural 
features. However, attempts have been made using superimposition of known KASIII crystal 
structures and multiple sequence alignments to predict residues and motifs affecting KASIII 
substrate preferences.  
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Structural analyses of KASIIIs from E. coli and S. aureus (17) showed that the rotamer 
conformation of a conserved Phe (corresponding to Phe304 of E. coli KASIII) differs between 
KASIIIs with narrow and broad substrate specificities, so it is proposed to affect the shape of the 
active site cleft and thereby, affecting the KASIII substrate preferences. Superposition of KASIII 
crystal structures revealed that this conserved Phe is oriented toward the active site (anti 
conformation) in KASIIIs that exhibit narrow substrate specificity (e.g. E. coli KASIII), whereas 
it faces away from the active site (gauche conformation) in KASIIIs that have broad substrate 
specificity (e.g. S. aureus KASIII) (figure 5). Two residues (corresponding to Val215 and 
Leu220 in E. coli KASIII) positioned in a layer removed from the active site vicinity are thought 
to orient the Phe in a particular rotamer conformation. KASIIIs that have broad substrate 
specificities typically have either a Phe or Trp corresponding to Val 215 in E. coli KASIII and 
Met or Ile that corresponding to the Leu220 of E. coli KASIII. These larger residues (Phe/Trp 
and Met/Ile) are thought to create steric hindrance so that the conserved Phe is forced to orient 
toward the active site, adopting the gauche conformation. This hypothesis has not been verified 
experimentally; its experimental validation may lead to of the discovery of the molecular basis 
 
for KASIII substrate specificity.  
Figure 5.  Different rotamer conformations of 
the conserved Phe residue in KASIIIs with 
narrow vs. broad substrate specificities. The 
conserved Phe adopts two different rotamer 
conformations – an anti rotamer in KASIIIs that 
exhibit narrow substrate specificities such as that 
from Gram-negative E. coli (F304 in yellow) and 
gauche rotamer in KASIIIs that exhibit broad 
substrate specificities, such as the KASIII from 
Gram-positive S. aureus (F298 in red). 
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KASIII as a target for antimicrobial drugs and for synthesizing bio-based chemicals 
KASIII is considered a promising target for antibacterial drug design owing to its 
essential role as an initiator and regulator of fatty acid biosynthesis in bacteria. Moreover, the 
active site residues are conserved across various bacterial species but not in mammalian systems, 
which presents an opportunity to block fatty acid synthesis in pathogenic bacteria while not 
impacting this pathway in human patients. Research on KASIII has been driven, in part, by a 
motivation to design novel antibacterial drugs against bacterial pathogens, including S. aureus, 
E. coli (50), Pseudomonas fluorescens (51) and Klebsiella pneumoniae (52). More recently, the 
KASIII from Mycobacterium tuberculosis (53) has received attention because of its potential to 
serve as a target for anti-tubercular drug design. Similarly, the KASIII from the malaria parasite 
Plasmodium falciparum, has become a target for the development of anti-malarial drugs (54,55), 
based on the recent demonstration that it possesses a type II FAS pathway.   
In plants, over-expression of KASIII has been studied in order to increase the seed oil 
content by altering the fatty acid composition (56). 
In addition to understanding the structure-function relationships of KASIII enzymes, 
objective of the research undertaken in this dissertation is to identify and develop novel KASIII 
biocatalysts that can utilize atypical substrates, such as hydroxylated, aromatic, acidic or 
unsaturated acyl-CoAs. Such unique KASIIIs will allow diversification of the fatty acid 
synthesis pathway to produce novel fatty acids with new functionalities at their terminal ω-ends. 
Such functionalized fatty acids can serve as replacements for petroleum based feedstock and can 
have potential applications in the current bio-based chemical industry (57).  
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Significance of this body of work 
Scientific significance 
The primary motivation dissertation research reported herein comes from the lack of 
understanding the structure-function relationships of KASIII and also from the realization that 
such an understanding can enable exquisite control over de-novo fatty acid synthesis. 
Specifically, the understanding of structure-function relationships will be immensely useful for 
designing novel KASIII biocatalysts with altered substrate specificities. Additionally, 
considering that KASIII enzymes exhibit a wide range of substrate specificities, it is important to 
explore the limits to this diversity by testing KASIII functionality with unique acyl-CoA 
substrates (e.g. cyclic-CoAs, hydroxylated-CoAs and unsaturated acyl-CoAs). Characterization 
of KASIIIs that act upon these unique substrates will not only enrich the existing knowledge 
base regarding substrate specificities but will also provide insights into structural diversity of 
these enzymes.  
Industrial significance 
This research was supported by the NSF-funded Engineering Research Center for 
Biorenewable Chemicals (CBiRC), and fits into the core projects of CBiRC with the ultimate 
aim of developing bio-based chemicals by combining biological and chemical catalysis into a 
united platform.  The biological catalysis component is focused on the metabolic engineering of 
the fatty acid synthesis pathway. Because KASIII is a key regulator of this pathway and also a 
determinant of fatty acid type, it is an excellent candidate biocatalyst for introducing novel 
functionalities into the final fatty acid products (57). Novel KASIII enzymes could be used to 
synthesize unique fatty acids, for example fatty acids with terminal hydroxyl, amino or 
halogenated groups that could have applications in the bio-based polymer, surfactant and 
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lubricants industries. Therefore, this research on KASIII enzymes was driven in part by CBiRC’s 
vision to find bio-based chemical replacements for petroleum-based chemicals, and also by the 
fundamental drive to understand the determinants of KASIII substrate specificity, so as to 
establish rules for rational design. 
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Abstract 
In a type II fatty acid synthase (FAS) that typically occurs in bacteria and plants, β-
Ketoacyl-ACP Synthase III (KASIII) catalyzes the initial condensation reaction in this process.  
This enzyme exhibits a broad range of substrate specificities that specifies the chemical structure 
at the -end of the FAS fatty acid product. For example, E. coli KASIII acts on straight chain 
acyl-CoA substrates, whereas the B. subtilis homologs, KASIIIa and KASIIIb, can utilize both 
straight and branched chain acyl-CoA substrates.  The structural basis for this functional 
diversity in KASIII enzymes remains obscure. Based on the hypothesis that the substrate 
specificity of these enzymes is determined by rotamer conformation of a conserved Phe residue 
(Phe-304 in E. coli; Phe-297 in B. subtilis KASIIIa and Phe-310 in KASIIIb), we mutated several 
residues that are located close to this Phe residue that could affect its rotamer conformation. The 
interactions of the mutated enzymes with their acyl-CoA substrates (both straight and branched 
chain) were studied using Saturation Transfer Difference (STD) NMR. STD NMR data indicate 
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that mutations of two residues that impact the rotamer confirmations of this conserved Phe of E. 
coli KASIII, with the equivalent but bulkier residues found in B. subtilis KASIIIa promote both 
straight and branched acyl-CoA substrate binding by E. coli KASIII. Whereas, in corollary 
experiments in which the B. subtilis KASIIIa was mutated at those sites to resemble the E. coli 
KASIII enzyme, the former lost its binding affinity for both straight and branched chain acyl-
CoA substrates. Similar mutations to B. subtilis KASIIIb were severely detrimental to its 
substrate binding capability. Specific catalytic activity measurements revealed partial loss of 
activity of these enzymes, irrespective of increase or decrease in binding of the substrate. These 
data collectively established the essentiality of the conserved Phe (corresponding to Phe304 of E. 
coli KASIII) and the nature of the two residues close to it for KASIII-ligand binding and 
catalysis. Additionally, we identified the epitopes of the straight and branched chain acyl-CoA 
ligands that directly interact with the KASIII enzymes. The binding epitopes were the same in 
both the ligands (specifically terminal adenosine group and the terminal acyl group) suggesting 
that the binding modes of both the ligands are similar. In conclusion, this study has enhanced our 
understanding of KASIII-ligand interactions and has experimentally confirmed the role of three 
residues critical for these interactions. 
 
Introduction 
The fatty acid biosynthesis is a diverse metabolic process that in bacteria and plants is 
initiated by β-Ketoacyl-ACP Synthase III (KASIII or FabH) (1), which catalyzes the initial 
Claisen condensation reaction of the process (2).  Typically this reaction is between a starter 
acyl-CoA substrate and an extender substrate (e.g. malonyl-ACP) to form a β-ketoacyl-ACP 
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intermediate, which is first fully reduced to an acyl-ACP, and then elongated via further cycles 
of condensation and reduction that constitutes fatty acid biosynthesis.  
KASIII has been characterized from several bacterial (3-17), protozoan (18,19) and plant 
species (20-26). Functionally characterized KASIII enzymes exhibit diverse substrate 
specificities, utilizing acyl-CoA substrates ranging from short straight chain acyl-CoAs (e.g. 
acetyl-CoA, propionyl-CoA (6,20,23)), branched chain acyl-CoAs (e.g. isobutyryl-CoA, 
anteisovaleryl-CoA (4,6,10,15,27)) to long chain acyl-CoAs (e.g. lauroyl-CoA, palmitoyl-CoA 
(7,28)).  
By virtue of this diverse substrate specificity of KASIII, this enzyme is thought to 
determine some of the diversity that occurs in fatty acid profiles of different organisms, 
specifically the chemical structure at the -end of the fatty acid products (6,16,17). For example, 
in many Gram-positive bacteria (i.e., Bacillus subtilis, Streptomyces glaucescens, 
Staphylococcus aureus), KASIII can utilize both branched chain and straight chain acyl-CoA 
substrates, resulting in the production of both iso- and anteiso-branched and straight chain fatty 
acids (4,6,17,27).  In contrast, KASIII from many Gram-negative bacteria (e.g., Escherichia coli) 
appears to prefer straight chain acyl-CoA substrates, such as acetyl-CoA, propionyl-CoA, which 
results in the production of straight chain even and odd carbon-numbered fatty acids (6). Based 
on a study showing inability of E. coli KASIII to accept branched chain acyl-CoAs as substrates 
in an in vitro reconstituted fatty acid synthase system, it was proposed that straight chain 
substrate preference of E. coli KASIII was the reason for absence of branched chain fatty acids 
in E. coli (6). However, a subsequent study demonstrated that in the presence of exogenously 
supplied branched chain substrates, E. coli KASIII could produce small amounts of branched 
chain fatty acids in vitro, and lack of branched chain fatty acids in vivo was attributed to 
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unavailability of suitable starting, branched chain acyl-CoA substrates (29).  Another study 
supported the above finding by reporting E. coli KASIII activity with isobutyryl-CoA, albeit this 
activity was ten times lower than that with acetyl-CoA (27).  Regardless of these differences in 
the reported KASIII substrate specificities, these studies demonstrate that functionality can vary 
greatly among KASIII enzymes.  
The E. coli KASIII has been studied most extensively and crystallized in either the 
presence (5,11) or absence of the substrate acetyl-CoA (8,9,16), and also with an indole analogue 
inhibitor (30). Besides E. coli KASIII, crystal structures are also available from eight other 
bacteria including Mycobacterium tuberculosis (28,31-33), Staphylococcus aureus (27) and 
several more (13,16,17). The catalytic triads, consisting of Cys-112, His-244 and Asn-274 of the 
E. coli protein (5,8,11) and the substrate binding pockets are well conserved among KASIIIs 
from different organisms (10,11,16,27). Despite the availability of crystal structures for nine 
KASIII enzymes, the molecular basis for KASIII’s diverse substrate preferences is not clearly 
understood.    
Recently in an attempt to understand underlying structural basis for diverse KASIII 
functionalities, superposition of active site residues from different KASIII crystal structures 
revealed that a particular conserved Phe residue at the base of the active site cleft (Phe-304 in E. 
coli KASIII, and its equivalent Phe in KASIIIs from other sources) exhibits opposite rotamer 
conformations in KASIII from Gram-negative (E. coli) and Gram-positive bacteria 
(Enterococcus faecalis, S. aureus) (16,17). The opposite conformations of this Phe residue in 
Gram-negative and Gram-positive bacteria are hypothesized to confer different substrate 
specificities to KASIII enzymes from the two bacterial classifications (16,17). It’s also been 
proposed that residues positioned a layer distal from the active relative to the substrate-selective 
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Phe residue affect the rotamer orientation of the Phe residue, namely Val-215 and Leu-220 in E. 
coli KASIII (Fig. 1A), and Phe-209 and Met-214 in S. aureus KASIII (16). Underlying rationale 
of this hypothesis is that Gram-positive bacteria, such as S. aureus utilize a bulky residue at the 
position corresponding to Val-215 in E. coli KASIII, forcing the conserved Phe to adopt a rare 
rotamer conformation that forces the phenyl side-chain into the active site (the gauche-rotamer), 
thereby affecting the active site cleft-size, and thus KASIII substrate specificity (16).  
In this study, we sought to experimentally validate this postulate.  Namely, we 
ascertained the role of these proposed more distal residues in defining the functionality of the E. 
coli KASIII, and the two KASIII homologs of B. subtilis (KASIIIa and KASIIIb); these latter 
enzymes share 45% and 38% identity with the E. coli KASIII, respectively (6).  Specifically, we 
mutated the residues proposed to affect the configuration of the substrate-selective Phe residue in 
the E. coli KASIII to make it resemble B. subtilis KASIIIa, and vice-versa to change the KASIIIa 
to make it resemble the E. coli enzyme.  The resulting mutant enzymes were characterized to 
determine whether the mutations affected the predicted alterations in substrate specificity in 
catalysis, and the ability of the enzymes to bind straight versus branched chain acyl-CoA 
substrates using Saturation Transfer Difference NMR (34,35).  
This study provides greater understanding of the structure-function relationship of 
KASIII enzymes in order to structurally predict how different KASIIIs determine substrate 
specificity.  Such predictive modeling of the KASIII enzyme should enable rational engineering 
of novel KASIII-based biocatalysts for production of distinct fatty acids with different -end 
chemistries, which would have a variety of applications, including new bio-based chemical 
molecules (36). 
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Materials and methods 
Tertiary structure prediction of B. subtilis KASIII enzymes 
Tertiary structures of the B. subtilis KASIII homologs (i.e. KASIIIa and KASIIIb) were 
predicted using homology modeling. An NCBI BlastP search against the PDB database was used 
to identify sequences that shared >40% sequence identity with KASIIIa and KASIIIb protein 
sequences. For KASIIIa, this was the S. aureus KASIII (PDB ID – 1ZOW; chain A), showing 
58% sequence identity, followed by Aquifex aeolicus KASIII (PDB ID – 2EBD; chain A) with 
52% sequence identity. We used these latter two KASIII experimentally determined structures as 
the template sequences for KASIIIa, and aligned each of these with the KASIIIa sequence using 
ClustalW alignment software (37). The target-template sequence alignments were used to model 
tertiary structures of KASIIIa using the alignment mode of Swiss Model 
(http://swissmodel.expasy.org) (38-40). The two different models obtained were assessed for 
their quality using Verify3D and Anolea (41,42), and the best model was chosen for further 
analysis. Similar approach was used for predicting tertiary structure of B. subtilis KASIIIb using 
as template sequences the Thermus thermophilus KASIII (PDB ID – 1UB7; chain A) that 
showed maximum sequence identity of 44%, and S. aureus KASIII that shared 42% identity. The 
PDB files of selected models were analyzed using PyMol software (www.pymol.org) (43).  
Gene cloning 
The E. coli fabH gene that encodes KASIII was PCR-amplified from E. coli strain 
MG1655 (E. coli Genetic Stock Center, New Haven, CT), and cloned into pDEST17 vector 
using Gateway cloning (Invitrogen, Carlsbad, CA), resulting in the pDEST_KASIII construct. 
The yhfB and yjaX genes encoding B. subtilis KASIIIa and KASIIIb respectively were PCR-
amplified from B. subtilis strain 168 (Bacillus Genetic Stock Center, Columbus, Ohio). These 
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genes were cloned into pET30a expression vector (Novagen, Merck, Germany) to construct 
pET30_KASIIIa and pET30_KASIIIb, and they were also cloned into the pDEST17 expression 
vector, using Gateway cloning to generate pDEST_KASIIIa and pDEST_KASIIIb. Each 
pDEST17 and pET30a construct carried an N-terminal His-tagged KASIII gene sequences. The 
resulting plasmids were all confirmed by sequencing.  
Expression and purification of recombinant wild-type and mutant KASIII proteins 
E. coli OverExpress
TM
 C41 (Lucigen, Middletown, WI) strain was used for expression of 
KASIII proteins from constructs pDEST_KASIII, pET30_KASIIIa, pET30_KASIIIb, 
pDEST_KASIIIa and pDEST_KASIIIb. The transformants were grown at 37°C in 50 ml Luria-
Bertani medium, supplemented with 100 µg/ml ampicillin (Research Products International 
Corps., Mount Prospect, IL) for pDEST_KASIII, pDEST_KASIIIa and pDEST_KASIIIb or 50 
µg/ml
 
kanamycin (RPI Corps.) for pET30_KASIIIa and pET30_KASIIIb. The cultures were 
induced by addition of IPTG (Gold Biotechnology, Olivette, MO) to a final concentration of 0.4 
mM when the OD600 of the culture was between 0.6-0.8.  After incubation for another 16-18 h at 
25°C, cells were harvested by centrifugation (10,000 X g, 4°C, 10 min). Soluble proteins were 
extracted by first suspending the cell pellet in lysis buffer (0.5 M NaCl, 5 mM imidazole, 20 mM 
Tris-HCl, pH 8.0, 0.1 mg/ml phenylmethylsulfonyl fluoride, 0.1% Triton-X 100), followed by 
sonication (10 s pulses separated by 3 s intervals for a total of 3 min) and centrifugation (10,000 
X g, 4°C, 30 min). The resulting supernatant (soluble protein fraction) was analyzed by SDS-
PAGE. Based on the small-scale expression experiments that optimized the conditions for 
obtaining the highest yield of soluble recombinant KASIII proteins, we used the constructs 
pDEST_KASIII, pET30_KASIIIa and pDEST_KASIIIb for large-scale expression and 
purification of wild-type and mutant proteins. Cultures were grown, induced, harvested and 
30 
 
 
soluble protein was extracted as described in small-scale expression methods. The soluble 
protein fraction was filtered through a 0.45 µ filter (Corning, the Netherlands) and applied to 8 
ml Ni-NTA His-bind resin. After washing the unbound protein with wash buffers I and II (0.5 M 
NaCl, 20 mM Tris-HCl, pH 8.0) supplemented with 20 mM and 40 mM imidazole respectively. 
The proteins of interest were eluted from the column with the same buffer containing 250 mM 
imidazole. The purified His-tagged KASIII protein preparations were dialyzed against sodium 
phosphate buffer, pH 7.4 and concentrated using 10,000 molecular weight cut-off ultrafiltration 
centrifugation filters (Millipore, Billerica, MA) at 4°C. The concentrated proteins were either 
supplemented with 16% glycerol and stored at -80°C or immediately used for 
spectrophotometric activity assays and Saturation Transfer Difference NMR experiments. 
Protein purity was assessed by Coomassie-staining SDS-PAGE gels, which showed presence of 
near-homogenous, pure proteins (greater than 95% purity).  Protein concentrations were 
determined by Bradford’s assay (BioRad, Hercules, CA).  
Site-directed mutagenesis of E. coli and B. subtilis KASIII enzymes 
QuikChange® Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used for 
introducing point mutations in the pDEST_KASIII, pET30_KASIIIa and pDEST_KASIIIb 
constructs. Four mutants were generated from each of these constructs as indicated in Table 1 
using the listed primers and their complements. 
Circular dichroism spectroscopy of KASIII proteins 
All CD spectra of purified KASIII proteins (0.1–0.25 mg/ml in 10mM sodium phosphate 
buffer, pH 7.2) were collected with Jasco J-710 Spectropolarimeter, in a 0.1cm cell at 25°C. Far-
UV spectra were recorded with a bandwidth of 1.0 nm and a time response of 8 s with total of 2 
data accumulations.  
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Purification of recombinant malonyl-CoA ACP transacylase (MCAT or FabD), β-ketoacyl 
ACP reductase (FabG), holo-acyl carrier protein (ACP) 
FabD, FabG and holo-ACP proteins are required for the spectrophotometric assay of 
KASIII, therefore genes encoding these proteins, (fabD, fabG and acpP) cloned in pCA24N 
expression vectors were obtained from National BioResource Project (NIG, Japan) (44). The 
acpP gene was further cloned into pETDUET vector (Novagen, Merck KGaA, Darmstadt, 
Germany) along with the aas gene (obtained from NBRP, Japan in pCA24N vector) that encodes 
for the fusion protein, 2-acylglycerophospho-ethanolamine acyl transferase/acyl-acyl carrier 
protein synthetase. These three recombinant proteins (FabD, FabG and holo-ACP), fused with N-
terminal His-tag, were purified to near-homogeneity using the same procedure as described for 
the purification for KASIII proteins. Purity of these proteins was assessed by SDS-PAGE. 
KASIII activity assays 
 Activity of KASIII enzymes was determined with different acyl-CoA substrates (acetyl-
CoA, isobutyryl-CoA) using an enzyme-coupled spectrophotometric assay.  The assay was 
performed in 96-well plate format with three replicates for each reaction condition.  In a total 
volume of 100 µl for each reaction the mix contained 100 µM holo-ACP, 200 µM malonyl-CoA, 
10 mM DTT, 50 µM acyl-CoA substrate (either acetyl-CoA or isobutyryl-CoA) and 200 µM 
NADPH in 0.1 M sodium phosphate buffer (pH 7.2).  This mix was pre-incubated with 60 µg of 
MCAT (FabD) for two minutes, and the reaction was started by the addition of 30 µg of KAR 
(FabG) and varying concentrations of KASIII enzyme (0.5-15 µg).  The rate of change in 
absorbance at 340 nm, due to the oxidation of NADPH to NADP
+
, in coupling with the reduction 
of 3-ketoacyl-ACP to 3-hydroxy-acyl ACP by KAR (FabG) was recorded using a Biotek multi-
plate reader. 
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Saturation transfer difference NMR experiments 
NMR experiments were performed at 25°C with a Bruker AV700 MHz spectrometer 
equipped with a 5 mm HCN cryoprobe. Samples for STD NMR experiments were prepared in 
0.1 M sodium phosphate buffer (pH 7.2) with 5% D2O. The protein/ligand ratio was set as 1:100 
with KASIII concentration in the 20-25 µM range. Saturation was applied as CW pulse with a 
power of 58-60 Hz, with on-resonance pulses at 0.62 ppm and 6.86 ppm for upfield and 
downfield respectively. The off-resonance pulse was applied at 45 ppm, and 3-9-19 
WATERGATE suppression was used with a T1-ρ filter. Saturation time of 5 s with an additional 
delay of 5.1 s was used. For each KASIII enzyme, a set of three replicates were acquired, with 32 
scans in each replicate, for each STD NMR experiment, with acetyl-CoA or isobutyryl-CoA as 
ligands (Sigma-Aldrich, St. Louis, MO). The reference and the saturated spectra were obtained 
in an interleaved manner. Resonance assignments of 1H NMR spectra of free ligands were 
completed using 1D 
1
H and COSY. 
Control experiments were carried out by applying on and off-resonance saturation pulses 
either to the ligand in the absence of protein, or to the ligand in the presence of denatured 
protein. Time dependence of the saturation transfer was calculated by varying the saturation 
times from 0.1ms to 100s, which showed that 5s was sufficient to transfer the saturation from 
protein to the ligand. Topspin (Bruker Biospin Corp., Billerica, MA) was used for processing the 
reference and saturated spectra and integrating areas of the peaks that showed STD effect.  
Relative STD effects (ASTD) were calculated according to the equation ASTD = (Io-Isat)/Io 
where Isat is the signal intensity of the saturated spectrum and Io is the signal intensity of the 
reference spectrum (34). STD amplification factor was calculated according to the equation, 
STDaf = ASTD X molar ligand excess. 
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Competition binding experiments were performed under the conditions described above, 
using the first ligand at a constant concentration of 10mM, and a competing ligand was present at 
molar ratios of 1, 2, 4, 8 and 10-fold higher with respect to the first ligand.  
 
Results 
Differences in active site residues of E. coli and B. subtilis KASIII based on homology 
modeling 
The tertiary structures of B. subtilis KASIII homologs (KASIIIa encoded by yjaX, and 
KASIIIb encoded by yhfB) were predicted via homology modeling using the methods described 
in the Experimental Procedures section. Superposition of the E. coli KASIII crystal structure 
(PDB code 3IL9) with predicted B. subtilis KASIIIa and KASIIIb structures allowed the 
identification of active site cleft residues that have different conformations in KASIII enzymes 
from the two organisms. A previous hypothesis suggests that the rotamer conformation of a 
conserved Phe (Phe-304 in E. coli) may impact substrate specificity of KASIII enzymes (16). In 
accordance with this hypothesis, we observed that while with the E. coli KASIII, this conserved 
Phe-304 residue faces away from the carbonyl group on Cα+1 carbon (i.e., its rotamer is in the 
anti-conformation with respect to the carbonyl group) (Fig. 1A), but in the predicted structure of 
the B. subtilis KASIIIa, Phe-297 faces towards the carbonyl group on Cα+1 carbon (i.e., it exhibits 
gauche-conformation with respect to the carbonyl group). Similarly, in the predicted structure of 
B. subtilis KASIIIb, Phe-310 rotamer is in the gauche-conformation. The conformation of this 
Phe residue correlates with the substrate specificity of the three KASIII enzymes, with the E. coli 
enzyme that shows a narrow substrate specificity having the anti-rotamer, whereas the two B. 
subtilis KASIIIs that have a broader substrate specificity having the gauche-rotamer 
34 
 
 
conformation for this Phe residue.  Consistent with this correlation is the observation that 
KASIIIs of organisms that produce branched chain fatty acids and presumably have a KASIII 
with a broader substrate specificity have bulky residues neighboring this substrate-selective Phe 
residue, and these bulky residues are assumed to force the phenyl side chain of the Phe residue to 
the gauche-rotamer conformation and orient the side chain towards the active site cleft (16,17).  
Homology modeling of the B. subtilis KASIII proteins identified these bulky residues as Phe-208 
and Met-213 of KASIIIa (Fig. 2A), and Trp-221 and Val-226 of KASIIIb, corresponding to the 
smaller residues in E. coli KASIII, i.e. Val-215 and Leu-220. We postulate that these bulkier 
residues in the B. subtilis KASIII enzymes causes the conserved substrate-selective Phe gauche-
rotamer to orient differently from the E. coli KASIII Phe-304’s anti-rotamer, thereby affecting 
the size and hydrophobicity of the active site pockets, and subsequently imparting broader 
substrate specificity to the B. subtilis KASIII enzymes. 
We reasoned therefore that if substrate specificity is governed by the orientation of the 
conserved Phe and its orientation is determined by the residues listed above, we hypothesize that 
E. coli KASIII, when mutated to resemble B. subtilis KASIII at these sites, will have broader 
substrate specificity for both straight and branched chain ligands (Fig. 1B). In contrast, B. subtilis 
KASIIIa and KASIIIb, when mutated to resemble E. coli KASIII at these sites would have 
narrower substrate specificity and be able to bind to only straight chain substrates (Fig. 2B).  To 
verify these hypotheses therefore, we mutated Val-215 and Leu-220 of E. coli KASIII to the 
corresponding residues occurring in B. subtilis KASIIIa, i.e. Phe and Met, respectively (Fig. 1B). 
Two single mutants (V215F and L220M) and one double mutant (V215F_L220M) were 
obtained. Similarly, the homologous residues in B. subtilis KASIIIa were mutated to equivalent 
residues in E. coli KASIII to generate two single mutants (F208V and M213L) and a double 
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mutant (F208V_M213L, Fig. 2B). In B. subtilis KASIIIb, similar set of mutations generated two 
single mutants (W221V and V226L) and a double mutant (W221V_V226L).  
Each of the wild-type and mutated enzymes were purified to near homogeneity with the 
exception of B. subtilis KASIIIb double mutant, which formed inclusion bodies and could not be 
purified.  CD spectra of all purified proteins were obtained to determine if the mutants folded the 
same as the wild-type KASIII proteins or had a different secondary structure folding (Fig. 6). 
Ligand binding epitopes for E. coli and B. subtilis KASIII enzymes 
STD NMR experiments elucidated interactions between purified KASIII enzymes (both 
wild-type and mutated) with a straight chain substrate (acetyl-CoA) and a branched chain 
substrate (isobutyryl-CoA).  These experiments also enabled mapping of binding epitopes on the 
two substrates. Relative saturation transfer to each of the binding epitopes was measured and 
converted to the STD amplification factor (STDaf), which is an indicator of ligand binding (34). 
Ligand epitopes with high STDaf values are concluded to be in close contact with the enzyme 
(34). STD NMR experiments with E. coli KASIII indicate that binding epitopes are quite similar 
in the acetyl-CoA and isobutyryl-CoA ligands irrespective of whether wild-type or mutant 
KASIII proteins were tested. With both the ligands, the HAP proton, positioned at C-2 of the 
adenine ring of CoA, received the maximum saturation transfer (Fig. 3A), indicating that this 
proton is in close contact with the KASIII enzyme. This result is in agreement with previous 
crystallographic data (5,11), which showed the adenine ring of CoA sandwiched between Trp-32 
and Arg-151 of E. coli KASIII. With acetyl-CoA, the second highest saturation was received by 
the terminal proton, HT (Fig. 3A), whereas with isobutyryl-CoA, proton HB, which is located on 
C-2 of the isobutyryl portion of the ligand and is close to the HT protons, received the second 
highest saturation transfer (Fig. 3B). Saturation transfer to all other protons in both acetyl and 
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isobutyryl-CoA was very low, less than 38% relative to HAP whose STDaf is normalized to 100%. 
Also, HAP is on the conserved pantetheine arm in each of the acyl-CoA ligands, whereas HT is on 
the variable acyl end that has been shown to interact with the active site Cys of KASIII 
(specifically, with Cys-112 of E. coli KASIII (11)).  
Similar to the E. coli KASIII, for B. subtilis KASIIIa the binding epitopes of acetyl-CoA 
are the methyl group of the acetyl moiety, carrying HT and the adenine moiety bearing HAP.  
These protons received the largest saturation transfer (Fig. 3D), whereas other protons received 
very little saturation transfer (less than 35% relative to HAP). In contrast, for isobutyryl-CoA the 
HB proton received maximum saturation; HAP, HT have the second and the third highest 
saturation transfer respectively (Fig. 3E). Interestingly, for B. subtilis KASIIIb, binding epitopes 
were slightly different from its homolog KASIIIa and its ortholog, E. coli KASIII. In addition to 
saturation transfer to HT and HAP of acetyl-CoA, and HT, HB and HAP of isobutyryl-CoA, a new 
binding epitope, HR, was identified which received strong saturation transfer in both acetyl and 
isobutyryl-CoA (Fig. 3F, 3G); HR is located on C-5 of the ribose moiety of these coenzyme A 
esters (Fig. 3A). 
With both the E. coli KASIII and B. subtilis KASIIIa, because HT, HAP protons in acetyl-
CoA, and HT, HB and HAP in isobutyryl-CoA received strong saturation transfer, and 
consequently had the highest STDaf, we focused on differences in saturation transfer to these 
protons. As HT is on the acyl end of the ligand, the amount of saturation transferred to it 
indicates the extent of KASIII active site’s interaction with the ligand (acetyl-CoA or isobutyryl-
CoA). In B. subtilis KASIIIb, in addition to HT, HAP in acetyl-CoA and HT, HB and HAP in 
isobutyryl-CoA, we also focused on HR for comparing the effect of mutations on substrate 
binding because it received strong saturation transfer in both acetyl and isobutyryl-CoAs. 
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Val215Phe and Leu220Met mutations of E. coli KASIII enhance binding with branched 
chain acyl-CoA substrate, but decrease catalytic activity 
Wild-type E. coli KASIII showed binding with acetyl-CoA (Fig. 3B) with STDaf values 
of ~5.0 and ~6.0 for the HT and HAP protons respectively.  In contrast, STD NMR of E. coli 
KASIII with isobutyryl-CoA as the ligand resulted in relatively lower saturation transfer, STDaf 
of 2.5 to the HT proton and ~4.0 to the HB proton, indicating lower binding with the branched 
chain ligand (Fig. 3C). The E. coli double mutant V215F_L220M, on the other hand, exhibited 
increased STDaf for HT, HB and HAP as compared to the wild-type enzyme for both acetyl-CoA 
and isobutyryl-CoA. This suggests that the double mutant, which was mutated to resemble the 
broad substrate specificity enzyme B. subtilis KASIIIa, is showing enhanced interactions with 
both straight and branched chain ligands.  
To identify which of the two mutations in the E. coli double mutant had a stronger effect 
on substrate binding, we examined STD amplification for each of the single mutants (i.e., E. coli 
KASIII V215F and E. coli KASIII L220M). As compared to the wild type enzyme the V215F 
mutation resulted in slight increase in STDaf for HT protons of both acetyl-CoA and isobutyryl-
CoA. However, the L220M mutation did not alter STDaf for acetyl-CoA proton HT but 
significantly increased STDaf for HT of isobutyryl-CoA (by ~66%) (Fig 3B, 3C).  These results 
indicate that the substrate binding by the KASIII is primarily affected by Leu-220 and Val-215 
has a lesser effect on substrate binding.  
Enzymological assays of E. coli wild-type and mutant KASIII enzymes showed that both 
individual mutations at Leu-220 and Val-215 reduced catalytic activity of the enzyme (Table 2). 
The double mutant had a decreased specific activity with both acetyl-CoA and isobutyryl-CoA as 
compared to the E. coli wild-type KASIII, whereas the single mutants showed negligible specific 
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activity.  In summary, these two mutations that are proposed to influence the rotamer 
confirmation of the conserved substrate-determining Phe residue (anti rotamer in E. coli KASIII 
and gauche rotamer in B. subtilis KASIIIs as depicted in Fig. 1), increased the binding of both 
branched chain and straight chain acyl-CoA substrates to the E. coli KASIII, but adversely 
affected the catalytic activity of the enzyme.  
Phe208Val and Met213Leu mutations negatively affect substrate binding and catalytic 
activity in B. subtilis KASIIIa 
STD NMR experiments with wild-type B. subtilis KASIIIa establish that the HT protons 
of both acetyl-CoA and isobutyryl-CoA had similar STDaf (1.5), whereas the HAP proton of 
isobutyryl-CoA received ~28% higher saturation as compared to the acetyl-CoA HAP proton of 
acetyl-CoA (Fig. 3D, 3E). The double mutant F208V_M213L, which is mutated to resemble the 
E. coli KASIII at two residues neighboring the proposed substrate-determining Phe-297 (Fig. 2), 
showed decreased binding with acetyl-CoA and isobutyryl-CoA, as evident by significantly 
decreased STDaf for each ligand (Fig. 3D, E). Although, the single mutant B. subtilis KASIIIa 
F208V did not significantly impact binding with acetyl-CoA; for isobutyryl-CoA this mutation 
significantly decreased saturation transfer to the HT and HB protons by ~40% in comparison to 
the wild-type. In the case of the M213L mutant, saturation transfer decreased to both acetyl-CoA 
and isobutyryl-CoA, with 40% decrease in STDaf for HT proton of acetyl-CoA, and 60-70% 
decrease in STDaf for HT and HB protons of isobutyryl-CoA.  
The decreased binding of acetyl-CoA and isobutyryl-CoA ligands by the B. subtilis 
KASIIIa mutants is accompanied by decreases in catalytic activity. Individual mutations of both 
the residues (F208V and M213L) resulted in loss of catalytic activity with acetyl-CoA as the 
substrate, and decreased catalytic activity towards isobutyryl-CoA (Table 2). These data clearly 
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indicate that both M213L and F208V mutations decrease binding and catalytic activity of B. 
subtilis KASIIIa enzyme with both straight and branched chain substrates. However, the M213L 
mutation has a more pronounced negative effect on the binding of substrates by B. subtilis 
KASIIIa, especially with the branched chain substrate (isobutyryl-CoA). Phe-208 also appears to 
influence branched chain substrate binding, but to a lesser extent.  
Trp-221 and Val-226 are critical for substrate recognition and catalytic activity of B. 
subtilis KASIIIb 
The wild-type B. subtilis KASIIIb enzyme exhibits very high STDaf values for both 
acetyl and isobutyryl-CoA, ranging between 5.0 – 10.0, as compared to STDaf values of between 
0.5 – 2.5 for the same ligands with B. subtilis KASIIIa (Fig. 3F, G). This could be either due to 
stronger enzyme-ligand interactions for B. subtilis KASIIIb or high koff rate for the ligands from 
the active site pocket of this enzyme. The double mutant of B. subtilis KASIIIb 
(W221V_V226L), that contains mutations to resemble E. coli KASIII at positions 221 and 226, 
could not be purified due to its poor solubility. The single mutants (B. subtilis KASIIIb W221V 
and B. subtilis KASIIIb V226L) were purified but they did not exhibit efficient saturation 
transfer to either of the ligands. As indicated by the negligible STDaf values, the W221V 
mutation appears to eliminate the interactions with both acetyl-CoA and isobutyryl-CoA, (Fig. 
3F, G), but the V226L mutation, resulted in less severe reduction of the STD amplification 
factors for both substrates.  
Enzymatic assays of the wild-type and mutant B. subtilis KASIIIb enzymes with either 
acetyl-CoA or isobutyryl-CoA, indicated a very high specific activity with isobutyryl-CoA and 
no activity with acetyl-CoA (Table 2). The W221V mutation complete eliminated of activity 
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with isobutyryl-CoA, whereas V226L mutation led to approximately 50% loss of this activity 
with isobutyryl-CoA.  
These observations, along with poor solubility of the B. subtilis KASIIIb double mutant, 
imply that both Trp-221 and Val-226 are important for substrate recognition by B. subtilis 
KASIIIb. Trp-221 residue in particular appears to be critical for binding the substrate and in 
catalytic functionality of B. subtilis KASIIIb. 
The role of the conserved potential substrate-determining Phe of KASIIIs 
The role of the conserved Phe residue that is thought to determine substrate specificity of 
KASIII enzymes was investigated by directly mutating this residue to Ala.  The B. subtilis 
KASIIIb F310A mutant could not be purified owing to poor expression and solubility, but 
mutant proteins were recovered and characterized with the E. coli KASIII and B. subtilis 
KASIIIa.  With the E. coli enzyme the F304A mutation lowers the saturation transfer to the HT 
protons of acetyl-CoA and isobutyryl-CoA by 60% (Fig. 4A, B), and with the B. subtilis enzyme 
the equivalent mutation (F297A) increases the STD amplification factors of protons HT and HAP 
for both acetyl-CoA and isobutyryl-CoA. These mutations eliminate all enzymatic activity of the 
E. coli KASIII (Table 2), but in the case of the B. subtilis KASIIIa, about 25% of the catalytic 
activity with the isobutyryl-CoA substrate is retained, but all activity with acetyl-CoA is 
eliminated (Table 2). 
Competition binding experiments reveal relative affinities of ligands by KASIII enzymes 
Competition binding experiments to determine the relative affinities of the two substrate 
ligands (acetyl-CoA and isobutyryl-CoA) to the KASIII enzymes. The concentration of acetyl-
CoA was kept constant and isobutyryl-CoA was titrated at increasing concentrations, and 
saturation transfer to the both the ligands was assayed to assess if the competing ligand replaced 
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the acetyl-CoA ligand. As evidenced by the fact that 4 times higher concentration of isobutyryl-
CoA is needed to displace acetyl-CoA, this experiment indicates that acetyl-CoA is the preferred 
substrate for E. coli KASIII (Fig. 5A).   
Similar experiments for B. subtilis KASIIIa and B. subtilis KASIIIb where conducted, 
which indicate that isobutyryl-CoA is the preferred substrate for B. subtilis KASIIIa and 
KASIIIb; with both enzymes, a higher STD amplification factor was observed for the HT proton 
of isobutyryl-CoA than that of acetyl-CoA HT (Fig. 5B and 5C).  
 
Discussion 
Key residues that govern substrate binding and catalytic activity of E. coli and B. subtilis 
KASIII enzymes 
Based on crystal structures of several KASIII enzymes from Gram-positive and Gram-
negative bacteria in previous studies, several residues were postulated to be influencing the 
rotamer conformation of a conserved Phe (which is usually anti with respect to the carbonyl 
group on Cα+1 carbon in Gram-negative bacteria’s KASIII, and gauche in Gram-positive 
bacteria’s KASIII), thereby altering the substrate specificities of KASIII enzymes (16,17). In this 
study, effects of mutations of those residues on KASIII substrate binding and catalytic activity 
were studied using STD NMR. Our STD NMR data indicated that in E. coli KASIII, residues 
Val-215 and Leu-220, when mutated to corresponding residues in B. subtilis KASIIIa i.e. Phe 
and Met respectively, result in increased branched chain substrate binding. By posing steric 
hindrance, the new bulky substitutes i.e. Phe and Met could be switching the rotamer 
conformation of the conserved Phe-304 of E. coli KASIII from anti to gauche, thereby 
promoting branched chain substrate binding. However, increased binding did not result in 
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increased catalytic activity with isobutyryl-CoA as evidenced by the specific activity data (Table 
2). This implies that although mutations to E. coli KASIII resulted in higher binding with the 
substrates, but the substrate pocket environment was altered resulting in either poor catalysis of 
the bound substrate or failure to release the final product.  
In case of B. subtilis KASIIIa, Met-213 appeared to have stronger negative effect on both 
branched and straight chain substrate binding as compared to Phe-208 which seemed to affect 
mainly branched chain binding. Specific activity data indicated that both the mutations result in 
loss of activity with straight chain substrate and decrease activity with the branched chain 
substrate.  Binding and activity data in conjunction implies that while both the residues, Met-213 
and Phe-208, are important for catalysis, they have different roles in substrate binding. 
Specifically, while Phe-208 is required for branched chain substrate binding, the Met-213 residue 
is essential for both branched and straight chain substrate binding.  
Insolubility of B. subtilis KASIIIb double mutant, poor saturation transfer and poor 
catalytic activity displayed by its single mutants suggest that both Trp-221 and Val-226 are 
indispensable for the enzyme’s functionality, and of the two residues, Trp-221 seems to 
influence substrate binding and catalytic activity more.  
To determine if the conserved Phe is critical for substrate recognition, we mutated it to 
Ala in all the three wild-type KASIII enzymes. In E. coli KASIII, F304A mutant resulted in 
decreased saturation transfer to both acetyl and isobutyryl-CoA substrates; and also resulted in 
complete loss of catalytic activity, indicating that Phe-304 is required for substrate binding and 
catalysis. Whereas in B. subtilis KASIIIa, F297A mutant enzyme resulted in increased saturation 
transfer for both straight and branched chain ligands. Increase in binding was not accompanied 
by increase in catalysis implying that F297 is required for catalytic activity of B. subtilis 
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KASIIIa. Poor expression and solubility of B. subtilis KASIIIb F310A mutant, which hindered 
its successful purification, affirms the importance of Phe-310 in maintaining this enzyme’s 
functionality.  
Binding mode of straight chain and branched chain ligands appears to be similar 
Binding epitopes of acetyl-CoA (the straight chain ligand) and isobutyryl-CoA (the 
branched chain ligand) were found to be the adenine moiety on the conserved CoA part of the 
ligands, and the terminal methyl groups on the variable acyl ends. Irrespective of the enzyme 
tested, adenine moiety received maximum saturation transfer suggesting that it has the closest 
contact with KASIII enzymes. Crystallographic data from previous studies, showing that ADP 
ring of acetyl-CoA is sandwiched between two conserved KASIII residues (Trp-32 and Arg-151 
of E. coli KASIII) and forms hydrogen bonding with carbonyls of Thr-28 and Arg-151 in E. coli 
KASIII, supports our data (5,11). From our data, similarity observed in the binding epitopes 
implies a similar binding mechanism of branched chain ligand and straight chain ligands to the 
enzyme; wherein coenzyme A tail tethers to the protein via interlocking of adenine moiety with 
the conserved KASIII residues (Trp-32 and Arg-151 in E. coli KASIII (5,11)) leaving rest of the 
pantothenate chain swinging loosely in the CoA tunnel of the enzyme. Lack of saturation transfer 
to the protons of pantothenate chain corroborates this hypothesis, and is consistent with previous 
findings that the pantothenate chain does not make strong contacts with the hydrophobic tunnel 
that leads to the KASIII active site (2). Strong saturation transfer to the terminal methyl groups 
of the ligands is expected as these methyl groups are close to the catalytic triad of KASIII 
enzymes for enabling condensation of acyl group of the ligands with malonyl-ACP.  
A similar binding mode of both the acyl-CoA ligands in which the CoA ring is stacked 
between Trp and Arg of the KASIII enzymes suggests that first the CoA ring binds to the 
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enzyme and possibly induces a conformational change that allows the rest of the pantothenate 
arm to enter the active site tunnel.   
Loss of catalytic activity by the mutants of E. coli and B. subtilis KASIII enzymes 
suggests that the conserved Phe, and the residues neighboring to it either aid in catalysis or aid in 
binding of the second substrate, malonyl-ACP.  
E. coli KASIII shows binding and activity with branched chain acyl-CoA 
Previous studies (6,27,29) have attempted to determine whether the fatty acid profile of 
an organism is determined by the substrate specificity of KASIII or by the availability of 
appropriate priming substrates (straight or branched chain acyl-CoAs) in vivo. As per 
conclusions of one study (6), E. coli KASIII is thought to be incapable of utilizing branched 
chain acyl-CoAs thereby resulting in only straight chain fatty acid production. In contrast, other 
studies (27,29) show that E. coli KASIII is capable of using branched chain primers, though at a 
lower efficiency compared to straight chain primers, suggesting that absence of branched primers 
in vivo hinders branched chain fatty acid production. Our STD NMR and activity assay data 
provides strong evidence that E. coli KASIII is capable of binding and processing isobutyryl-
CoA, however the binding affinity is very low as compared to that for acetyl-CoA as evident in 
competition binding experiments. Additionally, catalytic activity for isobutyryl-CoA is 
approximately 10 times low in comparison to acetyl-CoA, which is comparable to the report 
demonstrating branched chain fatty acids production is 10-15 folds lower than straight chain 
fatty acid production in cell-free extracts of E. coli to which appropriate straight and branched 
chain primers were added (29). An explanation for no production of branched chain fatty acids in 
vivo by E. coli KASIII in a previous study (6) could be low concentration of isobutyryl-CoA than 
what would be physiologically required by E. coli KASIII in vivo. Therefore, based on our 
45 
 
 
results that show that E. coli KASIII can bind (Fig. 3) and catalyze isobutyryl-CoA (Table 2), the 
lack of branched chain fatty acid production in E. coli may be explained by absence or low 
availability of isobutyryl-CoA primers in vivo. 
Functional and structural divergence of B. subtilis KASIII homologs 
B. subtilis has two KASIII homologs and the significance of this KASIII gene 
redundancy has not been identified yet. In our experiments, binding epitopes of B. subtilis 
KASIIIb were found to be slightly different from KASIIIa, which suggests that B. subtilis 
KASIIIa folds quite differently from KASIIIb and is more divergent from its E. coli counterpart.  
KASIIIb has much lower sequence similarity with E. coli KASIII (48%, (6)) as compared to B. 
subtilis KASIIIa, which shares 54% similarity with E. coli KASIII (6). Furthermore, the residues 
that appeared to be critical for substrate recognition in KASIIIb were not exactly equivalent to 
the residues in KASIIIa. In KASIIIa, Met-213 seems to be more important for substrate binding 
whereas in KASIIIb, Trp-221 appears to have major role in substrate binding and this residue 
corresponds to Phe-208 of B. subtilis KASIIIa. All these observations strongly imply that the two 
B. subtilis homologs have diverged evolutionarily to have distinct structures and different 
functionalities that appear to be non-redundant. Inability to purify the F310A and double mutant 
of B. subtilis KASIIIb also indicates that this enzyme is quite different from KASIIIa.  Structural 
analyses of these homologs would provide interesting insights into the structural differences that 
exist. 
To conclude, this study has provided new insights into binding interactions of straight 
and branched chain acyl-CoA substrates with KASIII enzymes, and identified and 
experimentally confirmed the role of key residues that determine the substrate specificity in E. 
coli and B. subtilis KASIII homologs. A deeper understanding of KASIII structure-function 
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relationships can enable rational engineering of novel KASIII biocatalysts with unique substrate 
specificities. These biocatalysts can have potential applications in production of value-added bio-
based chemicals.  
 
Footnotes 
The abbreviations used are: KASIII: β-Ketoacyl ACP Synthase III; STD: Saturation 
Transfer Difference; Phe: Phenylalanine; Val: Valine; Leu: Leucine; Met: Methionine; Trp: 
Tryptophan 
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Table 1. Primers for site-directed mutagenesis of E. coli and B. subtilis KASIII enzymes 
 
Gene Construct Mutation QuikChange Forward Primer (5’-3’) QuikChange Reverse Primer (5’-3’) 
E. coli fabH 
(KASIII) 
pDEST_K
ASIII 
V215F GCAACGAAGTCTTCAAGTTTGCGGT
AACGGAACTG 
CAGTTCCGTTACCGCAAACTTGA
AGACTTCGTTGC 
  L220M TTCAAGGTTGCGGTAACGGAAATG
GCGCACATC 
GATGTGCGCCATTTCCGTTACCG
CAACCTTGAA 
  V215F_L
220M 
GCAACGAAGTCTTCAAGTTTGCGGT
AACGGAACTG 
TTCAAGGTTGCGGTAACGGAAATG
GCGCACATC 
CAGTTCCGTTACCGCAAACTTGA
AGACTTCGTTGC 
GATGTGCGCCATTTCCGTTACCG
CAACCTTGAA 
  F304A GGTTCTGCTTGAAGCCGCTGGCGGT
GGATTCACC 
GGTGAATCCACCGCCAGCGGCTT
CAAGCAGAACC 
B. subtilis yjaX 
(KASIIIa) 
pET30_K
ASIIIa 
F208V GAATGGACGAGAAGTTTTCAAAGT
TGCAGTCCGCC 
GGCGGACTGCAACTTTGAAAACT
TCTCGTCCATTC 
  M213L CAAATTTGCAGTCCGCCAATTGGGA
GAATCATGCG 
CGCATGATTCTCCCAATTGGCGG
ACTGCAAATTTG 
  F208V_M
213L 
GAATGGACGAGAAGTTTTCAAAGT
TGCAGTCCGCC 
CAAAGTTGCAGTCCGCCAATTGGG
AGAATCATGCG 
CGCATGATTCTCCCAATTGGCGG
ACTGCAAATTTG 
CGCATGATTCTCCCAATTGGCGG
ACTGCAACTTTG 
  F297A GGTCGTTATGGTAGGGGCCGGCGG
AGGACTAACA 
TGTTAGTCCTCCGCCGGCCCCTA
CCATAACGACC 
B. subtilis yhfB 
(KASIIIb) 
pDEST_K
ASIIIb 
W221V GCAAAACGGACGCGAGGTATATAA
AGTGGCCGCAAGAACC 
GGTTCTTGCGGCCACTTTATATA
CCTCGCGTCCGTTTTGC 
  V226L GGCCGCAAGAACCCTCCCTGGCGA
ATT 
AATTCGCCAGGGAGGGTTCTTGC
GGCC 
  W221VV
226L 
GCAAAACGGACGCGAGGTATATAA
AGTGGCCGCAAGAACC 
GGCCGCAAGAACCCTCCCTGGCGA
ATT 
GGTTCTTGCGGCCACTTTATATA
CCTCGCGTCCGTTTTGC 
AATTCGCCAGGGAGGGTTCTTGC
GGCC 
  F310A AATCGTTTTGCTTTTCGGGGCTGGC
GGCGGATTAACCTAT 
ATAGGTTAATCCGCCGCCAGCCC
CGAAAAGCAAAACGATT 
4
7
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Table 2. Specific activity (nmol/min/mg) of wild-type and mutant KASIII with straight chain 
(acetyl) and branched chain (isobutyryl) acyl-CoA substrates. 
Enzyme Mutation Acetyl-CoA Isobutyryl-CoA 
E. coli KASIII 
Wild-type 447 ± 68    36 ± 14  
V215F Not detectable Not detectable 
L220M Not detectable Not detectable 
V215F_L220M 221 ± 104    18 ± 5 
F304A Not detectable Not detectable 
B. subtilis KASIIIa 
Wild-type    64 ± 32 205 ± 139 
F208V Not detectable Not detectable 
M213L Not detectable 156 ± 47 
F208V_M213L Not detectable 17 ±  7 
F297A Not detectable 56 ± 28 
B. subtilis KASIIIb 
Wild-type Not detectable 279  ±  8  
W221V Not detectable Not detectable 
V226L Not detectable 134  ±  6  
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Figure 1. Proposed effect of mutations on Phe-304 orientation and on substrate 
specificity in E. coli KASIII. E. coli KASIII active site consists of C112, N274 
and H244 (highlighted in purple) (PDB 3IL9 in (A)). F304 (highlighted in yellow) 
is close to the active site and is proposed to be affecting E. coli KASIII’s substrate 
specificity based on its orientation owing to V215 and L220 in the layer behind it. 
We propose that the mutations L220M and V215F (mutated residues modeled using 
PyMol (B)) will affect the orientation of F304 resulting in broad substrate 
specificity of E. coli KASIII enzyme. 
Figure 2. Proposed effect of mutations on Phe-297 orientation and on substrate 
specificity in B. subtilis KASIIIa’s modeled structure. Residues C122, N267 and 
H237 (predicted structure of B. subtilis KASIIIa using Swiss Model in (A)) are the 
active site residues. F297 has an orientation opposite to that of E. coli KASIII’s 
F304. F297 is proposed to be affecting the enzyme’s substrate specificity based on 
its orientation owing to M213 and F208 in the layer behind it. We hypothesize that 
the mutations M213L and F208V (mutated residues modeled using PyMol (B)) will 
affect the orientation of F297 resulting in narrow substrate specificity of B. subtilis 
KASIIIa enzyme.  
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Figure 3. Effect of mutations on KASIII interaction with straight and branched chain 
acyl-CoA ligands as elucidated by STD NMR data. Protons on the main binding epitopes 
for acetyl and isobutyryl-CoA with KASIII wild-types and mutants are highlighted (A). STD 
amplification factors for protons receiving the maximum saturation transfer is plotted for 
different alleles of E. coli KASIII with acetyl-CoA (B) and isobutyryl-CoA (C); for different 
alleles of B. subtilis KASIIIa with acetyl-CoA (D) and isobutyryl-CoA (E); and for different 
alleles of B. subtilis KASIIIb with acetyl-CoA (E) and isobutyryl-CoA (F). Data points are 
average of three experiments. Each data point is average of three independent experiments. 
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Figure 4. Effect of mutating the conserved Phe to Ala on substrate binding. For E. coli 
KASIII wild-type and F304A mutant, STD amplification factors for HT and HAP protons of 
acetyl and isobutyryl-CoA are shown in (A) and (B). For B. subtilis KASIIIa wild-type and 
F297A mutant, STD amplification factors for HT and HAP protons of acetyl and isobutyryl-
CoA are shown in (C) and (D). 
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Figure 5. Competition binding data for 
E. coli KASIII, B. subtilis KASIIIa and 
KASIIIb. Displacement of one ligand by 
another in the binding pocket of KASIII 
enzyme was observed by competition 
binding experiments for E. coli KASIII 
wild-type (A), B. subtilis KASIIIa wild-
type (B) and B. subtilis KASIIIb wild-
type (C). 
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Figure 6. CD spectra of E. coli KASIII, 
B. subtilis KASIIIa, KASIIIb wild-type 
and mutant proteins. To confirm if the 
mutated proteins were folding the same as 
wild-type, Circular Dichroism spectra 
were obtained for E. coli KASIII wild-
type and mutants (A), B. subtilis KASIIIa 
wild-type and mutants (B), and B. subtilis 
KASIIIb wild-type and mutants (C). 
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Abstract 
β-Ketoacyl-ACP Synthase III (KASIII) initiates type II fatty acid synthesis in bacteria 
and plants, and exhibit diverse substrate specificity in terms of their acyl-CoA substrates. Despite 
the availability of several crystal structures of KASIII from various organisms, the underlying 
molecular basis for the differences in substrate specificity remains unclear. Recent studies have 
hypothesized that a specific conserved Phe residue that lines the active site pocket and the nature 
of two residues behind this residue (corresponding to Phe304, Val215 and Leu220 respectively 
in E. coli KASIII) are responsible for defining the substrate specificity of KASIII enzymes. In 
this study, we used this hypothesis to predict substrate specificities of ten putative KASIII 
enzymes chosen from three bacterial sources that can produce >60% branched chain fatty acids, 
namely Capnocytophaga gingivalis, Legionella pneumophila and Myxococcus xanthus, and 
tested these predictions, and thus the underlying hypothesis via in vitro activity assays and 
fluorescence-based thermal shift assays using different acyl-CoA substrates. Of the ten selected 
enzymes, we identified four that exhibited KASIII catalytic activity, and our data support the 
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hypothesis that the nature of the two residues behind the critical Phe governs the substrate 
specificity of the KASIII enzymes. Several of the selected KASIIIs were paralogs from the same 
bacterial strain but sorted into different sequence-based clades of the KASIII phylogenetic tree. 
We therefore investigated functional differences between these paralogs and developed 
sequence-function correlations for their divergence. We used these correlations to categorize 
KASIII enzymes into four structure-function groups, and identified common features in the 
conserved loops L3 and L9 of each group that may be responsible for the different substrate 
specificities exhibited by these groups. In conclusion, we have developed a structure-function 
framework based on functionality of previously characterized KASIII enzymes, and this 
framework should be useful in predicting catalytic activities based on sequence and structural 
models.  
Introduction 
β-Ketoacyl-ACP Synthase III (FabH) initiates type II fatty acid synthesis in bacteria and 
plants via Claisen condensation of an acyl-CoA starter molecule (e.g. acetyl-CoA) and an 
extender molecule (e.g. malonyl-ACP)  to produce a β-ketoacyl-ACP intermediate (1).  This 
intermediate is fully reduced to acyl-ACP and undergoes iterative chain extension to produce, in 
most organisms, 16- and 18-carbon fatty acids. KASIII enzymes exhibit vast diversity in 
substrate specificities. For example, in Gram-negative bacteria such as Escherichia coli, KASIII 
is highly selective for the straight-chain acyl-CoA (acetyl-CoA) and is therefore considered to 
have narrow substrate specificity (2-5). In contrast, in the Gram-positive bacteria such as 
Bacillus subtilis and Staphylococcus aureus, KASIII can utilize both straight-chain and 
branched-chain acyl-CoAs (e.g., isobutyryl-CoA and isovaleryl-CoA), and thus have broad 
substrate specificities (6-8). Because KASIII functionality varies so widely among organisms, 
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KASIII is  thought to determine the fatty acid profile of an organism (9). For example, in E. coli, 
KASIII is highly selective for straight chain acyl-CoA, therefore it leads to production of straight 
chain fatty acids (10); whereas in B. subtilis and S. aureus, KASIII preference for branched chain 
substrates results in mainly branched chain fatty acid synthesis with small amounts of straight 
chain fatty acids (10). Therefore, depending on the nature of the starter acyl-CoA molecules 
(straight chain, branched chain), KASIII is capable of incorporating different functionalities into 
the terminal ω-end (omega-end) of the growing fatty acid chain. KASIII belongs to the thiolase 
family of condensing enzymes (1) and has been characterized functionally and structurally from 
several bacterial (2,6,7,11-20), protozoan (21,22) and plant (23-29) sources. Of all characterized 
KASIIIs, the KASIII from E. coli is the most extensively studied and well characterized and has 
been crystallized both in the presence and absence of acetyl-CoA and CoA(7,12-14,16). In 
addition to E. coli, KASIII crystal structures are available from eight Gram-negative bacteria, 
including Haemophilus influenzae, Aquifex aeolicus and several others (7,18). Structures are also 
available for KASIIIs from three Gram-positive bacteria (Staphylococcus aureus (7,8) and others 
(7,30)) as well as from the Gram-variable bacterium, Mycobacterium tuberculosis, that makes 
mycolic acids and its KASIII has high preference for lauroyl, palmitoyl-CoA, (31-34). However, 
the structure-function relationship for KASIII is not yet understood. 
In various attempts to understand the underlying basis of KASIII substrate diversity 
(7,30), KASIII structural and sequence information have been mined and several structural 
motifs and residues have been proposed to govern KASIII functionality. A recent study 
identified that the rotamer conformation of a conserved Phe (corresponding to Phe304 of E. coli 
KASIII) is different between KASIIIs exhibiting narrow and broad substrate specificities.  It has 
therefore been proposed that the rotamer conformation of the conserved Phe affects the shape of 
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the active site cleft and thereby affects the substrate preference for KASIII (7). Superposition of 
KASIII crystal structures revealed that this conserved Phe is oriented away from the active site 
(i.e. anti rotamer conformation) in KASIIIs that exhibit narrow substrate specificity (e.g. E. coli 
KASIII), whereas the Phe faces towards the active site (i.e. gauche rotamer conformation) in 
KASIIIs that exhibit broad substrate specificity (e.g. S. aureus KASIII). Two residues 
corresponding to Val215 and Leu220 in E. coli KASIII reside on the α-helix next to the β-sheet 
containing the conserved Phe and are predicted to orient the Phe in a particular rotamer 
conformation (anti vs. gauche). KASIIIs with broad substrate specificities typically have a 
Phe/Trp (corresponding to Val215 of E. coli KASIII) and a Met/Ile (corresponding to Leu220 of 
E. coli KASIII). These bulkier residues (Phe/Trp and Met/Ile) appear to create steric hindrance 
so that Phe is forced to orient toward the active site, adopting a gauche conformation. The nature 
of these two residues and the associated Phe rotamer conformations from the KASIIIs that have 
been characterized to date are consistent with the above stated hypothesis. However, validity of 
this hypothesis for previously uncharacterized KASIIIs remains to be established.   
In the current study, we have applied this hypothesis to predict the functionalities of ten 
uncharacterized putative KASIII enzymes derived from three bacterial strains that produce 
predominantly branched chain fatty acids (Capnocytophaga gingivalis, Legionella pneumophila, 
and Myxococcus xanthus) (35). Using a combination of computational, biochemical and 
biophysical approaches, we have identified functional KASIII enzymes from each of the three 
bacterial strains and have experimentally validated that the conserved Phe residue 
(corresponding to Phe304 in E. coli KASIII) and the two residues behind it (corresponding to 
Val215 and Leu220 in E. coli KASIII) define KASIII substrate specificity.  In addition, we have 
classified KASIIIs into four structure-function groups and have developed a sequence-function 
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correlation based on which functionality and substrate specificities of uncharacterized KASIII 
enzymes can be predicted. We have also demonstrated that KASIIIs from the same organism 
have can exhibit diverse substrate specificities and this functional divergence could explain the 
complex array of fatty acids produced by these organisms.  
 
Materials and Methods 
Gene cloning 
The cDNAs for cgKASIIIa, cgKASIIIb, and cgKASIIIc (NCBI reference sequences -  
WP_002669693, WP_002667978, WP_002669050, respectively) from Capnocytophaga 
gingivalis ATCC 33624;  lpKASIIIa, lpKASIIIb, lpKASIIIc, and lpKASIIId from Legionella 
pneumophila str. Paris (NCBI reference sequences – YP_123672.1, YP_124492, YP_124497, 
YP_123920 respectively); and mxKASIIIa, mxKASIIIb and mxKASIIIc from Myxococcus 
xanthus DK 1622 (NCBI reference sequences – YP_628497.1, YP_635461.1, YP_629114.1 
respectively) were codon-optimized for expression in E. coli, synthesized and cloned into the 
pUC57 vector by GenScript USA Inc. (Piscataway, NJ, USA). The synthesized genes were 
subsequently cloned into the pDEST-17 vector using Gateway Cloning (Invitrogen, Carlsbad, 
CA) according to manufacturer instructions, to generate the pDEST_cgKASIIIa, 
pDEST_cgKASIIIb, pDEST_cgKASIIIc, pDEST_lpKASIIIa, pDEST_lpKASIIIb, 
pDEST_lpKASIIIc, pDEST_lpKASIIId, pDEST_mxKASIIIa, pDEST_mxKASIIIb, and 
pDEST_mxKASIIIc constructs.  
Four pCA24N expression vectors, each encoding an N-terminal His tag and harboring 
fabD (encodes Malonyl CoA: ACP Transacylase; MCAT) , fabG (encodes β-Ketoacyl ACP 
Reductase; KAR), acpP (encodes acyl carrier protein; ACP) and aas (encodes fused 2-
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acylglycerophospho-ethanolamine acyl transferase/acyl-acyl carrier protein synthetase) 
respectively were obtained from the National BioResource Project (NIG, Japan) (36). The acpP 
and aas sequences were subcloned into the pETDUET expression vector (Novagen, Merck 
KGaA, Darmstadt, Germany) to generate pDUET_acpP_aas construct.  
Expression and purification of recombinant KASIII, FabD, FabG and holo-ACP proteins. 
The OverExpress
TM
 C41 (Lucigen, Middletown, WI) E. coli strain was used for 
expression of each KASIII protein from its respective pDEST-17 construct and for the 
expression of MCAT (FabD), KAR (FabG) from pCA24N expression vectors and holo-ACP 
from pDUET expression vector. The transformants were grown at 37°C in 4L Luria-Bertani 
medium, which was  supplemented with 100 µg/ml ampicillin (Research Products International 
Corps., Mount Prospect, IL). The cultures were induced by addition of IPTG (Gold 
Biotechnology, Olivette, MO) to a final concentration of 0.4 mM when the OD600 was between 
0.6-0.8.  After incubation for 16-18 h at 25°C, cells were harvested by centrifugation (10,000 X 
g, 4°C, 10 min). Soluble proteins were extracted by first suspending the cell pellet in lysis buffer 
(0.5 M NaCl, 5 mM imidazole, 20 mM Tris-HCl pH 8.0, 0.1 mg/ml phenylmethylsulfonyl 
fluoride, 0.1% Triton-X 100), followed by sonication (10 s pulses separated by 3 s intervals for a 
total of 3 min) and centrifugation (10,000 X g, 4°C, 30 min). The soluble protein fraction was 
filtered through a 0.45 µ filter (Corning, the Netherlands) and applied to 8 ml Ni-NTA His-bind 
resin. After washing the unbound protein in buffer (0.5M NaCl, 20 mM Tris-HCl, pH 8.0) 
supplemented with either 20 mM (Wash Buffer I) or 40 mM imidazole (Wash Buffer II), the 
proteins of interest were eluted with the same buffer containing 250 mM imidazole (Elution 
Buffer). The purified His-tagged KASIII proteins were concentrated and exchanged into sodium 
phosphate buffer, pH 7.2 at 4°C with Amicon centrifugal devices  (Millipore, Billerica, MA). 
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Protein purity was assessed by Coomassie-staining of SDS-PAGE gels, which showed presence 
of near-homogenous, pure proteins (greater than 95% purity). Protein concentrations were 
determined by Bradford assay (BioRad, Hercules, CA). The concentrated proteins were either 
stored at -80°C or used immediately for biochemical assays.  
Spectrophotometric assay to determine KASIII activity with different substrates. 
Activity of purified recombinant KASIII enzymes incubated with different acyl-CoA 
substrates (acetyl-CoA, propionyl-CoA, isobutyryl-CoA, isovaleryl-CoA (Sigma-Aldrich)) was 
ascertained using a coupled enzymatic assay.  The assay was performed in 96-well plate-format 
with three technical replicates for each reaction condition.  In a total volume of 100 µl per 
reaction, the reaction mix contained 100 µM holo-ACP, 200 µM malonyl-CoA, 10mM DTT, 50 
µM acyl-CoA substrate  and 200 µM NADPH in 0.1 M sodium phosphate buffer (pH 7.2).  This 
reaction mix was pre-incubated with 60 µg of MCAT (FabD) for two minutes, to initiate 
synthesis of malonyl-ACP.  The reaction was started by the addition of 30 µg of KAR (FabG) 
and varying concentrations of KASIII enzyme (0.5-15 µg).  As KASIII condensed acyl CoA and 
malonyl-ACP to form 3-ketoacyl-ACP, KAR (FabG) reduced this ketoacyl-ACP intermediate to 
3-hydroxy-acyl-ACP, with the concomitant oxidation of NADPH to NADP+. Change in 
absorbance of NADPH was recorded at 340 nm using a Synergy 2 Multi-Mode Microplate 
Reader (BioTek, Winooskit, VT). Specific activity was calculated by ascertaining the moles of 
NADP
+
 formed per unit time per µg of KASIII. 
Circular Dichroism (CD) spectroscopy of KASIII proteins. 
All CD spectra of purified KASIII proteins (0.1–0.25 mg/ml in 10 mM sodium phosphate 
buffer, pH 7.2) were collected using a Jasco J-710 Spectropolarimeter, in a 0.1 cm cell at 25°C. 
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Far-UV spectra were recorded with a bandwidth of 1.0 nm and a time response of 8 s with total 
of 2 accumulations of data.  
Thermal Shift assays of KASIII proteins incubated with different acyl CoA substrates. 
Thermal shift assays (37) were performed with a Light Cycler 480 System (Roche 
Applied System) using 20 μl reactions in a 96-well plate format. KASIII protein (2 μM-20 μM) 
was mixed with SYPRO Orange dye (5X – 10X) in 0.1 M sodium phosphate buffer, pH 7.2. 
Various acyl CoA ligands (coenzyme-A, acetyl-CoA, propionyl-CoA, butyryl-CoA, hexanoyl-
CoA, isobutyryl-CoA, isovaleryl-CoA, 3-hydroxybutyryl-CoA, malonyl-CoA, and 
methylmalonyl-CoA) were added in 50-fold excess of the KASIII protein being tested. For 
negative controls, water was used instead of an acyl-CoA ligand. Plates were sealed with an 
optical sealing tape, and then were heated in the Light Cycler 480 instrument from 20 °C to 85 
°C at the rate of x C/min. Melting temperatures for proteins incubated with different ligands were 
calculated using the LightCycler 480 Protein Melt program (Roche Applied Science, Penzberg, 
Germany).  
 
Results 
Sequence alignment-based predictions of substrate specificities of selected KASIIIs    
We rationally selected ten putative KASIII enzymes (cgKASIIIa, cgKASIIIb, cgKASIIIc 
from C. gingivalis; lpKASIIIa, lpKASIIIb, lpKASIIIc, lpKASIIId from L. pneumophila; and 
mxKASIIIa, mxKASIIIb, mxKASIIIc from M. xanthus) from a phylogenetic analysis of KASIIIs 
from diverse sources (38), based on two criteria: 1) the host bacterium is Gram-negative and 
makes 60-85% branched chain fatty acids (BCFA) (35) because so far KASIII that have been 
shown to have broad substrate specificities (i.e., can use both straight and branched chain acyl 
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CoA primers) belong to Gram-positive bacteria that predominantly synthesize BCFA such as B. 
subtilis (6), S. aureus (8), S. pneumoniae (15), S. glaucescens (11) and L. monogenes (20), and 
we wanted to determine if KASIII from Gram-negative bacteria with high BCFA content display 
broad substrate specificities too, and 2) the putative KASIII homologs selected from a single 
bacterial strain must sort into different phylogenetic sub-families (as defined in (38)), which 
would suggest that these homologs may be structurally and functionally distinct (figure 1).  The 
ten selected putative KASIIIs were analyzed for presence of conserved residues in specific 
domains of the protein by aligning their primary sequences with sequences of other KASIIIs that 
have been either functionally or structurally characterized (figure 2).   
The catalytic triad within the active site of KASIII is comprised of the residues, Cys, His 
and Asn. These three residues were strictly conserved in each of the ten candidate KASIIIs with 
the exception of M. xanthus KASIIIa, in which the His and Asn are replaced by Thr and Tyr 
(figure 2) respectively. Conservation of the catalytic triad among the nine remaining enzymes 
suggests that each of these putative KASIIIs belong to the thiolase family of condensing 
enzymes (1).  In addition to the catalytic triad, KASIII enzymes also have specific residues that 
bind to CoA and ACP (12,13,16,39,40) .  These binding residues were found to be conserved in 
only four of the putative KASIIIs, i.e., cgKASIIIa and cgKASIIIb, lpKASIIIa and mxKASIIIc. 
The remaining six enzymes (cgKASIIIc, lpKASIIIb, lpKASIIIc, lpKASIIId, mxKASIIIa and 
mxKASIIIb) show substantial divergence in the residues that are important for CoA and ACP 
binding (figure 2). Specifically, Trp32 and Arg151 of E. coli KASIII are required for stacking of 
the adenine ring of acyl-CoA (12,13,16); however only in cgKASIIIa, cgKASIIIb, lpKASIIIa 
and mxKASIIIc, these residues are strictly conserved. Likewise, the residues that participate in 
ACP binding (39,40) are conserved in cgKASIIIa, cgKASIIIb, lpKASIIIa, mxKASIIIb and 
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mxKASIIIc, whereas the remaining five KASIII enzymes have only 1-2 residues strictly 
conserved out of five residues considered crucial for ACP binding (figure 2).  
In addition to the catalytic site residues and the CoA and ACP binding residues, we also 
examined the conservation of residues proposed to affect KASIII substrate specificity. In a recent 
study, it was proposed that the rotamer conformation of a specific Phe residue (corresponding to 
Phe304 in E. coli KASIII, and we refer to it as the ‘swinging’ Phe) determines the shape of the 
active site cleft, thereby defining KASIII substrate specificity (7). It was proposed that the nature 
of two residues behind this conserved Phe residue (corresponding to Val215 and Leu220 in E. 
coli KASIII) forces the swinging Phe to adopt either an anti conformation (facing away from the 
active site) or a gauche conformation (facing toward the active site) (7). In the KASIII from E. 
coli, which exhibits narrow substrate specificity (i.e. selectivity for straight chain acyl-CoAs) the 
residues, Val215 and Leu220, are thought to force the swinging Phe304 to adopt an anti-rotamer 
conformation. In contrast, in KASIIIs from S. aureus and B. subtilis, which exhibit broad 
substrate specificities (i.e. selectivity for both straight and branched chain acyl-CoAs), a bulky 
residue (e.g. Phe or Trp), corresponding to Val215 of E. coli KASIII, is thought to force the Phe 
to adopt a gauche-rotamer conformation. In most broad substrate specificity KASIIIs that have 
been characterized (such as KASIII from B. subtilis KASIIIa, KASIIIb, S. aureus KASIII, S. 
aureus, S. pneumoniae, L. monogenes), there is a Met or Val corresponding to Leu220 of E. coli 
KASIII (figure 2), which is also thought to be crucial for determining the rotamer conformation 
of the swinging Phe residue.  
In the multiple sequence alignment, we observed that of the ten candidate KASIIIs, three 
enzymes, cgKASIIIa, cgKASIIIc and lpKASIIIa, have the swinging Phe and also Phe/Trp and/or 
Met corresponding to Phe209 and Met214 of the S. aureus KASIII, which exhibits broad 
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substrate specificity (figure 2). We therefore predicted that these three KASIIIs would be able to 
process both straight and branched chain acyl-CoA primers. cgKASIIIb has the swinging Phe, 
but behind this Phe it has Asn and Phe instead of Phe and Met. The effect of these two 
substitutions on substrate selectivity of cgKASIIIb could not be predicted (figure 2). The 
remaining six enzymes, lpKASIIIb, lpKASIIIc, lpKASIIId and mxKASIIIa, mxKASIIIb and 
mxKASIIIc do not have the swinging Phe residue (figure 2), but some of them have a Phe or a 
Met corresponding to Phe209 and Met214 of S. aureus KASIII. To date, no KASIII has been 
characterized that does not have the conserved swinging Phe. Therefore, we could not predict the 
substrate specificity of these six KASIII enzymes.  
We tested our hypothesis on the substrate specificities of these ten putative KASIII 
enzymes using two separate in-vitro biochemical approaches, i.e., fluorescence-based thermal 
shift assays and spectrophotometric enzyme assays.  
Thermal shift assays distinguished between narrow and broad substrate specificity KASIII 
enzymes  
Each of the ten candidate KASIII enzymes was purified to near homogeneity (figure 3) 
and confirmed to be folded using circular dichroism (data not shown).  To assess substrate 
specificities for each KASIII, substrate binding was determined via fluorescence-based thermal 
shift assays (or differential scanning fluorimetry), described in detail elsewhere (37,41). These 
assays measure the change in protein melting temperature (Tm) upon addition of a substrate, 
buffer, salt or other additives using hydrophobic fluorescent dye that binds to the exposed 
hydrophobic regions of the melting protein. Positive shift in Tm indicates binding and 
stabilization by the substrate, whereas negative shift in Tm suggests a destabilizing effect of the 
substrate.  The substrates tested with each KASIII included coenzyme A, straight chain (C2:0, 
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C3:0, C4:0, C6:0), branched chain (i-C4:0, i-C5:0), hydroxylated (3-hydroxybutyryl-CoA) and 
carboxylated (malonyl-CoA, methylmalonyl-CoA) acyl-CoAs. Water was used as a control for 
these experiments.  
For each of the candidate KASIIIs, differences were seen in their inherent Tms in water 
without any ligand (table 1). These melting temperatures were used as the baseline Tms to 
measure the shift in Tm by addition of substrates.  
The cgKASIIIa enzyme was most stabilized by the branched chain substrates, isobutyryl 
and isovaleryl-CoA, which resulted in Tm shifts significantly different from the control and all 
other substrates tested (p-value < 0.05; figure 5A). This suggests that cgKASIIIa most tightly 
binds the branched chain substrates. Short chain substrates (C2:0, C3:0) had a destabilizing 
effect on the protein, which was statistically different (p-value < 0.05) from all other substrates. 
In contrast, C4:0 and C6:0 straight chain substrates stabilized the enzyme to a small extent but 
ΔTm was not statistically significant with respect to the control. For cgKASIIIb, each of the 
straight, branched, hydroxylated or carboxylated substrates were unable to increase Tm of the 
enzyme relative to the control.  In the presence of some substrates (e.g., butyryl-CoA; figure 5A), 
the Tm for cgKASIIIb decreased, which suggests that these particular substrates had a 
destabilizing effect on the protein. Interestingly, cgKASIIIc was stabilized by straight chain acyl-
CoAs (C2:0, C3:0, C4:0 CoAs), branched chain acyl-CoAs (i-C4:0, i-C5:0) and methylmalonyl-
CoA, which showed significant change in Tm relative to the control and other substrates.  The 
degree of stabilization increased progressively with the length of the straight chain acyl-CoA; 
butyryl-CoA showed 1.5- and 1.3-fold increases in ΔTm when compared to acetyl and propionyl-
CoA, respectively. The C6:0 acyl-CoA substrate exceptionally destabilized cgKASIIIc resulting 
in a -20 °C shift in Tm relative to water. In summary, thermal shift assay data clearly showed that 
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cgKASIIIb was not stabilized by any of the substrates tested, but cgKASIIIa was stabilized 
preferentially by branched chain substrates and cgKASIIIc was stabilized by straight, branched 
chain and carboxylated substrates, suggesting divergence in function among the three enzymes.  
Amongst the four KASIIIs from L. pneumophila, lpKASIIIa was the only enzyme that 
could be thermally stabilized in the presence of CoA substrates, whereas the remaining three, 
lpKASIIIb, lpKASIIIc and lpKASIIId, could not be stabilized by any of the substrates tested 
(figure 5B). For lpKASIIIa, straight chain (C3:0, C4:0), branched chain (i-C4:0, i-C5:0) and 
carboxylated acyl-CoAs (malonyl, methylmalonyl-CoA) stabilized the protein and increased the 
Tm by 2-4°C relative to the control (p-value < 0.05). This implies that lpKASIIIa has a broad 
substrate preference. In contrast, the observation that the remaining three lpKASIIIs are 
incapable of binding acyl-CoA substrates is consistent with the observation that these three 
enzymes lack some of the conserved residues important for CoA binding (figure 2).  
In case of M. xanthus, mxKASIIIa was immensely destabilized by most of the CoA 
substrates that were tested, with the exceptions of CoA and 3-hydroxybutyryl-CoA, neither of 
which significantly affected the Tm of the protein (figure 5C). Absence of the catalytic triad in 
this enzyme could explain the observed destabilization by acyl CoA ligands probably because of 
lack of binding of the acyl moieties to the protein. In contrast to mxKASIIIa, mxKASIIIb, 
remained largely unaffected by each substrate (p-value > 0.05 for each substrate compared to 
water), suggesting that it does not have affinity for any of the substrates. This data is supported 
by the fact that mxKASIIIb lacks some of the conserved CoA binding residues (figure 2). 
KASIIIc from M. xanthus was the only enzyme that was stabilized by binding to acyl-CoA 
substrates, specifically straight chain acyl-CoAs (C2:0, C4:0 and C6:0) and malonyl CoA, which 
increased the Tm of mxKASIIIc by 2-4 °C compared to the control (p-value < 0.05). 
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Methylmalonyl-CoA and CoA destabilized mxKASIIIc by 4°C relative to the control. The strong 
destabilization effect of CoA is difficult to explain without a tertiary structure of the protein.  
Functional characterization of the putative enzymes  
After evaluating the substrate preferences of each of the selected KASIIIs over a wide 
range of substrates, we quantified their specific activities using an in vitro spectrophotometric 
enzyme activity assay. CoA substrates included even and odd straight chain (C2:0, C3:0), and 
even and odd iso-branched chain (i-C4:0, i-C5:0) acyl-CoAs, as these are the primers used in 
vivo for de novo even and odd, straight and branched chain fatty acid synthesis in bacteria (10).  
Of the C. gingivalis KASIIIs, the cgKASIIIa enzyme was most active with the branched 
chain acyl-CoAs, isobutyryl-CoA and isovaleryl-CoA, and had little to no activity with the 
straight chain substrates, propionyl-CoA and acetyl-CoA (table 2).  In contrast, cgKASIIIb 
enzyme did not show any activity with straight or branched substrates, which was consistent with 
thermal shift assay data in which no substrates increased its melting temperature (figure 5A). 
Interestingly, cgKASIIIc exhibited at least four-fold higher specific activity with straight chain 
substrates as compared to branched chain substrates. In combination, the substrate binding and 
enzyme activity data clearly highlighted functional differences between the three KASIIIs from 
C. gingivalis.   
Amongst L. pneumophila KASIII enzymes, lpKASIIIa was active with both straight and 
branched chain acyl-CoAs, with a stronger preference for branched chain substrates.  For 
example, lpKASIIIa was eleven-fold more active on isobutyryl-CoA compared to acetyl-CoA 
and three-fold more active as compared to propionyl-CoA (table 2). In contrast, lpKASIIIb, 
lpKASIIIc and lpKASIIId were not active on any of the acyl-CoA substrates that were tested. 
This enzyme activity data is consistent with the thermal shift data where lpKASIIIa was 
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stabilized the most by isobutyryl CoA and lpKASIIIb, lpKASIIIc and lpKASIIId could not be 
thermally stabilized by any of the acyl-CoAs used in this study. For M. xanthus, mxKASIIIa and 
mxKASIIIb did not show enzymatic activity with any of the substrates tested (table 1). This is 
consistent with the results from thermal shift assays where none of the substrates could stabilize 
these two proteins. Moreover, mxKASIIIa lacks the conserved catalytic triad, mxKASIIIb lacks 
the CoA and ACP binding residues and both mxKASIIIa and KASIIIb lack the swinging Phe. In 
contrast, mxKASIIIc contains the conserved catalytic triad and the CoA and ACP binding 
sequences, but lacks the swinging Phe.  Even so, mxKASIIIc displayed enzymatic activity with 
both straight and branched chain substrates, with a preference for straight chain substrates. This 
enzymatic preference for short chains is supported by the thermal shift data, in which straight 
chain substrates induced a higher shift in Tm as compared to branched chain substrates.  
 
Discussion 
Structural divergence among putative KASIII enzymes ensures at least one functional 
KASIII enzyme  
 This study has identified four functional KASIII enzymes, (i.e. C. gingivalis KASIIIa and 
KASIIIc, L. pneumophila KASIIIa and M. xanthus KASIIIc), from ten putative KASIII 
candidates chosen from three diverse bacterial sources. Although some of these putative KASIIIs 
enzyme were derived from the same bacterial strain, each enzyme sorted into a different sub-
family of the KASIII phylogenetic tree (38).  This evolutionary divergence among the sequences 
suggests that the proteins may have different structural features. The current study demonstrated 
that four of these ten proteins are functional KASIII enzymes based on their abilities to bind and 
enzymatically act upon at least one acyl-CoA substrate. Although KASIIIb from C. gingivalis 
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has important conserved features typical of KASIII enzymes (such as Cys-His-Asn catalytic 
triad, CoA and ACP binding residues), it did not show any binding and enzymatic activity with 
the substrates tested in this study. The remaining five KASIIIs in this study (i.e. L. pneumophila 
KASIIIb, KASIIIc and KASIIId, and M. xanthus KASIIIa and KASIIIb) did not show KASIII 
functionality and that can be correlated to absence of at least one of the following conserved 
domains in their primary sequences – 1) catalytic triad (for example, in mxKASIIIa), ii) or the 
CoA binding residues (such as in lpKASIIIb, lpKASIIIc, lpKASIIId, mxKASIIIb), or iii) the 
ACP binding residues (such as in lpKASIIIb, lpKASIIIc, lpKASIIId and mxKASIIIa).  
 In the case of the C. gingivalis KASIIIs, the two functional KASIIIs clearly exhibited 
functional divergence.  For example, cgKASIIIa displayed preference for branched chain 
substrates, whereas cgKASIIIc showed higher specificity towards straight chain substrates over 
branched substrates. These varied functionalities indicate that these enzymes have diverged 
evolutionarily and have developed specialized functions, and at the same time presence of at 
least one KASIII with high specificity for branched chain substrates, i.e. cgKASIIIa, explains 
predominance of branched chain fatty acids in C. gingivalis (>82% BCFA (35)). Typically, 
bacteria have one copy of KASIII gene with so far only one known exception to the rule, i.e. B. 
subtilis, which has two KASIII homologs, bsKASIIIa and bsKASIIIb, that show subtle 
differences in their substrate preferences (6). The bsKASIIIa enzyme displays higher preference 
for anteiso-branched chain substrates whereas bsKASIIIb exhibits preference for iso-branched 
chain substrates (6). Presence of two KASIII homologs in B. subtilis is thought to be correlated 
to modulation of iso- and anteiso- branched chain fatty acid content in response to temperature 
changes (Jin and Nikolau, unpublished data). Presence of two functionally distinct KASIII 
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homologs in C. gingivalis may serve a similar function which can be explored by gene knockout 
studies. 
 In the case of the KASIII homologs from L. pneumophila and M. xanthus, only one 
KASIII-like sequence from each bacterial strain has been confirmed in this study as a functional 
KASIII (i.e. lpKASIIIa and mxKASIIIc), both of which are active on straight and branched chain 
substrates with higher specificity for the former substrates. However, the remaining KASIIIs in 
L. pneumophila and M. xanthus seem to be non-functional with the substrates tested in this study. 
Sorting of these KASIIIs into different sub-families of the KASIII phylogenetic tree (38) 
reinforces our experimental observations that each of these KASIIIs is highly diverse 
functionally. Also, our observation that at least one functional KASIII from each bacterial strain 
is capable of processing branched chain primers is consistent with the accumulation of branched-
chain fatty acids in these bacterial strains, i.e. 62% and 65% BCFA in M. xanthus and L. 
pneumophila respectively (35). 
Classification of KASIII enzymes into four distinct structure-function groups 
 Phylogenetic analysis of KASIII enzymes functionally characterized in this study (i.e. 
cgKASIIIa, cgKASIIIc, lpKASIIIa, mxKASIIIc) and KASIIIs functionally or structurally 
characterized in other studies (6-8,11,12,20,30) suggest that KASIII can be classified into four 
different structure-function groups (groups 1a, 1b, 2 and 3) based on their primary sequence 
similarities (figure 5). Correlations can be drawn between structural and functional features of 
KASIII from these four groups by analyzing in detail the fatty acid profiles of their host bacteria, 
the structural information about the rotamer conformation of the conserved Phe and the observed 
functionalities towards different acyl CoA primers (table 3).   
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 Upon correlating the structural information with the functional data available, it is clear 
that KASIIIs in group 1 exhibit high specificity for straight chain acyl-CoA primers as 
exemplified by E. coli KASIII (2,12,16) (13) and belong to bacteria that make only straight chain 
fatty acids, such as E. coli, Y. pestis and H. influenza (35). This narrow substrate specificity 
towards straight chain acyl CoA correlates with the presence of Val and Leu (corresponding to 
Val215 and Leu220 of E. coli KASIII) in group 1 KASIIIs. Moreover, based on the crystal 
structures available from this group, specifically of E. coli (12,13,16) and H. influenzae KASIIIs 
(7), the conserved Phe in this group adopts an anti-rotamer conformation. This is in sharp 
contrast to group 3 KASIII enzymes that belong to bacteria predominantly synthesizing branched 
chain fatty acids, have bulkier Phe and Met residues (corresponding to Phe209 and Met214 of S. 
aureus KASIII) and exhibit high specificity for branched chain primers. For example KASIIIs 
from B. subtilis (6), S. aureus (8) and Listeria monogenes (20) have been shown to process iso-
butyryl and iso-valeryl-CoA substrates. cgKASIIIa, characterized in this study, also belongs to 
group 3 and its high specificity for branched chain primers is consistent with our prediction 
based on presence of the conserved Phe and the neighboring bulky Phe and Met residues. Crystal 
structures available from group 3 KASIII enzymes, i.e. of T. thermophilus (PDB code: 1UB7), S. 
aureus KASIIIs (7), show the conserved Phe (corresponding to Phe298 in S. aureus KASIII) in 
gauche-rotamer conformation. So, it is reasonable to predict that the remaining KASIII enzymes 
in this group also have the Phe in the same gauche-orientation, and uncharacterized enzymes 
from this group such as B. licheniformis KASIIIa and KASIIIb can be predicted to have high 
specificities for branched chain primers. 
 While KASIII enzymes in groups 1a and 3 show strong trends in their substrate 
preferences and presence of either Val/Leu or Phe/Met close to the conserved Phe, KASIII from 
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groups 1b and 2 do not exhibit a clear pattern in their functional and structural features (table 3). 
Group 1b KASIII enzymes either have the Phe (corresponding to the Phe298 of S. aureus 
KASIII) or a Met (corresponding to the Met214 of S. aureus KASIII) but do not have both the 
residues together. Functional activity data available for lpKASIIIa (characterized in this study) 
and S. pneumoniae KASIII (spKASIII) (15) from group 1b shows that these KASIIIs can utilize 
both straight and branched chain substrates with a higher preference for straight chain substrate. 
Structural information available for E. faecalis KASIII (7) from this group shows that its 
conserved Phe is oriented in gauche-rotamer conformation like the KASIIIS in group 3, but 
functional activity data is needed to further confirm if this enzyme has higher specificity for 
straight chain substrates like lpKASIIIa and spKASIII. Interesting feature of A. aeolicus KASIII 
(aaKASIII; PDB code: 2EBD) from this group is that it lacks the conserved Phe which is thought 
to be a critical residue for defining KASIII substrate specificity. Functional characterization of 
aaKASIII will provide insights into how absence of the conserved Phe influences substrate 
specificity of KASIII.   
 Group 2 KASIII enzymes bear resemblance to group 3 enzymes in terms of presence of 
Phe and Met close to the conserved Phe (table 3). Functional activity data for group 2 KASIIIs 
shows varied functionalities of enzymes of this group. For example, mxKASIIIc, cgKASIIIc, 
characterized in this study, can process both straight and branched chain substrates but have 
higher preference for straight chain substrates. Interesting feature of mxKASIIIc is the lack of 
the conserved Phe but it still shows KASIII functionality. X. oryzae KASIII (xaKASIII), that also 
belongs to this group, also lacks the conserved Phe and has non-conserved residues, Ile and Ala, 
corresponding to Phe209 and Met214 of S. aureus KASIII. xaKASIII has been structurally 
characterized (18) and shows high sequence divergence which raises questions about its 
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functionality as a KASIII enzyme. Functional characterization of both mxKASIIIc and xaKASIII 
will be insightful as both of these proteins lack the conserved Phe. This group also contains 
unique KASIII enzymes that can process long chain acyl-CoA substrates, i.e. M. tuberculosis 
and M. luteus KASIIIs (30,32,42). S. glaucescens KASIII, which shows high sequence identity 
to M. tuberculosis and M. luteus KASIII, and also has a Thr instead of Phe87 of E. coli KASIII, 
could also be capable of utilizing long chain acyl-CoA substrates. Overall, KASIII from this 
group show diversity in their substrate preferences. Identification and characterization of 
additional KASIIIs that belong to this group will help in defining the characteristic features of 
the group.   
Other residues affecting KASIII substrate specificity  
 In addition to the conserved Phe (corresponding to Phe298 of S. aureus KASIII) which is 
thought to determine the shape of the active site cleft (7), there may be other residues that differ 
in KASIIIs from different groups and contribute to their substrate preferences. Previously, length 
of loop L9 and loop-loop interactions at the KASIII dimer interface (specifically between loop 
L9-L9’ and loop L9-L3’) have been suggested to be involved in determining KASIII substrate 
selectivity (43). Phe87’ from loop L3 and Arg196’ from loop L9 of E. coli KASIII extend from 
one sub-unit of the KASIII dimer into the other sub-unit, and are thought to have a role in 
defining KASIII substrate specificity (12,13,16).  We, therefore, compared the loops L3 and L9 
of the KASIIIs from the four phylogenetic groups and observed similarities and differences 
among groups which can be correlated to their observed functional differences (figure 6). For 
example, loop L3 of group 1a KASIII enzymes is different at three positions (corresponding to 
Thr81, Thr84 and Ser89 of E. coli KASIII) from the rest of the groups. Groups 1b, 2 and some 
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members of group 3 have a conserved Pro and Asp corresponding to positions 83, 84 of E. coli 
KASIII which have Ala and Thr respectively.   
 The Phe87 of E. coli KASIII is conserved in other group 1a enzymes, in some of the 
group 1b and in all of the group 3 members except for cgKASIIIa. Group 2 shows divergence 
corresponding to the Phe87 of E. coli KASIII, the classical examples of this group being M. 
tuberculosis, M. luteus KASIIIs that have a smaller Thr enabling selectivity for longer chain acyl 
CoAs (31,32,34). Presence of Thr in S. glaucescens at this position suggests that this enzyme 
may also be capable of processing long chain acyl-CoAs; a proposition which needs to be 
validated experimentally. Saturation point mutagenesis of Phe87 in E. coli KASIII in a previous 
report showed that substitution to Ile and Val resulted in activity towards C6:0 acyl-CoA 
substrates in vivo (44). mxKASIIIc, which has Ile in place of Phe87, shows binding with 
hexanoyl-CoA in our thermal binding assays consistent with the results of the previous report, 
but cgKASIIIc, which has Leu in place of Phe87, does not show binding with hexanoyl-CoA 
suggesting there may be other residues hindering binding of C6:0 acyl-CoA chains. 
Loop L9 also shows marked differences at specific positions. For example, group 1a 
members have bulky Tyr/Phe corresponding to Tyr185 of E. coli KASIII, whereas group 3 
members have a smaller residue, Gly at this position. However, group 3 members possess a 
bulky Tyr corresponding to Thr190 of E. coli KASIII. Additionally, Arg196 of E. coli KASIII is 
conserved amongst group 1a only and is not found in other groups suggesting a role of this Arg 
in limiting substrate specificity of group 1a members to short straight chain-acyl CoAs. In the 
same way, group 3 has Asn and Arg corresponding to Ala208 and Asn210 of E. coli KASIII 
respectively.  
80 
 
 
From these observed dissimilarities in the loops L3 and L9 of the four groups of KASIII 
enzymes, we can infer that in addition to the conserved Phe (corresponding to the Phe304 of E. 
coli KASIII that adopts different conformations in different KASIIIs (7)), subtle differences in 
the residues lining L3 and L9 loops, that form the KASIII dimer interface, might also be 
responsible for defining the KASIII primer specificity. Strategic mutations in these loop regions 
may enhance our understanding of the role of specific conserved residues in these loops and can 
help us engineer novel KASIII enzymes with unique substrate specificities. Additionally, 
previously uncharacterized KASIII enzymes can be sorted into one of the four phylogenetic 
groups based on their sequence similarities and their functionality can be predicted using the 
structure-function correlations drawn in this study. 
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Table 1. Melting temperatures of each of the ten selected KASIII enzymes in water and in 
the absence of an acyl CoA ligand. These temperatures were used as the baseline 
temperatures against which the effect of adding different CoA substrates was measured.  
 
 
  
 
 
Table 2. Specific activity (nmol/min/mg) of KASIII enzymes from C. gingivalis, L. 
pneumophila, M. xanthus with straight chain (acetyl, propionyl) and branched chain 
(isobutyryl, isovaleryl) acyl-CoA substrates. 
 
Organism Enzyme Acetyl-CoA  Propionyl-
CoA 
Isobutyryl-
CoA 
Isovaleryl-
CoA 
C. gingivalis KASIIIa Not detectable  25 ± 2.7   166.08 ± 82.3  53.5 ± 6.1 
KASIIIb Not detectable Not detectable  Not detectable  Not detectable  
KASIIIc 102.8 ± 5.7 213  ± 70 26 ± 9.1 22 ± 8.3 
      
L. 
pneumophila 
KASIIIa 27.5 ± 9.7 83.2 ± 17 304.9 ± 25.3 90.5 ± 17.7 
KASIIIb Not detectable Not detectable  Not detectable  Not detectable  
KASIIIc Not detectable  Not detectable  Not detectable  Not detectable  
KASIIId Not detectable  Not detectable  Not detectable  Not detectable  
      
M. xanthus KASIIIa Not detectable  Not detectable  Not detectable  Not detectable  
KASIIIb Not detectable  Not detectable  Not detectable  Not detectable  
KASIIIc 45.2 ± 10.0 37.4  ± 12.9 19.8 ± 3.0 7.6 ± 1.8 
Organism Enzyme Melting 
temperature (°C) 
C. gingivalis KASIIIa 68.3 ± 0.17 
KASIIIb 67.8 ± 0.03 
KASIIIc 56.8 ± 0.62 
   
L. 
pneumophila 
KASIIIa 54.0 ± 0.36 
KASIIIb 60.2 ± 0.16 
KASIIIc 62.0 ± 0.03 
KASIIId 65.8 ± 0.18 
   
M. xanthus KASIIIa 64.6 ± 0.13  
KASIIIb 54.5 ± 0.15 
KASIIIc 61.4  ± 0.5 
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Table 3. Comparison of structural and functional features of KASIII identified in this study (marked with *) and 
other studies. Also included are some KASIIIs that are previously uncharacterized. KASIII enzymes are grouped into four 
groups based on the phylogenetic analysis presented in this study (figure 5). Non-functional KASIII proteins identified in this 
study are highlighted in gray. (N.D. – Not determined). 
 
  
8
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Figure 1. Putative KASIII genes chosen for functional characterization.  Ten putative 
KASIII genes were chosen from previously computationally identified 2,308 KASIII 
sequences (38). We selected three KASIII homologs from Capnocytophaga gingivalis 
(cgKASIIIa, cgKASIIIb, cgKASIIIc), four KASIII homologs from Legionella pneumophila 
(lpKASIIIa, lpKASIIIb, lpKASIIIc, lpKASIIId) and three KASIII homologs from 
Myxococcus xanthus (mxKASIIIa, mxKASIIIb, mxKASIIIc) which all sort into different 
sub-families of the KASIII phylogenetic tree. 
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Figure 2. Alignment of conserved residues of the ten putative KASIII enzymes with 
KASIII enzymes from both Gram-negative and Gram-positive bacteria. Seventeen 
conserved residues, grouped into five categories, are aligned for experimentally confirmed 
and putative KASIII enzymes from Gram-negative bacteria (highlighted in blue) and Gram-
positive bacteria (highlighted in green). Branched chain fatty acid content of each bacterium 
is listed and color coded so that darker green color shade indicates higher branched chain 
fatty acid content, and blue indicates very low or no branched chain fatty acids.  
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Figure 2 (contd.). Coloring scheme for residues: Black – residues conserved in KASIIIs 
from both Gram-negative and Gram-positive bacteria, Gray – homologous substitutions for 
the conserved residues, Blue – residues similar to those in E. coli KASIII but not in S. aureus 
KASIII, Green – residues similar to those in S. aureus KASIII but not in E. coli KASIII, 
White – non-conserved residues.  Numbering scheme corresponds to the E. coli KASIII 
residues.  
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Figure 3. Expression and purification of the candidate KASIII proteins. Each of the ten 
putative His-tagged KASIII proteins were purified by Ni-NTA affinity chromatography and 
assessed for homogeneity and purity using Coomassie-stained gels. Panel (A) shows purified 
C. gingivalis KASIIIa, KASIIIb and KASIIIc (1: Protein ladder, 2: Crude extract, 3:  First 
wash, 4: Elution with 80 mM imidazole, 5: Elution with 250 mM imidazole), Panel (B) shows 
purified M. xanthus KASIIIa, KASIIIb and KASIIIc (1: Protein ladder, 2: Crude extract, 3:  
Flow through, 4: First wash with 20 mM imidazole, 5: Second wash with 20 mM imidazole, 6: 
Wash with 40 mM imidazole buffer, 7: Elution with 80 mM imidazole, 8: Second elution with 
80 mM imidazole, 9: Elution with 250 mM imidazole). Panel (C) shows purified L. 
pneumophila KASIIIa, KASIIIb, KASIIIc and KASIIId (1: Protein ladder, 2: Crude extract, 3:  
Flow through, 4: First wash with 20 mM imidazole, 5: Second wash with 20 mM imidazole, 6: 
Wash with 40 mM imidazole buffer, 7: Elution with 80 mM imidazole, 8: Second elution with 
80 mM imidazole, 9: Elution with 250 mM imidazole). 
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Figure 4. Comparison of 
substrate preferences of the 
ten candidate KASIII 
proteins via fluorescence-
based thermal shift assay. 
Change in the melting 
temperature (ΔTm) with 
respect to the baseline Tm in 
water upon adding different 
acyl CoA substrates was 
studied for selected KASIII 
proteins, i.e., C. gingivalis 
KASIIIa, KASIIIb and 
KASIIIc (A), L. pneumophila 
KASIIIa, KASIIIb, KASIIIc 
and KASIIId (B), and M. 
xanthus KASIIIa, KASIIIb 
and KASIIIc (C). Each data 
point represents average of 
four technical replicates. 
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Figure 5. Classification of KASIII enzymes into four distinct structure-
function groups. Phylogenetic tree was created for the functional KASIII 
enzymes identified in this study (marked with *) and other KASIII enzymes for 
which structural data is available (highlighted in green) or functional data is 
available (highlighted in blue) or are still uncharacterized. ClustalW2 Phylogeny 
program was used to create the tree. 
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Figure 6. Comparison of conserved L3 and L9 loop regions of KASIII from four 
phylogenetic groups. Residues from loops L3 and L9 are aligned for KASIII characterized in 
this study and other studies. Conserved residues in each group are highlighted by a colored 
box around them (red – residues conserved in group 1a, blue – residues conserved in groups 
1b and 2, orange – residues conserved in group 3). Strictly conserved residues among all 
KASIII sequences are highlighted in black; homologous substitutions are highlighted in gray. 
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Abstract 
Most organisms typically synthesize straight chain fatty acids.  A few organisms 
however produce unusual fatty acids that carry chemical functionalities near the ω-end of the 
molecule, for example ω-cyclic, ω-phenylic, ω-branched, or ω-halogenated fatty acids. There 
are two enzymatic determinants that control this ω-group functionality, the availability of 
appropriate acyl-CoA primer for fatty acid synthase, and the substrate specificity of the 
enzyme that initiates fatty acid synthesis, 3-ketoacyl-ACP synthase III (KASIII).  In this 
study, we have biochemically and biophysically characterized unique KASIII enzymes from 
four diverse bacterial sources, C. gingivalis, B. subtilis, T. aquaticus and A. acidocaldarius. 
From this set, we have identified several KASIIIs that possess novel substrate specificities 
towards atypical fatty acid synthesis primers, including hydroxylated (3-hydroxybutyryl-
CoA), unsaturated (crotonyl-CoA) and aromatic (benzoyl-CoA) primers. Additionally, we 
have demonstrated in-vivo production of ω-1 hydroxy-fatty acids in a modified strain of R. 
rubrum, by recombinantly expressing the A. acidocaldarius KASIII, which utilizes 3-
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hydroxybutyryl-CoA. Identification of such unique KASIII enzymes introduces the 
opportunity to synthesize diverse ω-functionalized fatty acids, which can serve as chemical 
intermediates for production of bio-based chemicals. 
 
Introduction 
Fatty acids form an integral component of bacterial and plant cell membranes, and 
their synthesis and nature (straight chain or branched chain) is regulated by a highly 
functionally diverse enzyme, β-ketoacyl acyl carrier protein synthase III (KASIII) (1).  
KASIII initiates type II fatty acid synthesis in bacteria and plants, which involves dissociable 
enzyme units that carry out various steps of fatty acid synthesis. Specifically, KASIII 
catalyzes Claisen condensation by condensing a starter molecule (an acyl-CoA), typically 
acetyl-CoA in case of Escherichia coli, with an extender molecule, malonyl-ACP, to give a 
β-ketoacyl-ACP intermediate that undergoes a series of iterative reactions leading to 
saturated fatty acids that are usually 14-18 carbon long (2).  
KASIII has been characterized from many bacterial (3-17), plant (18-25) and 
protozoan (26,27) sources and several of these characterized KASIII enzymes have been 
crystallized (3-5,8,10,11,13,17,28-32). E. coli KASII is the most extensively characterized 
KASIII, which has been crystallized both in the presence (3,4) and absence of ligands 
(8,11,28), and also with an indole analogue inhibitor (33). Functionally, KASIII exhibits vast 
diversity because it can utilize a variety of substrates. For example, KASIII has been shown 
to utilize straight chain primers (e.g. acetyl-CoA, propionyl-CoA) in Gram-negative bacteria 
like E. coli, which leads to the production of straight chain fatty acids (6,9,34-36).  Several 
Gram-positive bacteria, such as Bacillus subtilis and Staphylococcus aureus, have been 
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shown to utilize medium chain and branched chain primers (e.g. butyryl-CoA, isobutyryl-
CoA, isovaleryl-CoA), resulting in both straight and branched chain fatty acids (5,9,28). The 
KASIII from Mycobacterium tuberculosis is unique in that it can utilize long chain acyl-CoA 
primers (e.g. lauroyl-CoA), and therefore produce very long chain fatty acids, such as 
mycolic acids (10,29,30,32). These collective works demonstrate that KASIII enzymes have 
the ability to incorporate different functionalities into the omega end of the precursor fatty 
acid and thereby can diversify the products of fatty acid pathway.  
Although KASIII enzymes from different organisms have been shown to be active 
with straight, branched and long chain acyl-CoA primers (5,7,9,12,15,35-38), specificity 
toward other acyl-CoAs (e.g. hydroxyl, aromatic, cyclic) have yet to be explored. The 
presence of unusual fatty acids within some plants and bacteria suggest that KASIIIs within 
these organisms are capable of utilizing unusual CoAs.  For example, ω-fluorinated fatty 
acids are found in the toxic plant, Dichapetalum toxicarium (39) and seed oils from Araceae 
sp. (40) are rich in phenyl-terminated fatty acids. The thermophilic bacterium, 
Alicyclobacillus acidocaldarius naturally produces ω-alicyclic fatty acids (41-43) and other 
bacterial strains, including Geobacillus stearothermophilus, Meiothermus ruber (44) and 
Bacillus subtilis (45) have been shown to produce ω-alicyclic fatty acids upon feeding with 
appropriate starter ω-cyclic acids (cyclohexane, cycloheptane). Taken together, these 
observations suggest that the KASIIIs in these organisms are capable of utilizing unusual 
CoA thioesters that have cyclic, fluorinated or phenylic terminal groups. It is tenable to 
hypothesize that such KASIIIs may even be able to accept substrates that do not occur 
naturally in bacteria, such as hydroxylated, aromatic or unsaturated acyl-CoAs.  
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Using both in vivo and in vitro characterization methods, the current study, identified 
four KASIII enzymes that utilize unusual substrates, specifically hydroxylated, unsaturated 
and aromatic acyl-CoAs. A KASIII with specificity toward 3-hydroxy butyryl-CoA was 
selected to demonstrate in vivo production of novel ω-functionalized fatty acids by co-
expressing one of the KASIIIs with enzymes that synthesize its specific substrate. The 
KASIII was co-expressed with the phaA and phaB genes from Rhodospirillum rubrum (46), 
which make hydroxylated acyl-CoA precursors, and the resulting strain produced omega-
branched-hydroxy fatty acids. This study, therefore, unveils the new biocatalytic potential of 
KASIII enzymes and provides proof of concept for the synthesis of omega-functionalized 
fatty acids. Such novel functionalized fatty acids may have myriad applications in a bio-
based chemical industry (47), and could help in replacement of petroleum based feedstock 
for producing commercial chemicals. 
 
Materials and Methods 
Construction of a B. subtilis fabH deletion mutant 
The genes yjaX, which encodes bsKASIIIa, and yhfB, which encodes bsKASIIIb in B. 
subtilis, were deleted using derivatives of the pMUTIN4 vector, pMU4A and pMU4B, 
respectively (48). The pMU4A vector contains two yjaX-derived fragments, one upstream 
and one downstream of the fabH open reading frame (ORF).  The upstream portion (897 bp 
in total) spanned from 860-bp upstream of the bfabHA ORF to 37-bp within this ORF.  The 
downstream fragment spanned from 799-bp downstream to 98-bp within the 3’-end of the 
bfabHA ORF.  These two fragments were initially PCR amplified from B. subtilis str. 168 
((Bacillus Genetic Stock Center, Columbus, Ohio)) with the primer pairs (Table 1), AUf-PacI 
and AUr-SalI, and ADf-SalI and ADr-PstI, and both fragments were cloned into pMUTIN4, 
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at the PacI and PstI sites, respectively.  The resulting pMU4A vector contains an in-frame 
135 bp-bfabHA fragment that was missing 804-bp from the middle of the ORF; the fact that 
this deletion allele carries an in-frame ORF avoids any polar effect on the downstream genes 
of the bfabHA-containing transcription unit.  The vectors pMU4B and pUCB-erm, which 
were used to generate deletion allele for bfabHB, were constructed by an analogous 
procedure, except that the vector pUCB-erm was constructed from plasmid pUC19 and the 
erythromycin-resistant gene erm was inserted between the downstream and upstream DNA 
fragments of the bfabHB ORF.  
Two single deletion strains of B. subtilis, each lacking either bfabHA or bfabHb, were 
generated by homologous recombination via a two-step procedure using the vectors, pMU4A 
and pMU4B, respectively. Briefly, plasmid pMU4A or pMU4B was transformed into the 
wild-type strain B. subtilis str. 168, followed by selection for erythromycin-resistance. The 
recovered integrant colonies were grown in LB liquid medium without erythromycin, and the 
overnight cultures were diluted 1:10
7
, and 100 µl of the diluted culture was plated on LB 
medium with IPTG and X-gal.  Resultant white colonies indicated the loss of the lacZ-
containing pMUTIN4 sequence, which would result in the deletion of the appropriate 
KASIII-coding gene.  Deletion mutants were confirmed via PCR amplification across the 
deleted portion of either bfabHA or bfabHB.   
The double deletion mutant strain, ΔbfabHA ΔbfabHB::erm was generated by 
homologous recombination via a one-step procedure. The bfabHB-deletion plasmid, pUCB-
erm was linearized via digestion with EcoRI and subsequently transformed into the mutant 
ΔbfabHA strain.  Resultant ΔbfabHA ΔbfabHB double mutant colonies were selected on 
media containing erythromycin and anteiso-C16:0 fatty acid.  PCR confirmation of the 
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ΔbfabHB and ΔbfabHB::erm alleles were performed using the primer pairs (Table 1), 
lofAf/lofAr and lofBf /lofBr, respectively. 
Complementation of the B. subtilis fabH deletion mutant with recombinant KASIII  
The pUCB-erm-fabH vector was constructed from plasmid pUC19.  The 
erythromycin-resistant gene, erm and the exogenous fabH gene (a KASIII-encoding gene 
from C. gingivalis, A. acidocaldarius or T. aquaticus) under the control of the promoter 
Pspac, were inserted between the downstream and upstream DNA fragments of the 135-bp 
ORF in the ΔbfabHB allele of the ΔbfabHA ΔbfabHB double mutant. Complementation of the 
B. subtilis fabH deletion mutatnt with the recombinant KASIII was checked by growing the 
resultant B. subtilis construct in absence of branched chain fatty acids.  
Fatty acid analysis bacterial strains containing recombinant KASIII genes 
A 0.5 ml aliquot of an overnight B. subtilis culture normalized for equal cell density 
was collected by centrifugation at 13,200×g for 30 seconds.  The cell pellet was suspended in 
50 ml minimal medium or LB rich medium.  Cell cultures were shaken at 250 rpm. Cells 
were collected at late log phase by centrifugation at 5,000×g for 10 minutes.  The collected 
cell pellets were lyophilized and stored at -20 °C until analysis.  Lipids were extracted from 
lyophilized bacterial cell pellets using chloroform/methanol (49) and fatty acids were then 
converted to picolinyl esters (lipidlibrary.aocs.org/ms/ms02/index.htm) (50) or methyl esters 
using methanolic-HCl at 80 °C for 60 minutes (51,52).  The recovered picolinyl esters or 
fatty acid methyl esters were concentrated under a stream of nitrogen gas and analyzed with 
GC-MS interfaced with a Mass Detector 5973 (Agilent Technologies, Santa Clara, CA). The 
double bond positions in unsaturated fatty acids were determined by GC–MS analysis of 
dimethyl disulfide adducts (53).  
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Gene cloning  
The cDNAs for cgKASIIIa, cgKASIIIb, cgKASIIIc (NCBI reference sequences -  
WP_002669693, WP_002667978, WP_002669050, respectively) from Capnocytophaga 
gingivalis ATCC 33624;  aaKASIII from Alicyclobacillus acidocaldarius subsp. 
acidocaldarius DSM 446 (NCBI reference sequence – YP_003183476.1); and taKASIII from 
Thermus aquaticus (NCBI reference sequence – WP_003048115.1) were codon-optimized 
for expression in E. coli, synthesized and cloned into the pUC57 vector by GenScript USA 
Inc. (Piscataway, NJ, USA). The synthesized genes were subsequently cloned into the 
pDEST-17 vector via Gateway Cloning (Invitrogen, Carlsbad, CA) according to 
manufacturer instructions to generate pDEST_cgKASIIIa, pDEST_cgKASIIIb, 
pDEST_cgKASIIIc, pDEST_aaKASIII and pDEST_taKASIII constructs. Each pDEST17 
construct encoded an N-terminal His-tag. The E. coli fabH gene was PCR-amplified from E. 
coli strain MG1655 (E. coli Genetic Stock Center, New Haven, CT), and cloned into 
pDEST17 vector using Gateway cloning (Invitrogen, Carlsbad, CA), resulting in the 
pDEST_ecKASIII construct. The yhfB gene encoding B. subtilis KASIIIb was PCR-
amplified from B. subtilis strain 168 and cloned into the pDEST17 expression vector via 
Gateway cloning methods to generate pDEST_bsKASIIIb. The resulting plasmids were 
confirmed by sequencing.  
pCA24N expression vectors were obtained from the National BioResource Project 
(NIG, Japan) (54) that harbor the fabD, fabG, acpP and aas genes, which encode Malonyl-
CoA: ACP Transacylase (MCAT or FabD), β-Ketoacyl ACP Reductase (KAR or FabG), 
holo-ACP and fused 2-acylglycerophospho-ethanolamine acyl transferase/acyl-acyl carrier 
protein synthetase, respectively. The acpP and aas genes were subsequently cloned together 
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into the pETDUET vector (Novagen, Merck KGaA, Darmstadt, Germany).  Each of these 
constructs encodes an N-terminal His-tag. 
Expression and purification of recombinant KASIIIs, FabD, FabG and holo-ACP 
proteins 
The OverExpress
TM
 C41 (Lucigen, Middletown, WI) strain was used for expression 
of all KASIII proteins from their respective pDEST17 constructs. The transformants were 
grown at 37°C in 4L Luria-Bertani medium, which was supplemented with 100 µg/ml 
ampicillin (Research Products International Corps., Mount Prospect, IL). The cultures were 
induced by addition of IPTG (Gold Biotechnology, Olivette, MO) to a final concentration of 
0.4 mM when the OD600 was between 0.6-0.8.  After incubation for 16-18 h at 25°C, cells 
were harvested by centrifugation (10,000 X g, 4°C, 10 min). Soluble proteins were extracted 
by first suspending the cell pellet in lysis buffer (0.5 M NaCl, 5 mM imidazole, 20 mM Tris-
HCl, pH 8.0, 0.1 mg/ml phenylmethylsulfonyl fluoride, 0.1% Triton-X 100), followed by 
sonication (10 s pulses separated by 3 s intervals for a total of 3 min) and centrifugation 
(10,000 X g, 4°C, 30 min). The soluble protein fraction was filtered through a 0.45 µ filter 
(Corning, the Netherlands) and applied to 8 ml Ni-NTA His-bind resin. After washing the 
unbound protein in buffer (0.5M NaCl, 20 mM Tris-HCl, pH 8.0) supplemented with either 
20 mM (Wash Buffer I) or 40 mM imidazole (Wash Buffer II), the proteins of interest were 
eluted with the same buffer containing 250 mM imidazole (Elution Buffer). The purified His-
tagged KASIII proteins were dialyzed against 0.1 M sodium phosphate buffer, pH 7.2 and 
concentrated using 10,000 molecular weight cut-off ultrafiltration centrifugal filters 
(Millipore, Billerica, MA) at 4°C. The concentrated proteins were stored at -80°C or 
immediately used for spectrophotometric activity assay and thermal shift assays. Protein 
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purity was assessed by Coomassie-staining SDS-PAGE gels, which showed presence of near-
homogenous, pure proteins (greater than 95% purity).  Protein concentrations were 
determined by Bradford’s assay (BioRad, Hercules, CA). The concentrated proteins were 
either stored at -80°C or immediately used for spectrophotometric activity assays and thermal 
shift assays. 
Also, the three recombinant proteins (FabD, FabG and holo-ACP encoding for 
Malonyl-CoA: ACP Transacylase, β-Ketoacyl ACP reductase and holo-ACP) with N-
terminal His-tag were purified to near-homogeneity using the same procedure as described 
for the purification for KASIII proteins. Purity of these proteins was assessed by running an 
SDS-PAGE gel. 
Spectrophotometric assay to determine KASIII activity with different substrates 
The enzymatic activities of the purified recombinant KASIII enzymes were 
ascertained via a coupled enzymatic assay.  Six acyl-CoA substrates were used in this assay, 
acetyl-CoA, hexanoyl-CoA, isobutyryl-CoA, 3-hydroxybutyryl-CoA, crotonyl-CoA and 
benzoyl-CoA (Sigma-Aldrich).  The assay was performed in 96-well plate format with three 
technical replicates for each reaction condition.  In a total volume of 100 µl for each reaction, 
the reaction mix containing 100 µM holo-ACP, 200 µM malonyl-CoA, 10 mM DTT, 50 µM 
acyl-CoA substrate and 200 µM NADPH in 0.1 M sodium phosphate buffer (pH 7.2) was 
pre-incubated with 60 µg of MCAT (FabD) for two minutes to initiate synthesis of malonyl-
ACP.  The reaction was started by the addition of 30 µg of KAR (FabG) and varying 
concentrations of KASIII enzyme (0.5-15 µg).  As KASIII condensed acyl-CoA and 
malonyl-ACP to form 3-ketoacyl-ACP, KAR (FabG) reduced this ketoacyl-ACP 
intermediate to 3-hydroxy-acyl ACP in presence of NADPH. Change in absorbance of 
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NADPH, as it was being consumed by KAR and was being converted to NADP+, was 
recorded at 340 nm using Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooskit, 
VT). Specific activity was calculated by ascertaining the moles of product (NADP
+
) formed 
per unit time per µg of KASIII. 
Circular Dichroism (CD) spectroscopy of KASIII proteins 
All CD spectra of purified KASIII proteins (0.1–0.25 mg/ml in 10 mM sodium 
phosphate buffer, pH 7.2) were collected using a Jasco J-710 Spectropolarimeter, in a 0.1cm 
cell at 25°C. Far-UV spectra were recorded with a bandwidth of 1.0 nm and a time response 
of 8 s with a total of 2 accumulations of data.  
Thermal Shift assays of KASIII proteins incubated with different acyl-CoA substrates 
Thermal shift assays (55,56) were performed with a Light Cycler 480 System (Roche 
Applied System) using 20 μl reactions in a 96-well plate format (56). KASIII protein (2 μM-
20 μM) was mixed with SYPRO Orange dye (5X – 10X) in 0.1 M sodium phosphate buffer, 
pH 7.2. Various acyl-CoA ligands (coenzyme-A, acetyl-CoA, propionyl-CoA, butyryl-CoA, 
hexanoyl-CoA, isobutyryl-CoA, isovaleryl-CoA, 3-hydroxybutyryl-CoA, malonyl-CoA, 
methylmalonyl-CoA, crotonyl-CoA, benzoyl-CoA and phenylacetyl-CoA) were added in 50-
fold excess of the KASIII protein being tested. For negative controls, water was used instead 
of an acyl-CoA ligand. Plates were sealed with an optical sealing tape, and then were heated 
in the Light Cycler 480 instrument from 20 °C to 95 °C at the rate of 1 °C/min. Melting 
temperatures for proteins incubated with different ligands were calculated using the 
LightCycler 480 Protein Melt program (Roche Applied Science, Penzberg, Germany).  
Cloning of A. acidocaldarius KASIII into Rhodospirillum rubrum, and co-expression 
with phaA, phaB genes  
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The A. acidocaldarius KASIII gene was cloned into the phaC2 locus (Aru_2413) in 
the R. rubrum genome via a double crossover recombination event.  The R. rubrum recipient 
strain for this experiment was the phaC triple mutant (ΔphaC1ΔphaC2ΔphaC3) that lacked 
any PhaC activity (46). First, the upstream flanking sequence (922bp) of the R. rubrum 
phaC2 gene was cloned upstream of the A. acidocaldarius KASIII sequence, and this 
chimeric construct was introduced into the E. coli strain, S17-1. Transconjugation was 
induced by overnight co-incubation of the R. rubrum phaC triple mutant 
(ΔphaC1ΔphaC2ΔphaC3) with the S17-1 strain harboring the chimeric construct on a 0.22 
µm filter.  The bacterial mixture was subsequently cultured on minimal medium containing 
25 µg/ml gentamicin for one to two weeks.  The resulting colonies carried the product of a 
single recombination crossover event, which integrates the A. acidocaldarius KASIII gene at 
the phaC2 gene (Aru_2413) locus in the R. rubrum ΔphaC1ΔphaC2ΔphaC3 strain.  These 
colonies were streaked out on another minimal medium containing 25 µg/ml gentamicin for 
colony purification.  The resulting colonies were cultured in SMN rich medium for two to 
three days in the light without gentamicin selection.  Finally, double-crossover events were 
identified via selection on SMN rich medium containing 5% sucrose.  Resultant 
ΔphaC1ΔphaC2ΔphaC3 aaKASIII strains were confirmed via PCR amplification.   
 
Results 
Strategic selection of KASIII genes from diverse bacterial sources  
Six KASIII genes were selected from bacteria that produce high percentages of either 
branched chain fatty acids (either iso- or anteiso-), or ω-cyclic fatty acids, based on the 
hypothesis that the KASIII enzymes from such bacteria will have large enough substrate 
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binding pockets that can accommodate other bulky substrates such as aromatic or 
hydroxylated or unsaturated acyl-CoAs. Specifically, we selected a KASIII gene from the 
acidothermophile, A. acidocaldarius, which synthesizes 59% ω-alicyclic fatty acids and 36% 
branched chain fatty acids (57), and a KASIII gene from the thermophile, T. aquaticus, 
which produces 95% branched chain fatty acids (57).  Three KASIII genes (cgKASIIIa, 
cgKASIIIb, cgKASIIIc) were selected from the bacterium C. gingivalis, which make 84% 
branched chain fatty acids (57).  Finally, the KASIIIb gene from B. subtilis was selected 
based on previous reports that ω-alicyclic fatty acids could be produced by a B. subtilis strain 
that was fed precursor alicyclic carboxylic acids (e.g. cyclobutanecarboxylic acid, 
cyclohexanecarboxylic acid) (45). The KASIII from E. coli (ecKASIII) was selected as a 
control enzyme based on its highly selectivity for acetyl-CoA and its inability to process 
branched-chain substrates (9,34-36,58).  
Whereas the three KASIIIs from C. gingivalis (cgKASIIIa, cgKASIIIb, cgKASIIIc) 
and the B. subtilis KASIIIb (bsKASIIIb) have been functionally characterized ( (9); Chapters 
2 and 3 of this dissertation) with branched and straight-chain substrates, the KASIII proteins 
from A. acidocaldarius (aaKASIII) and T. aquaticus (taKASIII) have not yet been 
characterized.  Bioinformatics analyses of the primary structures of aaKASIII and taKASIII 
revealed that each possesses the catalytic triad composed of Cys, His and Asn (figure 1), 
suggesting that both belong to the family of decarboxylating thiolase enzymes (2).  
A comparative analysis of aaKASIII and taKASIII sequences with other functionally 
characterized KASIII enzymes (figure 1) showed that each has the conserved CoA and ACP 
binding residues.  Both aaKASIII and taKASIII also have the conserved Phe (figure 1), 
which is thought to adopt different rotamer conformations in different KASIII enzymes and 
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thereby determine substrate specificities (17,28). The two neighboring residues behind this 
conserved Phe are Leu222 and Met227 in aaKASIII, and Phe306 and Met222 in taKASIII, 
which correspond to the bulky residues that are typically found in KASIIIs that have broad 
substrate specificities (e.g. Phe298 and Met303 in S. aureus KASIII) (figure 1). Based on the 
conservation of the conserved Phe (anti-rotamer or gauche-rotamer (nomenclature defined in 
Chapter 2 of this dissertation), and presence of either Phe or Met behind it, aaKASIII and 
taKASIII both belong to can be predicted to have broad substrate specificities (Chapter 3 of 
this dissertation).  As described in Chapter 3, bsKASIIIb, cgKASIIIa and cgKASIIIc also 
have broad substrate specificities whereas cgKASIIIb does not exhibit any functional 
activity.  
In vivo analysis of KASIII function in the ΔfabH B. subtilis strain  
The bacterium B. subtilis primarily synthesizes branched chain fatty acids, and the 
two KASIII homologs, yjaX  (bsKASIIIa) and yhfB (bsKASIIIb), have been shown to 
possess high specificity for branched chain primers (9). Deletion of these two endogenous 
KASIII genes results in a lethal phenotype (10), which can be rescued by growing the ΔyjaX 
ΔyhfB double mutant in the presence of branched-chain fatty acids.  To assess whether the 
five selected KASIII proteins can catalyze the production of branched chain fatty acids, each 
KASIII was integrated into the genome of theΔΔyjaX ΔΔyhfB double mutant, as described in 
the Methods. KASIII expression in these ΔyjaX ΔyhfB KASIII strains was induced by IPTG 
and grown in the absence of exogenously supplied branched-chain fatty acids. Thus, we used 
a B. subtilis fabH deletion mutant system to screen for KASIII enzymes that have propensity 
for branched chain acyl-CoA primers and can synthesize branched chain fatty acids, and 
therefore, are capable of rescuing the lethal fabH deletion phenotype. Of the five KASIII 
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genes tested (i.e. cgKASIIIa, cgKASIIIb, cgKASIIIc, taKASIII and aaKASIII) in the ΔyjaX 
ΔyhfB double mutant, only aaKASIII, taKASIII and cgKASIIIa could rescue the lethal 
phenotype, suggesting that these KASIIIs can initiate synthesis of branched chain fatty acids.  
Fatty acid analysis of the ΔyjaX ΔyhfB strains harboring aaKASIII, taKASIII or 
cgKASIIIa revealed that the KASIII from A. acidocaldarius could produce 48% anteiso-fatty 
acids and 30% odd number iso-fatty acids when expressed in the B. subtilis ΔyjaX ΔyhfB 
strain (table 2). T. aquaticus KASIII could make the highest percentage of anteiso-fatty 
acids, i.e. 52%, and synthesized 27% odd number iso-fatty acids (table 2). C. gingivalis 
KASIIIa synthesized the least amount of anteiso-fatty acids (27%), but maximum amount of 
odd number iso-fatty acids (59%) (table 2). These data collectively suggest that aaKASIII 
and taKASIII have preferences for anteiso branched acyl-CoA primers (which could be ante-
isovaleryl-CoA), whereas cgKASIIIa is more selective for iso-acyl-CoA primers (which 
could be isobutyryl-CoA or isovaleryl-CoA).  
The inability of cgKASIIIb and cgKASIIIc to rescue the lethal B. subtilis fabH 
deletion mutant implies that either these KASIII enzymes cannot utilize branched chain acyl-
CoA primers in vivo or they do not utilize the branched chain primers at a level sufficient to 
rescue the lethal phenotype observed for the B. subtilis ΔyjaX ΔyhfB strain.  
Identification of KASIII enzymes that can process atypical substrates 
The three enzymes (aaKASIII, taKASIII and cgKASIIIa) that rescued the lethal 
phenotype of the B. subtilis fabH deletion mutant were purified to homogeneity (figure 2) 
and then screened for binding with both typical and atypical KASIII substrates. Typical 
substrates included straight and branched chain acyl-CoA primers, whereas atypical 
substrates included diacid (malonyl-CoA, methylmalonyl-CoA), hydroxylated (3-
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hydroxybutyryl-CoA), unsaturated (crotonyl-CoA), and aromatic (such as benzoyl- and 
phenylacetyl-CoA) acyl-CoAs (figure 3). As standards, we included E. coli KASIII, which is 
a well-characterized KASIII enzyme that is highly selective for straight chain acyl-CoAs, and 
B. subtilis KASIIIb, which is highly selective for branched chain acyl-CoAs. We predicted 
that B. subtilis KASIIIb would be more receptive to atypical substrates than E. coli KASIII 
because of the former enzyme’s propensity to process branched chain substrates, it should 
have a bigger substrate binding pocket as compared to E. coli KASIII allowing binding by 
bulkier substrates such as hydroxylated, unsaturated or aromatic acyl-CoAs. 
The ability of KASIIIs to bind to these substrates was measured via a fluorescence-
based thermal shift assay (55,56,59), which measures the thermal stability of a protein in the 
presence and absence of a specific ligand or substrate. A positive shift in melting temperature 
of the protein (Tm) in the presence of a substrate is correlated with substrate binding and 
concomitant stabilization of the enzyme, whereas a negative shift in Tm suggests 
destabilization of the protein by the substrate. Thermal shift analysis showed that the 
KASIIIs from B. subtilis, A. acidocaldarius and T. aquaticus bound a broad range of 
substrates, whereas C. gingivalis KASIIIa and E. coli KASIII bound to a relatively narrow 
range of substrates.  
Inherent Tms in water without any ligand were measured for each of the KASIIIs 
(table 3). These melting temperatures were used as the baseline Tms to measure the shift in 
Tm by addition of substrate.  An interesting feature that we noted in the thermal shift assays is 
the unusual thermal stability of A. acidocaldarius and T. aquaticus KASIII enzymes that had 
baseline Tms of ~73°C and ~84°C respectively (table 3). These melting temperatures are 
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considerably higher than those for other KASIIIs studied in this report and can be correlated 
to the ability of these two bacteria to survive at extremely high temperatures. 
Consistent with previous reports that E. coli KASIII has narrow substrate specificity, 
ecKASIII could bind only short, straight chain acyl-CoAs, (acetyl- and propionyl-CoA) 
(figure 3). In contrast, C. gingivalis KASIIIa mainly bound branched chain (i.e. isovaleryl- 
and isobutyryl-CoAs) and unsaturated (crotonyl-CoA; Tm shift of 2°C) substrates that 
resulted in statistically significant thermal shifts (figure 3).  
B. subtilis KASIIIb and A. acidocaldarius KASIII exhibited the broadest ranges of 
substrate specificities. In particular, B. subtilis KASIIIb could bind the straight chain 
substrates (propionyl-CoA and butyryl-CoA), the branched isobutyryl- and isovaleryl-CoAs, 
a diacidic substrate (methylmalonyl-CoA), an unsaturated substrate (crotonyl-CoA) and 
aromatic substrate (phenylacetyl-CoA).  Each of these substrates induced at least a 6°C 
increase in the Tm of bsKASIIIb (figure 3). In contrast some substrates (e.g. hexanoyl-CoA 
and benzoyl-CoA) apparently destabilized the protein, as evidenced by a decrease in the Tm 
of bsKASIIIb. The binding capacity of A. acidocaldarius KASIII was equally broad.  
aaKASIII bound to the straight chain acetyl-CoA and hexanoyl-CoA substrates, the branched 
isobutyryl- and isovaleryl-CoAs, a hydroxylated substrate (3-hydroxybutyryl-CoA), an 
unsaturated substrate (crotonyl-CoA) and the aromatic substrate (benzoyl-CoA), each of 
which resulted in at least a 4°C increase in the Tm of the enzyme. Malonyl-CoA and 
phenylacetyl-CoA also bound to aaKASIII, inducing a 2°C increase in Tm.  
T. aquaticus KASIII bound with rather a small range of substrates, specifically 
straight butyryl- and hexanoyl-CoA, and branched isobutyryl- and isovaleryl-CoA substrates 
that resulted in 2-6°C increase in Tm as compared to the baseline Tm.   
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Demonstration of in vivo production of omega-branched hydroxy fatty acids using a 
novel KASIII  
The KASIII from A. acidocaldarius binds to 3-hydroxybutyryl-CoA (figure 3), 
suggesting that aaKASIII could produce 3-hydroxy fatty acids within a bacterial strain that 
generated the 3-hydroxybutyryl-CoA.  Recently, a set of three PHA polymerase genes 
(phaC1, phaC2, and phaC3) was shown to be necessary for the production of 
polyhydroxyalkanoates (PHAs) in the bacterium, Rhodospirillum rubrum (46). The triple 
phaC mutant (ΔphaC1ΔphaC2ΔphaC3) is incapable of accumulating PHA polymer, and 
shows only a slight impact on growth characteristics.  This strain, therefore, has the capacity 
to generate 3-hydroxybutyryl-CoA via phaA mediated condensation of two acetyl-CoA 
molecules to give acetoacetyl-CoA which is then reduced by phaB to give 3-hydrxybutyryl-
CoA (figure 5). This substrate could potentially be utilized by a KASIII to produce ω-1-
hydroxy-fatty acids.  We tested this hypothesis by recombinantly expressing the A. 
acidocaldarius KASIII in an R. rubrum strain that lacks functional phaC enzymes 
(ΔphaC1ΔphaC2ΔphaC3 triple mutant) and then analyzing the fatty acids produced. 
Our data showed that the substrate 3-hydroxybutyryl-CoA in R. rubrum was being 
utilized by A. acidocaldarius KASIII and was metabolized via fatty acid synthesis pathway 
resulting in C15:0 ω-1 hydroxy fatty acids (figure 4). This result demonstrated in-vivo 
production of bi-functional fatty acids in a recombinant bacterial host. 
 
Discussion 
 Typical substrates for KASIII enzymes are either linear chain acyl-CoAs (for 
example, acetyl-CoA and propionyl-CoA in case of E. coli KASIII (9,60)) or branched chain 
acyl-CoAs (for example, isobutyryl-CoA and isovaleryl-CoA in case of B. subtilis and S. 
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aureus KASIIIs (5,9)). Substrate specificity for M. tuberculosis KASIII is unique as it can 
utilize long chain acyl-CoA, i.e. lauryl CoA, owing to the presence of a long hydrophobic 
tunnel that can accommodate C-12 chain of the substrate (10,30,32,38). Besides these three 
classes of acyl-CoA substrates (linear, branched and long chain linear acyl-CoAs), KASIII 
activity has not been explored with other types of substrates, such as hydroxylated, 
unsaturated or aromatic acyl-CoA thioesters. However, presence of ω-alicyclic (41,44,45,61), 
ω-halogenated (62) and ω-phenyl fatty acids in certain bacteria and plants suggests that 
KASIII enzymes from such organisms may have capabilities to utilize substrates other than 
linear or branched chain acyl-CoAs. In the current study, our data clearly validated the 
proposition that KASIII enzymes from certain organisms, especially from bacteria with high 
branched chain fatty acid content, can utilize unusual primers, such as hydroxylated acyl-
CoAs (3-hydroxy butyryl CoA), aromatic acyl-CoAs (benzoyl CoA, phenylacetyl-CoA) and 
even unsaturated acyl-CoAs (crotonyl CoA).  
New in vivo and in vitro screens for KASIII characterization  
 Traditionally, low through-put filter disc assays or conformationally sensitive urea 
gels have been used to assay KASIII activity using  
14
C-labeled starter units (either 
14
C-acyl-
CoA or 
14
C-malonyl ACP) (9). Herein we report both an in vivo and an in vitro method for 
rapidly screening KASIII substrate specificity with multiple substrates. The in-vivo screen is 
based on lethal fabH deletion mutant of B. subtilis bacteria which otherwise in its wild-type 
form makes 95% branched chain fatty acids (57,61). This lethal mutant can be rescued by 
either supplying branched chain fatty acids in the growth medium, or by introducing an 
exogenous KASIII gene into it which is capable of utilizing branched chain acyl-CoA 
primers (Jin et al, unpublished data). It is possible to detect KASIII functionality with other 
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acyl-CoA substrates by providing appropriate precursor carboxylic acids to the B. subtilis 
fabH deletion mutant. Our work, therefore, has established a novel in-vivo screening system 
to identify KASIII enzymes which have high specificity for branched chain primers and may 
also possess interesting substrate specificities.  
 The fluorescence-based thermal shift assay to survey the range of KASIII substrate 
specificity serves as a sensitive, rapid and reliable in-vitro screen, and complements the B. 
subtilis in-vivo screen to identify KASIII enzymes with novel substrate preferences. This 
technique was originally developed for high-throughput drug discovery (63,64) and recently, 
it has gained popularity as a quick method to determine optimal conditions for enhancing 
protein stability and crystallization (55,56,59). The current study illustrates the use of the 
thermofluor-based approach to biophysically characterize KASIII enzymes in a rapid and 
reliable manner.  
Preference for unusual substrates by select KASIII enzymes 
 The current study establishes that several KASIII enzymes are capable of utilizing 
atypical substrates that do not naturally occur in many bacteria or plants (e.g. aromatic, 
unsaturated and hydroxylated acyl-CoAs).  Our results demonstrate that KASIIIs derived 
from bacteria that produced branched chain or alicyclic fatty acids (such as B. subtilis 
KASIIIb, C. gingivalis KASIIIa, A. acidocaldarius KASIII and T. aquaticus KASIII) have a 
propensity for accepting atypical substrates as compared to the KASIII from E. coli, which 
does not synthesize branched chain fatty acids.  
 Overall, specific structural features of these KASIIIs that enable binding and catalysis 
of atypical substrates have not yet been determined. A possible explanation could be 
presence of a bigger hydrophobic tunnel that can accommodate the bigger, bulkier substrates.  
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A common feature of these four enzymes that could accept atypical substrates was the 
presence of the hinging Phe suggesting that they belong to group 3 KASIII enzymes which 
exhibit broad substrate specificities with higher preference for branched chain acyl-CoAs 
(chapter 3). The four enzymes, aaKASIII, taKASIII and cgKASIIIa showed less binding with 
short straight chain substrates such as acetyl- and propionyl-CoA and more interaction with 
branched chain acyl-CoAs. This is consistent with presence of high content of branched 
chain fatty acids in their host bacteria. Additionally, loops L3 and L9 of aaKASIII and 
taKASIII resemble those of group 3 KASIII enzymes. For example, similar to other group 3 
KASIIIs that exhibit broad substrate specificities, aaKASIII and taKASIII have conserved 
Pro and Asp which are absent in loop L3 of group 1a enzymes that exhibit high specificity 
for straight chain primers (chapter 3 of this dissertation). Similarly, in loop L9 of aaKASIII 
and taKASIII, there is bulky Tyr/Phe in place of Thr190 of E. coli KASIII. Similarities in the 
L3, L9 loop regions of these enzymes with other group 3 KASIII enzymes suggest that other 
enzymes from group 3 may also be capable of utilizing atypical substrates.  
A. acidocaldarius KASIII was the only KASIII that showed binding with benzoyl 
CoA, whereas both B. subtilis KASIIIb and A. acidocaldarius KASIII bound to phenylacetyl-
CoA. Specific structural differences that allow B. subtilis KASIIIb to interact with 
phenylacetyl-CoA and not with benzoyl CoA can be understood in future by comparing its 
crystal structure with A. acidocaldarius KASIII’s structure. Additionally, A. acidocaldarius 
KASIII bound with hexanoyl-CoA, whereas C. gingivalis KASIIIa, B. subtilis KASIIIb and 
T. aquaticus KASIII could not. This could be explained on the substitution of Val91 in C. 
gingivalis KASIIIa, Phe88 in B. subtilis KASIII and Phe86 in T. aquaticus KASIII with 
Leu88 in A. acidocaldarius KASIII that may be allowing longer acyl-CoA chains to fit in the 
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substrate binding pocket. The corresponding Phe87 in E. coli KASIII that extends from one 
subunit of the KASIII dimer into the acyl-CoA binding pocket of the other subunit is thought 
to limit substrate specificity to short chain acyl-CoAs (3,4,8). Previous studies have revealed 
that ability of M. tuberculosis KASIII and M. luteus KASIII to accept longer acyl-CoA 
substrates emanates from presence of a smaller Thr87 instead of Phe87 found in E. coli 
KASIII (10,17,30).   
New possibilities for bio-based synthesis of novel functionalized fatty acids.  
 Typically bacteria and plants synthesize either straight or branched chain fatty acids 
initiated by the presence of straight or branched chain acyl-CoA primers. With the 
identification of KASIII enzymes that can process unusual CoA starter units, it is possible, as 
we have demonstrated, to synthesize novel ω-functionalized fatty acids that have different 
functional groups (such as hydroxyl, aromatic) at their terminal ends.  Isolation and 
structural-functional characterization of KASIII genes from organisms like Streptomyces 
cattleya, Dichapetalum toxicarium which synthesize ω-fluorinated fatty acids, will help in 
further understanding of how KASIIIs are tailored to process halogenated substrates.   
Potential applications of such ω-functionalized fatty acids are in the bio-based chemical 
industry for production of various polymeric compounds (such as polyesters, polyamines, 
polystyrenes) and even lubricants and surfactants manufacturing industry. Such bio-based 
chemical intermediates can eventually replace the non-renewable petroleum based carbon 
feedstock in the current chemical industry and help in transitioning towards a bio-based 
economy.  
 
 
115 
 
 
Acknowledgements 
 This work was supported by the NSF ERC grant for Center for Biorenewable 
Chemicals (CBiRC), and was also supported in part by the CBiRC SLC sponsored grant. We 
would like to thank undergraduate students, Ruben Garcia and Morgan Becker, for their help 
in protein expression, purification and enzyme assays.  We would also like to acknowledge 
the W.M. Keck Metabolomics lab where enzyme assays were conducted. 
 
116 
 
 
 Table 1. Primer pairs for DNA manipulation in B. subtilis 
 
Targeted amplification 
fragment 
Vector Primer 
name 
Primer sequence 
897-bp upstream 
fragment of the bfabHA 
ORF  
pMU4A AUf-Pac I TTAATTAATATTAACCATCA
CGGTGCAA  
AUr-Sal I GTCGACGAATGTAACGTCCA
ACACCA  
799-bp downstream 
fragment of the bfabHA 
ORF  
pMU4A ADf-Sal I GTCGACTGGAAGCCGGTAA
AATCAA  
ADr-Pst I CTGCAGGCCGACAATTTCTC
CGTAAA  
836-bp upstream 
fragment of the   bfabHB 
ORF  
pMU4B BUf-Pst I CTGCAGATATAAAACCGCCG
GGACAT  
BUr-Sal I GTCGACGCATAGGTGCCGAT
AGCTGTA  
802-bp downstream 
fragment of the bfabHB 
ORF  
pMU4B BDf-Sal I GTCGACTCAAATCGTTTTGC
TTTTCG  
BDr-Pac I TTAATTAACCAAACAGGAGA
TATCGATGC  
836-bp upstream 
fragment of the bfabHB 
ORF  
pUCB-erm BUf2-Eco 
RI 
GAATTCATATAAAACCGCCG
GGACAT  
BUr2-Sal I GTCGACGCATAGGTGCCGAT
AGCTGTAA  
738-bp downstream 
fragment of the bfabHB 
ORF  
pUCB-erm BDf2-Sal I GTCGACTCAAATCGTTTTGC
TTTTCG  
BDr2-Hin 
dIII 
AAGCTTCCAAAGATGATGCC
ATTCA  
erm gene fragment  pUCB-erm ermf GTCGACCAAATTTACAAAAG
CGACTCA  
ermr GTCGACGAGGCCCTTTCGTC
TTCAA  
Verification of bfabHA 
deletion 
Not 
applicable 
lofAf GCATACGCCTCCTTTCCATA  
lofAr TTTGCCGGATATTCTTCAGC  
Verification of bfabHB 
deletion 
Not 
applicable 
lofBf CAATGTTAAGCCGGAAGGA
A  
lofBr AGCAGCCGTAAATGCCATA
C  
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Table 2. Fatty acid production in B. subtilis fabH deletion mutants expressing exogenous 
KASIII enzymes  
Source of 
KASIII 
Fatty acid content (mole %)  
Anteiso-
fatty 
acids 
Even-
number 
iso-fatty 
acids 
Odd-
number 
iso-fatty 
acids 
Even-
number 
normal 
fatty 
acids 
Odd-
number 
normal 
fatty 
acids 
Total 
branche
d chain 
fatty 
acids 
C. gingivalis 
KASIIIa 
27.24 1.28 58.94 12.46 0.08 87.46 
T. aquaticus 
KASIII 
52.1 1.09 26.89 19.84 0.12 80.08 
A.  
acidocaldarius 
KASIII 
48.13 3.64 30.44 17.73 0.05 82.21 
B. subtilis 
KASIIIb* 
54 13 28 5 0 95 
E. coli KASIII* 0 0 0 95 5 0 
 
 
 
 
 
 
 
Table 3. Melting temperatures (Tm) of the selected KASIII enzymes without ligand. 
These temperatures were used as the baseline temperatures against which the effect of 
addition of different substrates was measured. 
 
 
 
 
 
 
 
 
 
 
Organism Enzyme Melting temperature 
(°C) 
C. gingivalis KASIIIa 68.3 ± 0.17 
KASIIIb 67.8 ± 0.03 
KASIIIc 56.8 ± 0.62 
   
A. acidocaldarius KASIII 73.2 ± 0.05 
   
T. aquaticus KASIII 84.1 ± 0.11 
   
B. subtilis KASIIIb 48.7 ± 0.24 
   
E. coli KASIII 55.0 ± 0.18 
* - Ratledge & Wilkinson, Microbial Lipids, Volume 1 
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Figure 1. Alignment of conserved residues of the five putative KASIII enzymes with 
KASIII enzymes from both E. coli (narrow substrate specificity KASIII) and B. subtilis 
(broad substrate specificity KASIII). Fourteen conserved residues that define KASIII 
catalytic site, CoA and ACP binding sites and active site cleft shape are grouped into four 
categories respectively. These residues are compared for experimentally confirmed KASIIIs 
(E. coli narrow substrate specificity KASIII and B. subtilis broad substrate specificity 
KASIIIb) and five putative KASIII enzymes. Branched chain fatty acid content of each 
bacterium is listed. Coloring scheme for residues: Black – strictly conserved residues, Gray – 
homologous substitutions for the conserved residues, Blue – residues similar to those in E. 
coli KASIII but not in B. subtilis KASIIIb, Green – residues similar to those in B. subtilis 
KASIIIb but not in E. coli KASIII, White – non-conserved residues.  Numbering scheme 
corresponds to the E. coli KASIII residues.  
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Figure 2. Expression and purification of the candidate KASIII proteins. Each of the 
five putative His-tagged KASIII proteins were purified by Ni-NTA affinity chromatography 
and assessed for homogeneity and purity using Coomassie-stained SDS PAGE gels. (A) 
Purified E. coli KASIII (1: Protein ladder, 2: Empty lane, 3: Crude extract, 4: Flow through, 
5: First wash with 20 mM imidazole, 6: Wash with 40 mM imidazole buffer, 7: Elution 
with 80 mM imidazole, 8: Elution with 250 mM imidazole, 9: Empty lane). (B) Purified B. 
subtilis KASIIIb (1: Protein ladder, 2: Crude extract, 3:  Flow through, 4: First wash with 
20 mM imidazole, 5: Second wash with 20 mM imidazole, 6: Wash with 40 mM imidazole, 
7: Elution with 80 mM imidazole, 8: Second elution with 80 mM imidazole, 9: Elution with 
250 mM imidazole). (C) Purified T. aquaticus and A. acidocaldarius KASIIIs (1: Protein 
ladder, 2: Crude extract, 3:  Flow through, 4: First wash with 20 mM imidazole, 5: Second 
wash with 20 mM imidazole, 6: Wash with 40 mM imidazole, 7: Elution with 80 mM 
imidazole, 8: Second elution with 80 mM imidazole, 9: Elution with 250 mM imidazole). 
(D) Purified C. gingivalis KASIIIa, KASIIIb and KASIIIc (1: Protein ladder, 2: Crude 
extract, 3:  First wash, 4: Elution with 80 mM imidazole, 5: Elution with 250 mM 
imidazole). 
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Figure 3. Binding of straight, branched, hydroxy, acidic, unsaturated and aromatic acyl-CoA substrates with the 
selected KASIIIs. Change in the melting temperatures (Tm) of the selected KASIIIs with respect to the baseline Tm upon 
addition of different acyl-CoA substrates is measured using fluorescence-based thermal shift assays. ecKASIII: E. coli 
KASIII, cgKASIIIa: C. gingivalis KASIIIa, taKASIII: T. aquaticus KASIII, aaKASIII: A. acidocaldarius KASIII, 
bsKASIIIb: B. subtilis KASIIIb. Each data point represents average of four technical replicates. 
1
2
0
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Figure 4. Production of ω-1-hydroxy-fatty acids by the expression of the A. 
acidocaldarius KASIII in R. rubrum.  (A) GC-profile of the fatty acid products by the 
recombinant R. rubrum strain lacking PhaC activity, but expressing the A. acidocaldarius 
KASIII (red-line); the black-line is the parallel analysis of the profile from the control R. 
rubrum strain, lacking the A. acidocaldarius KASIII. (B). Mass-spectra of Peak 1 and Peak 
2. Consistent with the analytical chemistry used to prepare these samples, Peak 1 is 
identified as the silylated-form of the methyl-ester of 15-hydroxypalmitate, while the 
absence of this metabolite in the control (Peak 2) established that the A. acidocaldarius 
KASIII is responsible for the production of (ω-1)-hydroxy-fatty acids. 
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Figure 5. Engineered pathway for production of (ω-1)-hydroxy-fatty acids in R. 
rubrum strain. Poly-β-hydroxybutyrate (PBHB) is synthesized in R. rubrum via 
condensation of two acetyl-CoA molecules by β-ketothiolase (phaA) to form acetoacetyl-
CoA (a), followed by reduction of acetoacetyl-CoA to β-hydroxybutyryl CoA by 
acetoacetyl-CoA reductase (phaB) (b), which is then polymerized by phaC to form PBHB 
(c). In a R. rubrum strain that lacks phaC, A. acidocaldarius KASIII was introduced that 
can condense β-hydroxybutyryl CoA with malonyl-ACP to form a hydroxylated β-
ketoacyl-ACP (d), which can be then elongated by enzymes of fatty acid synthesis 
pathway (e) to synthesize ω-1-hydroxy-fatty acid. 
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CHAPTER V 
GENERAL CONCLUSIONS 
 
This dissertation investigates the structure-function relationship of 3-Ketoacyl ACP 
Synthase III enzymes and explores their functional diversity. The two main goals of this 
dissertation were: 1) to understand the structure-function relationships of KASIII enzymes 
and identify key residues governing the KASIII substrate specificity, and 2) to explore the 
functional diversity of KASIII enzymes and identify KASIII enzymes with novel substrate 
specificities. Through this work, our fundamental understanding of the KASIII structure-
function relationship has been enhanced and we have identified several structural 
determinants of KASIII substrate specificity. Moreover, we have identified several KASIIIs 
with novel substrate specificities.  Taken together, this expanded understanding of KASIII 
will help us to expand the biosynthetic repertoire of the fatty acid synthesis pathway to make 
novel functionalized fatty acids that could have applications in the bio-based chemical 
industry (1). Presented herein are the main conclusions from this work. 
 
The conserved Phe determines KASIII substrate specificity and is crucial for substrate 
binding and catalysis 
 
Experimental results from chapter 2 demonstrated the importance of the conserved 
Phe and the two residues in its vicinity (corresponding to Phe304, Val 215 and Leu220 of E. 
coli KASIII that exhibits narrow substrate specificity for straight chain primers) in substrate 
binding and catalysis in addition to determining the substrate specificity of KASIII. B. 
subtilis KASIIIa and KASIIIb enzymes, which have broad substrate specificity for straight 
and branched chain primers, have the conserved Phe but the two neighboring residues that 
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are thought to affect its rotamer conformation are bulky Phe and Met in bsKASIIIa (Trp and 
Val in bsKASIIIb) respectively.  
Previously it was believed that KASIII from Gram-negative bacteria possessed 
residues similar to the ones found in E. coli KASIII at these positions (i.e. Val215 and 
Leu220), and KASIII from Gram-positive bacteria had residues similar to the ones in 
bsKASIIIa (i.e. Phe and Met). Our phylogenetic analysis from chapter 3 and 4 clearly 
showed that irrespective of the Gram-character of the host bacterium, the KASIII had 
residues similar to E. coli KASIII if the host bacterium makes only straight chain fatty acids. 
In contrast, if the host bacterium synthesizes branched chain fatty acids or alicyclic fatty 
acids, then the residues neighboring the conserved Phe are similar to the ones occurring in B. 
subtilis KASIII enzymes.  
Interestingly, we also identified a functional KASIII enzyme, Myxococcus xanthus 
KASIIIc, that does not have the ‘conserved’ Phe but still shows KASIII functionality and is 
more active with straight chain acyl-CoA substrates and has little activity with branched 
chain primers. Previously, only two KASIIIs have been structurally characterized, i.e. A. 
aeolicus KASIII (PDB code: 2EBD) and X. oryzae KASIII (2), that do not possess the 
conserved Phe. Functional characterization of these enzymes will be instrumental in 
determining if absence of the conserved Phe limits the KASIII activity to straight chain acyl-
CoA substrates as observed in the case of M. xanthus KASIIIc. 
In conclusion, we experimentally validated the importance of the conserved Phe and 
the two neighboring residues in determining KASIII substrate specificity and catalysis. We 
also identified five KASIII enzymes from Gram-negative and Gram-positive bacteria that 
have bulky residues close to conserved Phe, and therefore exhibit broad substrate specificity. 
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Future perspective – In addition to the residues studied in chapter 2, there may be 
other residues that determine KASIII substrate specificity. For example, Phe87 in E. coli 
KASIII at the base of the substrate binding pocket extends from one subunit of the KASIII 
dimer into the active site of the other subunit (3-5).  In the KASIII from M. tuberculosis, 
which accepts longer acyl CoA substrates such as lauroyl CoA (6-8), this Phe residue is 
replaced by a smaller residue, Thr.  Therefore, it is proposed that the larger Phe87 residue 
may be hindering entrance of longer acyl-CoA substrates into the E. coli KASIII substrate 
binding pocket. Likewise, Arg196 in E. coli KASIII, which also participates in dimer 
interface formation, may also have a role in limiting the specificity of ecKASIII to straight 
chain substrates, because this residue is mostly conserved in KASIIIs from bacteria that make 
straight chain fatty acids, such as Haemophilus influenzae and Yersinia pestis. The roles of 
these specific residues could be experimentally tested to attain better understanding of the 
KASIII structure-function relationship. 
 
E. coli KASIII is capable of binding and processing branched chain primers, such as 
isobutyryl CoA 
 
E. coli KASIII is known to have high selectivity for acetyl-CoA (9-13), however 
there has been ambiguity regarding its capability to utilize branched chain substrates, such as 
isobutyryl-CoA. One study demonstrated that E. coli KASIII is incapable of utilizing 
isobutyryl-CoA (14). In contrast, another report demonstrated that E. coli KASIII, when 
supplied with appropriate branched-chain precursors, is capable of producing branched chain 
fatty acids, although at a rate ten-fold lower than for straight-chain fatty acids (15). Our 
experimental data from saturation transfer difference NMR experiments and enzymatic 
activity analysis (Chapter 2) supported the results of the second study (15), by showing that 
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E. coli KASIII is capable of binding isobutyryl-CoA. Via STD-NMR, epitopes were 
identified on isobutyryl-CoA that directly interact with the KASIII enzymes. These ligand 
binding epitopes are similar to the ones on the straight chain acyl-CoA ligand (acetyl-CoA), 
which suggests that the binding modes of straight and branched chain substrates are identical. 
The enzymatic activity data further illustrated that E. coli KASIII is capable of processing 
branched-chain substrates, but at a lower specific activity than straight chain substrates (e.g. 
acetyl CoA). Taken together, these results suggest that the formation of branched chain fatty 
acids in E. coli is not limited by the substrate specificity of KASIII alone, but also by the 
unavailability of branched-chain precursors in vivo.  
Future perspective –  Disordered form of E. coli KASIII has been observed in crystal 
structure suggesting large conformational changes in this enzyme  and models have been 
suggested for E. coli KASIII conformational flexibility (16), so it is quite possible that 
binding of straight chain substrates induces conformational changes that branched chain 
substrates are incapable of inducing. Such molecular dynamics and conformational changes 
in KASIII structure have not been experimentally explored yet. Therefore, NMR based 
structures in solutions of these particular KASIII enzymes will be instrumental in advancing 
the existing structural knowledge of KASIII enzymes and could provide insights into the 
conformational changes induced in ecKASIII upon binding different ligands (i.e. straight vs. 
branched chain substrates).   
 
KASIII can be categorized into four structure-function groups based on which their 
substrate specificity can be predicted 
 
Collectively, in chapters 3 and 4, we identified and characterized six functional 
KASIII enzymes out of twelve previously uncharacterized KASIII enzymes from five diverse 
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sources. All these enzymes, specifically C. gingivalis KASIIIa, KASIIIc, L. pneumophila 
KASIIIa, M. xanthus KASIIIc, A. acidocaldarius KASIII and T. aquaticus KASIII, exhibited 
activity and binding towards both straight and branched chain substrates. In addition to the 
six KASIIIs functionally characterized here, functional data is available for nine other 
KASIIIs from different bacteria, i.e. E. coli (17-19), B. subtilis (11), S. aureus (20), M. 
tuberculosis (21), M. luteus (22), L. monocytogenes (23), S. pneumoniae (24), S. glaucescens 
(25), F. tularensis (26). Structural information, however, is available for KASIII from 12 
diverse sources, which include E. coli (3-5,27), M. tuberculosis (6,7,28), M. luteus (22), S. 
aureus (27), X. oryzae (2), B. pseudomallei (PDB code: 3GWE), A. aelocius (PDB code: 
2EBD), T. thermophilus (PDB code: 1UB7), H. influenza (27), E. faecalis (27), B. 
xenovorans (PDB code: 4DFE) and P. aeruginosa (PDB code: 2X3E). There are only four 
KASIIIs from these two groups for which both structural and functional information is 
available, so there is still a huge gap between structural and functional features of KASIII 
enzymes. 
We correlated the sequence and function information for all the characterized 
KASIIIs to date and categorized KASIII enzymes into four structure-function groups 
(chapter 3) based on primary sequence similarities and functional similarities. From this 
classification, two groups emerged that showed either high selectivity for straight chain 
primers (group 1a consisting of KASIII from E. coli, Y. pestis) or high selectivity for 
branched chain primers (group 3 consisting of B. subtilis KASIIIa, KASIIIb, T. thermophilus 
KASIII). Group 1b had KASIII that could accept both straight and branched chain primers 
but higher activity for the former substrates. Group 2 also had KASIII with similar substrate 
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preferences but it also contained some unique KASIIIs, such as M. tuberculosis and M. luteus 
KASIIIs that can bind to long chain acyl-CoA substrates (21,22).  
Additionally, we also identified common structural features in the loops L3 and L9 of 
these four groups which could be responsible for conferring different substrate specificities to 
each of the groups. These two loops form the dimer interface of KASIII enzyme, and may 
therefore have an important role in inducing conformational changes in the KASIII structure 
upon binding of the appropriate substrates.  
Future perspective –As mentioned before, there are only four KASIII enzymes for 
which both structural and functional data is available. To further enhance our understanding 
of KASIII enzymes, it is imperative that functional data is collected for the KASIIIs that have 
been crystallized, and likewise structural information should be gathered for the KASIIIS 
that have only been functionally characterized. Such efforts will tremendously help in 
answering the remaining questions about KASIII structure-function relationships. The most 
interesting candidates for structure-function studies would be C. gingivalis KASIIIa, B. 
subtilis KASIIIb, A. acidocaldarius KASIII that can bind to unusual substrates as 
demonstrated by our data from chapter 4.  
 
Phylogenetic divergence of KASIIIs results in at least one functional homolog in each 
bacterial strain 
 
In chapter 3 we characterized multiple KASIII homologs from three different 
bacterial sources and established that at least one KASIII homolog per strain was functional.  
In the case of KASIII homologs from C. gingivalis, cgKASIIIa and cgKASIIIc that belong to 
sub-families IV and X of the KASIII phylogenetic tree respectively, showed marked 
dissimilarities in their substrate preferences. cgKASIIIa is highly selective for branched-
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chain acyl CoA substrates whereas cgKASIIIb has a stronger preference for straight chain 
primers, but can also utilize branched chain primers. In case of L. pneumophila, four KASIII 
paralogs belonged to different sub-families but only one of these exhibited KASIII 
functionality. Likewise, only mxKASIIIc from M. xanthus displayed KASIII activity and 
could process both straight and branched chain substrates, whereas mxKASIIIa and 
mxKASIIIb did not show KASIII functionality. In summary, each of these three bacteria had 
atleast one functional KASIII that was active with branched chain substrates. This is 
consistent with the production of branched chain fatty acids in these bacteria, and sequence 
analysis of the functional KASIIIs revealed that these had features similar to those of other 
KASIIIs that are active with branched chain primers, such as B. subtilis KASIIIa and S. 
aureus KASIII.  
Future perspective – The physiological significance of multiple functional KASIII 
homologs within a single bacterial strain is not yet understood. Bacillus subtilis is a very well 
characterized organism that has two KASIII homologs, bsKASIIIa and bsKASIIIb, that show 
differences in their substrate preferences (11). However, physiological significance of this 
duplication in function is still under investigation. Preliminary data from some studies 
suggest that bsKASIIIa is expressed constitutively whereas bsKASIIIb is expressed at lower 
temperatures, suggesting a role of the two KASIIIs in helping Bacillus adapt to temperature 
changes (Jin & Nikolau, unpublished data). Similar roles could be predicted for C. gingivalis 
KASIIIa and KASIIIc, i.e. cgKASIIIa that can utilize branched chain acyl CoAs might be 
expressed constitutively resulting in high branched chain fatty acid content of C. gingivalis, 
whereas cgKASIIIc could have non-constitutive expression. Gene knockout experiments 
would provide more insights into their physiological functions. 
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KASIII from specific organisms are capable of utilizing novel acyl CoA substrates 
In chapter 4, four novel KASIII enzymes were shown to utilize at least one of several 
atypical acyl CoA substrates, including diacid (malonyl and methylmalonyl-CoA), 
hydroxylated (3-hydroxybutyryl-CoA), aromatic (benzoyl-CoA and phenylacetyl-CoA) and 
unsaturated (crotonyl-CoA) acyl-CoAs. These four enzymes belong to bacterial species that 
either produce high percentages of branched-chain fatty acids (Bacillus subtilis, 
Capnocytophaga gingivalis, Thermus thermophilus (29)) or make more than 50% alicyclic 
fatty acids (Alicyclobacillus acidocaldarius) (29). Typically, bacteria and plants synthesize 
either straight or branched chain fatty acids, initiated by the presence of straight or branched 
chain acyl CoA primers. With the identification of KASIII enzymes that can process unusual 
CoA starter units, it is possible to synthesize novel ω-functionalized fatty acids that have 
different functional groups (e.g. carboxylic acid or hydroxyl or aromatic) at their terminal 
ends.  Such functionalized fatty acids can have applications in the bio-based chemical 
industry for the production of value-added chemicals and the replacement of the non-
renewable petroleum-based carbon feedstock. 
Future perspective – The KASIII that can utilize atypical substrates, such as A. 
acidocaldarius, C. gingivalis KASIIIs share structural features with KASIIIs that can process 
branched chain substrates. However, there may be some specific structural differences that 
enable binding and catalysis of atypical substrates. Structural studies of KASIIIs identified in 
chapter 4 will be very helpful in advancing the existing knowledge of KASIII enzymes, and 
can also help in engineering novel biocatalysts that can utilize substrates with varied groups 
such as halogens and amines that could enable synthesis of novel bio-based polyesters (e.g. 
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polyamines, or polymers containing halogen groups for enhanced physiochemical 
properties). 
KASIII can be used for the in vivo production of novel ω-functionalized fatty acids 
In collaboration with Dr. Huanan Jin, a former post-doctoral fellow in the Nikolau 
group, we demonstrated that KASIII from A. acidocaldarius can process 3-hydroxybutyryl-
CoA starter units for the in vivo production of ω-1-hydroxy-branched fatty acids in 
Rhodospirillum rubrum (Chapter 4). Production of ω-1-hydroxy-branched fatty acids was 
made possible via co-expression of a specific KASIII in conjunction with two R. rubrum 
genes, phaA and phaB, that synthesize 3-hydroxybutyryl-CoA, which is then utilized as a 
substrate by the recombinant KASIII. A. acidocaldarius KASIII (aaKASIII) was used for this 
proof-of-production of hydroxylated fatty acids because our results showed that aaKASIII is 
most effective in utilizing hydroxylated substrates (Chapter 4). This result illustrates the 
practical application of novel KASIII enzymes identified in chapter 4 for the in vivo 
production of unique ω-functionalized fatty acids 
Future perspective – The developing technology described in this dissertation is the 
basis of a start-up company, OmegaChea Biorenewables LLC (see Appendix for the 
company’s business plan), and has vast potential in terms of expanding the fatty acid 
synthesis metabolic platform to create other diverse fatty acid products, such as fatty acids 
with amino, sulphate or carboxylic acid groups at their terminal ω-ends. This technology 
needs further development in the scale-up and production of higher yields of ω-
functionalized fatty acids. Re-construction of this metabolic pathway in a lab-friendly 
organism such as E. coli followed by an industrially relevant strain and the future 
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optimization of production and separations processes can de-risk this technology and make it 
commercially competent.  
 
Concluding remarks 
 To summarize, in this dissertation, I have identified residues that are key to KASIII 
substrate binding and catalysis, however engineering of KASIII to fine-tune its substrate 
specificity will require either subtle mutations close to the active site or a directed evolution 
approach to build a functionally robust enzyme. Additionally, I have functionally 
characterized a dozen previously uncharacterized KASIII enzymes and correlated their 
diverse substrate specificities with features of their primary structure. This has enabled me to 
develop a bioinformatics-based structure-function correlation that can be used to predict 
KASIII functionality, which can be tested quickly using a combination of the in vivo and in 
vitro screens described in this dissertation.  However, a vast diversity of KASIII enzymes is 
yet to be explored, and through this work, I have been successful in only touching the tip of 
the ice-berg.  In this work I have provided a detailed characterization of fifteen KASIII 
enzymes from a collection of approximately 2,300 KASIII genes identified in public 
databases, which is not even 1% of the existing KASIII diversity. This presents rich 
opportunities for applying the bioinformatics approach to these KASIIIs to identify candidate 
enzymes to test further.  It is possible that within this large collection of candidate KASIIIs, 
there exist unique KASIII enzymes with functionalities for aromatic, sulfonated or 
halogenated precursor molecules, identification of which will diversify products of the fatty 
acid synthesis pathway.  
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APPENDIX 
BUSINESS PLAN FOR OMEGACHEA BIORENEWABLES LLC 
 
Executive Summary 
Mission 
OmegaChea Biorenewables LLC is a startup company that will commercialize a new 
scalable manufacturing capability by designing microorganisms to produce bio-based 
chemicals for surfactants, lubricants and polymers.  
Background 
The core technology of OmegaChea was developed based on the KASIII technology 
described in chapter 3 of this dissertation as a part of the NSF-funded Engineering Research 
Center for Biorenewable Chemicals (CBiRC) at Iowa State University. The core business 
concept and commercial feasibility was explored and developed within an NSF I-Corps 
award made to the OmegaChea founders.  
Company Status 
OmegaChea is a 
start-up company and is 
in the initial stages of 
research and 
development. 
OmegaChea has received an i6 Green grant from the State of Iowa to develop its technology, 
and has secured $225,000 from NSF STTR Phase I award in July 2013. It aims to apply for 
Figure 1. The problem and the solution.  OmegaChea strives to 
solve the existing problem of non-renewable petro-based chemical 
feedstock through its unique bi-functional molecules that can serve 
as precursors for making bio-based chemicals. 
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Phase II of NSF STTR award in Dec 2014. Status of the OmegaChea technology is described 
separately in a section below. 
The Problem 
The vast majority of the current feedstock for the chemical industry is petroleum 
derived, and is imported to a large extent. Moreover, petroleum-based chemical precursors 
do not offer flexibility in their structures. 
The Solution 
Fatty acids provide attractive bio-based alternative “green” chemicals for both bio-
polymers and surfactants or lubricants.  They are attractive because they offer chemical 
structures and physical properties that are similar or even better than the petroleum-derived 
chemicals that are commonly used by these industries today.  OmegaChea will produce bi-
functional fatty acids that can replace current petroleum-based feedstock chemicals (Fig. 1). 
Product and the Technology 
The technological basis for OmegaChea is the bioengineering of a key enzyme that 
determines the chemical nature of the -end (the omega-end) of fatty acid molecules. 
OmegaChea will use diverse versions of this enzyme that exert an exquisite degree of control 
over the synthesis of -functionalized fatty acids.  OmegaChea’s objective is to 
commercialize the use of these enzymes in a bioengineered microbial manufacturing 
platform to sustainably produce bi-functional chemicals.  
Market Opportunity 
The OmegaChea technology will address two potential market opportunities with new 
bio-based chemicals.  The first of these is the polymer industry (plastics of many types), 
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which currently uses bi-functional monomers (i.e., a molecule with chemical functionalities 
at both ends) that are predominantly generated from non-sustainable petroleum feedstocks.  
The second market opportunity is the surfactant/lubricant industry, which is seeking bio-
based bi-functional fatty acids (specifically branched chain fatty acids) that offer enhanced 
chemical-physical lubricity and tribological properties.  The surfactant / lubricant industry 
has lower barriers to entry and therefore will be the market initially targeted.   
Business Model 
The core business concept of OmegaChea was developed by the CBiRC team within 
an NSF I-Corps award (NSF award #IIP-1237247).  The commercial potential of this 
technology was explored in conversations with possible OmegaChea customers, which 
include Genencor, BASF, DSM, Procter & Gamble, and Cargill Industrial Oils and 
Lubricants.  These conversations identified an initial customer-base, and led to development 
of a business model detailed in the business plan.  
Typical Customers 
Through the NSF I-Corps program, an initial base of customers consisting of 
surfactant and lubricant formulators/manufacturers was identified for OmegaChea. Procter 
and Gamble, which said, “You give us 1kg of product, we can evaluate”, will be one of our 
early-vangelists. In addition to P&G, several other surfactant, lubricant manufacturers 
expressed interest in our technology.  
Minimum Viable Product 
Although the patent-pending OmegaChea technology has the potential to produce a 
variety of different -functionalized fatty acids (i.e., hydroxy-, halo-, branched-, or cyclic-
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fatty acids), OmegaChea will initially target the production of ω-hydroxy-branched fatty 
acids, which have applications in both surfactants (detergents, household cleaners) and 
lubricants (motor lubricants, cutting tool lubricants) and in polymers (i.e., polyesters).   
Status of the Technology 
OmegaChea has been successful in providing a proof-of-principle of production of bi-
functional fatty acids, specifically ω-hydroxy-branched fatty acids in engineered microbial 
hosts, and has applied for a patent for this technology. The next step for OmegaChea is to 
optimize the production conditions and then scale-up the yields of the bi-functional fatty 
acids, and overcome any toxic effects of these products on microbial hosts.  
Financial Projections 
For proof-of-concept development, OmegaChea will require upto $250,000 over next 
one year. For prototype development, it will need additional $750,000 for a period of 2-3 
years. Following prototype development, we will seek funding from venture capitalists (up to 
$5million) for pre-pilot scale and then pilot scale development. For scale-up, we might 
partner with third-party scale up providers (like Tate and Lyle, Poet) to reduce our capital 
investment costs.  
We envision that we will generate systems that produce products at different scales of 
yield, and our technology will enable the replacement of existing petroleum-based molecules 
with unique, bio-based bi-functional molecules. 
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Background 
OmegaChea Biorenewables LLC is a startup entity that is seeking to expand upon and 
commercialize technological innovations made by the NSF-funded Engineering Research 
Center for Biorenewable Chemicals (CBiRC). This technology has the potential to impact the 
development of the local and national objective of growing the bioeconomy using advanced 
manufacturing processes.  OmegaChea’s initial target is to develop a new “designer” 
microorganism that will become a key part of a scalable bio-based process that manufactures 
bi-functional fatty acids, and subsequently establish a new sustainable bio-manufacturing 
platform for chemicals. Multiple biorenewable products can be envisioned that will have 
customers in the polymer, lubricant and surfactant industries. A dialog has already been 
established between OmegaChea and some existing commercial entities that currently derive 
their chemical intermediates from petroleum sources, but see opportunities and premiums to 
switching to bio-based feedstocks.  Therefore, OmegaChea will provide these customers 
access to new “designer” molecules that will represent an alternative, sustainable resource for 
Figure 2. 
Position of 
OmegaChea 
in the value 
chain.  
OmegaChea is 
positioned 
between the 
biomass 
providers and 
chemical 
formulator 
companies in 
the value 
chain.  
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their chemical needs (Fig. 2). OmegaChea expects to reach the marketplace through close 
interactions and partnering with larger companies. This partnering relationship is being 
developed from existing exposure and interactions with the significant member company 
portfolio of CBiRC.  
Founding History 
The concept of OmegaChea began to take shape for the Founders in December 2011, 
and as a startup entity the company is at an early stage of development. The technology that 
OmegaChea is seeking to commercialize has its origins in the PhD research studies of Ms 
Shivani Garg, which was supported in part by CBiRC funding (Fig. 3).  Co-founder Dr. Basil 
Nikolau serves as Ms Garg’s PhD major professor, and Co-founder Dr. Yandeau-Nelson is 
Ms Garg’s co-mentor in Iowa State University’s Molecular, Cellular and Developmental 
Biology PhD program.   
Technology-led entrepreneurship course and the NSF I-Corps program 
As the Founding Interim President of OmegaChea, Ms Garg has established a startup 
commercial entity, which provides her with an opportunity to expand her technical expertise, 
and integrate her entrepreneurial drive.  Ms Garg has taken multiple initiatives to expand her 
expertise in entrepreneurship.  Initially this was via a formal course at ISU; “Technology-led 
Entrepreneurship” taught in Spring 2011 by Dr. Peter Keeling, Innovation Director of CBiRC 
and co-founder of OmegaChea.  Subsequently, as the concept of OmegaChea as a 
commercial entity began to take shape, Garg, Nikolau and Keeling began exploring the 
commercial potential of the startup with funds from an NSF I-Corps award (award #IIP-
1237247). In the I-Corps program, the OmegaChea team (Garg as the Entrepreneurial Lead, 
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Nikolau as the Principal Investigator, and Keeling as the Industry Mentor) explored the 
potential customer base for the OmegaChea technology.  
 
Management Team 
The OmegaChea management team consists of the four Founders of OmegaChea 
(Garg, Nikolau, Yandeau-Nelson and Keeling) who developed the technological and business 
aspects of the start-up. Their expertise and roles within this project are described below.   
Shivani Garg (Founder and President, OmegaChea) 
Garg is currently a graduate student conducting research towards a PhD in Molecular, 
Cellular and Developmental Biology with a co-major in Biorenewables at Iowa State 
University.  She obtained her Bachelor of Engineering at Panjab University, India majoring 
in Biotechnology Engineering (2002-06), and then worked with Infosys, India a leading 
software development company (2006-08).  Ms Garg joined the Nikolau group in 2009 for 
Figure 3. Establishment of OmegaChea. OmegaChea technology is based on the 
technology developed at the NSF-funded Center for Biorenewable Chemicals based at 
Iowa State University. OmegaChea is now seeking funding from state and federal 
sources (STTR, SBIR) to expand its IP and develop its production platform.  
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her graduate studies, and began the CBiRC-sponsored project on KASIII technology that is at 
the core of the OmegaChea innovation.  As the entrepreneurial lead on the NSF I-Corps 
project, she explored the commercial potential of KASIII technology and developed a 
business model, which is the basis for foundation of OmegaChea as a business entity. She is 
also the co-PI on an i6 grant awarded by State of Iowa to further advance the OmegaChea 
technology towards commercialization.  
Marna Yandeau-Nelson (Founder and Vice-President Research Operations, 
OmegaChea) 
Dr. Yandeau-Nelson is trained in plant molecular genetics and molecular biology 
(Ph.D. 2005) and biochemistry (post-doc, Penn State). Since 2009 Yandeau-Nelson 
(Associate Scientist and Graduate Faculty) has coordinated research efforts within CBiRC. 
Yandeau-Nelson’s role as Interim Vice-President Research Operations in this STTR is to 
directly manage the proposed project, and particularly to liaise and coordinate the 
management of the efforts between OmegaChea and the CBiRC researchers.   
Basil J. Nikolau (Founder and Chief Scientific Officer, OmegaChea) 
Dr. Nikolau is the Frances M. Craig Professor of Biochemistry at Iowa State 
University.  Dr. Nikolau is trained in the areas of biochemistry and molecular biology. He 
has published nearly 100 peer-reviewed manuscripts in the field, being supported by research 
grants from the NSF, the USDA, US DoE, and the NIH.  Currently he serves as the Deputy 
Director of the NSF-funded Engineering Research Center, CBiRC, based at Iowa State 
University.  Nikolau’s role as the Interim Chief Scientific Officer of OmegaChea is to 
provide guidance and expertise to the collaboration between OmegaChea and the ISU 
research of Ms Shivani Garg, to ensure the technical success of the combined project.   
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Peter L. Keeling (Founder and Vice-President Business Operations, OmegaChea) 
Dr. Keeling is trained in biochemistry and has more than twenty-five years of 
industry experience in the biotechnology sector. Dr. Keeling’s current position is Director of 
Innovation with the NSF-funded CBiRC. Dr Keeling is Founder and Director of startup 
companies (ExSeed 1994; EnaGen 2007; EneGea 2009; GlucanBio 2011) that have focused 
on technology development. In his role within CBiRC, his efforts have resulted in forming 
the CBiRC’s Biobased Foundry. Dr Keeling also coordinates with ISURF and the State of 
Iowa Economic Development Authority to steer investment dollars into startups. Since the 
inception of CBiRC’s Biobased Foundry, this effort has nurtured 6 startup entities, including 
GlucanBio, SusTerea, SolysTE, RecyclaR, Abios as well as the current startup, OmegaChea. 
Keeling’s role as the Interim Vice-President for OmegaChea is to provide guidance and 
expertise to the collaboration between OmegaChea and the CBiRC and steer the 
commercialization and investment strategy for the growth and success of OmegaChea.  
 
Problem and its solution 
Problem 
The US imports almost 10 million barrels of petroleum a day (1), to create a multi-
billion dollar plastics and specialty chemical industry that obtains its monomers from 
petroleum feedstocks. Currently, only a limited number of bio-based products are available in 
the market including polylactic acid (PLA), polyhydroxy-butyrate (PHB), polyethylene 
terephthalate (PET) based on 1,3-propanediol, and emerging products based on succinic acid 
and adipic acid (2). However, the global marketplace for the bio-plastics “green” market is 
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Reaction 1. KASIII-mediated synthesis of bi-functional 
fatty acids. 
  
projected to expand to over a billion dollars (3). With increasing awareness of reduced 
environmental impacts of bio-based plastics, the market for these products will continue to 
grow.  
Solution 
In this project, OmegaChea will develop a new, proprietary microbial fermentation 
host (a unique E. coli strain) that will produce scalable quantities of -hydroxy-branched-
fatty acids.  -Hydroxy-branched-fatty acids rarely occur in nature, but they offer many new 
opportunities for the chemical industry, particularly with polymer, lubricant and surfactant 
applications. E. coli has been 
chosen for this as a 
manufacturing host because 
it offers many technological advantages, and it is widely used in industrial fermentation 
capabilities. 
 The proposed innovation is based on new gene technology developed by CBiRC 
researchers (Garg, Yandeau-Nelson and Nikolau), which includes identification and 
characterization of diverse 3-ketoacyl-ACP synthase III (KASIII) enzymes. KASIII catalyzes 
the initial reaction of fatty acid biosynthesis using an acyl-CoA primer as its substrate 
(Reaction 1). By bioengineering a unique E. coli organism with novel KASIII enzymes that 
can use unusual substrates like hydroxy-acyl-CoA and/or branched-acyl-CoA primer-
substrates, it is OmegaChea’s proposition that a new microbial based manufacturing platform 
can be designed to produce novel -hydroxy-branched-fatty acids that are not known to 
occur in nature, but have wide-ranging applications in chemical industries. 
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Product Details 
Specifically, our technology will enable production of bi-functional, bio-based fatty acid 
products.  We are initially targeting the production of hydroxy-branched-fatty acids, based on 
market feedback and following reasons –  
1. These are bi-functional carboxylic acids and serve as excellent handles for chemical 
reactions. 
2. Chain lengths of these acids can be customized between  C8-C16 and offers 
flexibility to detergent, lubricant manufacturers.  
3. Positions and number of branches in these molecules can also be customized, which 
improves their performance as detergents and lubricants at lower temperatures by 
preventing solidification of these molecules at low temperatures. 
These molecules can be used as chemical feedstocks in the manufacture of detergents, 
surfactants, lubricants and specialty chemical synthesis. Therefore, typical customers of the 
technology would be specialty chemical producers and surfactant/lubricant manufacturers, 
like companies such as Procter and Gamble, DSM, BASF, and Evonik. Additionally, 
biotechnology companies could be possible customers, but such companies may be more 
interested in the genetic elements that encode our bioengineered enzymes or bacterial strains 
that express these enzymes. 
Status of technology and critical milestones 
OmegaChea has demonstrated proof-of-principle by producing -hydroxy-branched-fatty 
acids in an engineered microbial host (Rhodospirillum rubrum) which has novel KASIII 
genes in it. The next key milestone for OmegaChea is to engineer the pathway for production 
of -hydroxy-branched-fatty acids in a lab friendly microbe, i.e. Escherichia coli and then 
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optimize the production process. Currently, we are working on optimization of the KASIII 
biocatalysts that are at the core of this technology. After biocatalyst optimization, next step 
will be E. coli platform construction and optimization, followed by efforts to scale-up the 
production of bi-functional fatty acids (Fig. 4).  
To get the first viable product to marketplace, OmegaChea must achieve certain critical 
milestones, which include:  
i) Demonstration of proof-of-concept of production of bi-functional fatty acids in E. coli 
and other microbial hosts. 
ii) Identification of optimized KASIII biocatalysts for the maximal production of 
hydroxy-branched-fatty acids. 
Figure 4. Technology and business development timeline for OmegaChea. 
Currently, OmegaChea is in the biocatalyst optimization stage, and has funding from i6 
Green grant. The next goal for OmegaChea will be to construct E. coli platform using 
optimized biocatalysts to produce bi-functional fatty acids in E. coli. OmegaChea has 
recently been awarded $225,000 NSF STTR Phase I funding to support its research and 
development plans. 
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iii) Yield optimization of bi-functional fatty acids by engineering biocatalysts in 
appropriate microbial hosts. 
iv) Optimization to minimize the processing and separations costs. 
v) Scale-up by partnering with third-party scale-up providers; and product testing by 
partnering with earlyvangelists. 
vi) Finally, product customization and initial market launch. 
 
Competitive Advantage 
The value proposition for the product 
The value proposition of OmegaChea is to translate early-stage technology into a viable, 
de-risked and scalable process to manufacture, use and sell bio-based products. If it is 
successful, OmegaChea will have developed a portfolio of technologies that deliver an array 
of marketable bi-functional chemicals. In this form the company will become a target for 
acquisition by one of its partnering large multinationals. More specifically OmegaChea will 
have a competitive advantage in market because of the following value proposition for its 
products -  
i) Sustainable raw materials for surfactant, lubricant industry 
ii) Flexibility in molecular carbon chain-length and branching of chemical products 
iii) Higher performance surfactants and lubricants due to molecular branching of 
chemical products 
iv) Green ‘fermentative’ technology 
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This value proposition will be offered by our technological advances that will spur new 
bio-based manufacturing platforms for bi-functional carboxylic acids (hydroxy-fatty acids, 
branched chain fatty acids) with chain lengths that can be customized to between 8 and 16 
carbon atoms. A summary of minimum viable products of OmegaChea for each market 
segment and their specifications are provided in Table 1.  
Green technology with better performance 
The value for customers lies in a ‘green’ product that offers better performance than 
the existing petroleum based chemical precursor molecules. Some of the customers we talked 
to during the I-Corps program indicated that they will be willing to pay a premium for a bio-
based product as long as it has the same or better performance than the petroleum derived 
products. Additionally, some companies, like Procter and Gamble, BASF, DuPont reserve a 
portion of their budget for developing bio-based technologies. Such chemical companies 
would be our first target customers.  
Competition 
Three potential market segments exist for our bi-functional fatty acid products. Each 
of the market segments offers a different competitive landscape, with the polymers market 
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being fiercely competitive, offering very limited room for a new bio-based startup, like 
OmegaChea to find its own niche. In contrast, the surfactant and lubricant markets are 
relatively less crowded with bio-based products and hence, they provide more opportunities 
for OmegaChea to grow.  
The main 
competition for 
OmegaChea is from 
other early-stage bio-
based chemicals 
technology developers 
such as Amyris and 
Metabolix. These 
companies have similar 
aspirations to exploit 
the microbial enzymatic 
machinery to produce a 
wide-array of bio-based 
chemicals and fuels. Some of these bio-based companies have partnered with giant chemical 
manufacturers (like Unilever, Procter & Gamble). These partnerships are designed to create a 
consistent and long-term demand for their products. OmegaChea will adopt a similar strategy 
in that, after initial technological de-risking, it will partner with its early-vangelists identified 
through the I-Corps program, and seek synergies within CBiRC’s Innovation Ecosystem 
Distributor	
Monomer		
manufacturer	
Surfactant		
formulator	
Surfactant		
user	
Consumer	facing	
company	
Consumer	
	 Market	Pull	
(Sustainability	agenda)	
Decision	
Makers	
Biomass 	 	15	c/lb*	
	 	Biomass	Range	5-20c/lb	
Monomer 	 	80	c/lb	
	 	Detergent	alcohols	80c/lb	
Formula on 	90	c/lb	
	 	Formulated	Surfactant	90c/lb	
Surfactant	 	100	c/lb	
	 	Formulated	Detergent	100c/lb	
Detergent 	 	200	c/lb	
	 	10%	Surfactant	in	Detergent	
Product	
A.	 B.	 C.	
Figure 5. Customer Value Chain and Payment Flow 
Hypothesis for OmegaChea. A. Immediate customers for 
OmegaChea, the monomer manufacturer, will be the surfactant 
formulators which eventually sell the formulations to 
surfactant users like Procter & Gamble, Unilever. OmegaChea 
will need to partner with these surfactants users to create a 
demand for its products.  B. Market pull for ‘green products’ 
from the consumer end will create demand for OmegaChea 
products. C. Payment flow chart for OmegaChea where cost of 
production of bi-functional fatty acids is targeted at <80c/lb to 
make a profitable business. 
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(e.g., DSM, Evonik and Procter & Gamble) to create a supply-demand chain for its products 
and begin to establish itself in the marketplace.  
To be competitive in market, OmegaChea will have to bring its production costs 
under 80c/lb and sell its products at 80c/lb to make profits. Market pull for the bio-based 
products will help in competing against established petroleum-based competitors’ products. 
Additionally, strategic partnership with giant companies like P&G, Unilever will help create 
demand for OmegaChea’s bio-based products (Fig. 5).   
Customer Segments 
By providing access to new bio-based chemical feedstocks, the OmegaChea 
technology will address the needs of three potential customer segments –   
i) Surfactants formulators, 
ii) Lubricants formulators, and  
iii) The bio-based polymer manufacturers. 
The surfactant and lubricant formulators are seeking bio-based branched-chain fatty 
acids that offer enhanced chemical-physical lubricity and tribological properties, particularly 
at low temperature application.  The polymer industry uses bi-functional monomers that can 
be used to chemically react and polymerize to form, for example polyesters or polyamides.  
All of these customer segments currently derive their feedstocks predominantly from non-
sustainable petroleum sources.  Modified fatty acids that will be offered by OmegaChea 
provide attractive bio-based alternative “green” chemicals for both these applications.  This 
is because they offer chemical structures and physical properties that are similar or even 
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better than the petroleum-derived chemicals that are commonly used by these industries 
today.    
Market Opportunity 
The market opportunity for OmegaChea was explored and defined by market studies 
and meetings with industry representatives that occurred within the NSF-funded I-Corps 
grant.  These studies and interactions with CBiRC member companies revealed that there are 
4-5 different products 
that could be developed 
with the new KASIII-
manufacturing process.  
OmegaChea’s first 
viable product will aim 
to target the surfactants 
market segment that has significant value to potential customers.   Eventually, OmegaChea’s 
bio-based market segments will include surfactants and lubricants formulators and the bio-
based polymer manufacturers. The surfactants and lubricants markets have a customer-driven 
premium on the bi-functional chemicals that can be impacted by OmegaChea’s technology.  
The lubricant and surfactant formulators desire -branched fatty acids, which provide added 
functionality in low temperature lubrication applications. In contrast, the bio-based polymer 
manufacturers desire -hydroxy-fatty acids, which can be used in the assembly of polyesters, 
a process that is much less transparent to the consumer.  Thus, the initial product that 
OmegaChea has targeted for manufacture meets all of these specifications by incorporating 
hydroxyl-group functionality in the -1 position of fatty acids, providing both a branched-
Figure 6. Market opportunity for OmegaChea. There is 
$24 bn surfactant and $49 bn lubricant market and bio-based 
chemicals are growing at 15% p.a. offering room for 
OmegaChea to grow. 
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structure for improved lubrication and surfactant properties, whereas the hydroxyl-group can 
be used in other reactions to assemble polyesters as is typically done in chemical industry. 
Typical Customers 
Some examples of our typical customers in each of the three segments are Procter & 
Gamble (www.pg.com), Seventh Generation (www.seventhgeneration.com), and Target Up 
& Up (www.target.com) in the surfactants segment; Cargill Industrial Oils and Lubricants 
(www.cargill.com), and Stepan (www.stepan.com) in the lubricants segment; and BASF 
(www.basf.com), DSM (www.dsm.com), and Danisco/DuPont (www.dupont.com) in the 
bio-based polymers segment. We also identified some earlyvangelists for our products 
through the I-Corps program, namely Procter & Gamble and Evonik (www.evonik.com), 
which will be our first target customers as we move closer to commercializing our product. 
Market Size and Market Share 
The total market size for petrochemicals industry is estimated to be $1 trillion, of 
which bio-based chemicals share a small percentage. However, market for bio-based 
chemicals grows at 15% per annum. The main market share for OmegaChea will be the 
growing 15% bio-based sector of the $24 billion surfactants and $49 billion lubricants 
markets (Fig. 6).   
Distribution Channels 
OmegaChea will use the indirect channel of wholesale distributors for distributing its 
products. During the I-Corps program, OmegaChea identified various distributor networks 
operating in mid-west that distribute bio-based chemicals similar to OmegaChea’s first target 
160 
 
 
products. National Association of Chemical Distributors (NACD) will be another channel 
that will help OmegaChea reach its customers throughout the country.  
Entry Barriers 
Our I-Corps sponsored discussions with representatives of the polymer industry 
indicate that the polymer segment is a broad market and OmegaChea would find it difficult 
to enter this market as a startup entity. The main reason is that polymer manufacturers are 
large, integrated entities that have their own capital investments to synthesize feedstock 
monomers. Therefore, it is challenging for a bio-based startup company (such as 
OmegaChea) to dislodge the existing petroleum based feedstock system in the polymer 
markets.  On the other hand, the surfactants and lubricants markets, which are each worth 
more than $20 billion, have separate entities for formulation and utilization. Entry barriers 
are much lower than the polymers industry, and wide-ranging applications are possible. 
Additionally, there is a strong market pull from the consumer end as demand increases for 
green, sustainable products (Fig. 5). This market pull helps shift focus of the surfactant 
users/formulators towards feedstocks that are bio-based.  Therefore, OmegaChea’s initial 
market-target is a product that has potential in both the polymer and surfactant industries, but 
because of the findings of our I-Corps investigations the priority for OmegaChea will be the 
surfactant formulators.   
Marketing Plan 
OmegaChea’s marketing strategy will involve co-creating value proposition with the 
customer to earn customer trust and create customer satisfaction and good-will. Active 
participation in bio-based products/technology conferences, such as ICIS World Surfactant 
Conference, International Conference on Green and Sustainable Chemistry, and trade-shows 
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will help OmegaChea reach its target customer base effectively. Joining customer 
communities and surveying their needs/changing demands will help us tailor our marketing 
plan as OmegaChea evolves (Table 2).   
 
 
Operations Plan 
The key challenge for OmegaChea will be to manufacture and sell its products at a 
price that is competitive with the current market prices of surfactants and lubricants. Based 
on our discussions with various bio-based industry representatives and our techno-economic 
analysis, we have discovered that to build a profitable entity, the target cost of production for 
bi-functional fatty acids should be less than 100¢/lb (Fig. 7). This cost was calculated by 
considering current biomass costs (15¢/lb) and the current estimated costs of surfactants 
(100¢/lb). The eventual customers will be formulation companies that typically pay 90-
100¢/lb for raw monomers, which are formulated, and then sold to surfactant and lubricant 
manufacturers. To meet our target costs of <100¢/lb for bi-functional monomers, we will 
ultimately need a highly scalable process. This requires three mega-deliverables: 
Table 2. Marketing Plan for OmegaChea 
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i) Pre-pilot-scale optimization 
of the fermentation and 
separations processes;  
ii) Scale up to pilot-scale 
production that 
demonstrates the scalability 
of the overall process, and 
iii) Commercial-scale 
production will require at 
least ~500,000 lb/day, as is 
done by other value-added bio-based chemical manufacturers. 
Financial Projections and Plan 
Until OmegaChea reaches pilot-scale production stage, we envision seeking 
additional resources from State (e.g., State of Iowa Development Fund and the ISURF 
Technology Funds for Applied Research) and federal funding sources (e.g., SBIR, STTR 
Phase II and PFI-AIR). Because OmegaChea is a CBiRC-associated startup, the STTR and 
NSF-PFI-AIR funding programs will be specifically targeted, as these are programs designed 
for the development of innovations from ERCs. The envisioned future federal funding will 
help foster partnerships with larger companies identified through the I-Corps program, and 
CBiRC’s Innovation Ecosystem. We envision working closely with these larger entities to 
explore partnering to fund the scaling-up of our technology to a level needed to compete in 
the marketplace. There are significant financial challenges ahead for the expected 
commercialization. Even pilot-scale production may require investments in the order of a few 
 
Figure 7. Scale-up and production cost 
requirements for OmegaChea. In order to bring 
production costs under 100c/lb, OmegaChea will 
need to partner with scale-up providers to achieve 
scale-up up to 500,000 lb/day. Some of the 
customers that expressed interest in evaluating our 
products are listed as the ‘earlyvangelists’. 
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2013 2014 2015 2016 2017 2018 
R&D DELIVERABLES	
E. coli based platform for manufacturing ω-functionalized fatty acids (STTR) 
Prototype development of  the fermentation and separations systems 
Pre-pilot-scale optimization of  the fermentation and separations process 
Scale up to pilot-scale production demonstrating scalability 
Commercial-scale production (requires at least ~500,000 lb/day) 
BUSINESS DELIVERABLES	
Company Formation and Preliminary Business Strategy Development 
Intellectual Property Development 
Pilot Scale Company Partnerships for Commercial Development 
REVENUE PROJECTIONS (Sources of  Funding)	
I6-Green (Characterization of  biocatalysts) $100k	
State of  Iowa, Development Funds (Biocatalyst Optimization) $50k	 $100k	
STTR Phase-I (E. coli platform proof  of  concept) $100k	 $125k	
STTR Phase-II (Prototype development) $150k	 $400k	 $200	
SBIR Phase-I (Pre-pilot scale proof  of  feasibility) $150k	
SBIR Phase-II (Pre-pilot scale development) $150k	 $400k	 $200k	
Company Partnerships (Pre-Commercial Pilot Scale Development) $5,000k	
TOTAL $250k	 $375k	 $550k	 $350k	 $400k	 $5,200k	  
Figure 8. Revenue projections for OmegaChea for next 5 years to meet its R&D and 
business deliverables (CONFIDENTIAL) 
million dollars and full-scale production will require even greater investments (Fig. 8). These 
kinds of investments are hard to reach by a small entity, making it necessary to envision 
acquisition rather than doing it alone. OmegaChea anticipates that the unique exposure to 
CBiRC’s diverse innovation ecosystem, combined with partnering arrangements with larger 
entities will reap a long-term benefit. 
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